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1 1. Introduction and Aim of the Thesis 
1.1. Introduction 
 
1.1.1.  History of purinergic transmission 
 
More than 70 years ago, the effects of extracellular adenosine  5'-triphosphate 
(ATP), a newly identified and purified biomolecule at that time (Fiske and 
Subbarow, 1925; Lohmann, 1929) were observed by Drury and Szent-Györgyi 
(1929). Since then, many pharmacological studies were carried out with 
extracellular adenine nucleotides in various intact organ systems, isolated tissues, 
and purified cell preparations. Yet it was not until 1972 that Burnstock introduced 
the concept of "purinergic nerves" and suggested that ATP might fulfil the criteria 
generally regarded as necessary for establishing a substance as a 
neurotransmitter, summarised by Eccles (1964): 
 
 synthesis and storage of transmitter in nerve terminals 
  Strips of guinea-pig taenia coli (GPTC) were shown to take up large amounts of 
tritium-labelled adenosine when incubated with tritium-labelled adenosine, 
adenosine  5'-monophosphate (AMP), adenosine 5'-diphosphate  (ADP)  and 
ATP. The nucleoside was rapidly converted into and retained largely as 
[
3H]-ATP (Su et al., 1971). 
 release of transmitter during nerve stimulation 
  Spontaneous relaxation of GPTC as well as relaxations induced by nerve 
stimulation or nicotine, respectively, in the presence of compounds which block 
adrenergic and cholinergic responses were accompanied by a remarkable 
increase in release of tritium-labelled material from taenia coli incubated in 
[
3H]-adenosine (Su et al., 1971). 
 postjunctional responses to exogenous transmitters that mimic responses to 
nerve stimulation 
  Burnstock et al. (1966) characterised ATP and ADP as the most potent 
inhibitory purine compounds in the gut and observed that the effects of ATP 
mimic more closely the inhibitory response of the taenia to non-adrenergic 
nerve-stimulation than to adrenergic nerve stimulation (Burnstock et al., 1970). 
 enzymes that inactivate the transmitter and/or uptake systems for the 
transmitter or its breakdown products 
  When ATP was added to a perfusion fluid recycled through the vasculature of 
the stomach, very little ATP remained, but the perfusate contained substantially 
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increased amounts of adenosine and inosine, as well as some ADP and AMP 
(Burnstock et al., 1970). 
 drugs that can produce parallel blocking of potentiating effects on the 
responses of both exogenous transmitter and nerve stimulation 
  Tachyphylaxis to ATP produced in the rabbit ileum resulted in a consistent 
depression of responses to non-adrenergic inhibitory nerve stimulation, 
whereas responses to adrenergic nerve stimulation remained unaffected 
(Burnstock et al., 1970). Lower concentrations of quinidine reduced and finally 
abolished relaxation of GPTC induced by noradrenaline (NA) and by adrenergic 
nerve stimulation. Using higher concentrations of the compound, relaxant 
responses of GPTC to ATP as well as to non-adrenergic inhibitory nerve 
stimulation were abolished (Burnstock et al., 1970). 
 
Based on these observation it was proposed that ATP and/or adenosine, released 
as major neurotransmitter or as a co-transmitter from putative purinergic nerves, 
might mediate the non-adrenergic, non-cholinergic (NANC) signalling observed in 
the gut. 
 
Although there has been some reluctance to fully accept the idea that nucleotides 
have the capacity to act as autocrine and paracrine cellular messengers, the 
purinergic theory was strengthened by a great body of experimental evidence 
supporting the role of ATP as a transmitter or co-transmitter with noradrenaline, 
acetylcholine (ACh) and other substances and by the identification of specific 
receptors mediating the variety of physiological effects induced by purines. 
 
P1 and P2 receptors 
 
In 1978, Burnstock proposed a basis for distinguishing two types of purinergic 
receptors: the P1 receptor preferentially activated by adenosine, and the 
P2 receptor preferentially activated by ATP. This original classification was mainly 
based on the following criteria: 
 
 the relative potencies of ATP, ADP, AMP and adenosine (P1: adenosine  AMP 
> ADP  ATP; P2: ATP  ADP > AMP  adenosine); 
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 the selective actions of methylxanthines (theophylline, caffeine, and 
aminophylline), which competitively antagonised adenosine, but not ATP 
actions; 
 the modulation of adenylate cyclase (AC) by adenosine, but not by ATP; 
 and the induction of prostaglandin synthesis by ATP, but not by adenosine. 
 
P2X and P2Y purinoceptors 
 
In 1985, a further subdivision of P2 receptors was introduced by Burnstock and 
Kennedy. Their definition rested mainly on agonist selectivities:  
 
 potency order of ,-methylene-ATP (,-mATP),  ,-methylene-ATP 
(,-mATP) > ATP = 2-methylthio-ATP (2-MeSATP), and antagonism by 
arylazido-aminopropionyl-ATP (ANAPP3) as well as desensitisation of 
contractile responses of guinea-pig and rat vas deferens (ratVD) and urinary 
bladder following administration of ,-mATP mediated by subtype  1 
(designated P2X purinoceptor); 
 potency order of 2-MeSATP >> ATP > ,-mATP = ,-mATP, weak 
antagonism of ANAPP3 and no or poor desensitisation following administration 
of ,-mATP of relaxant responses of GPTC and the longitudinal muscle layer 
of rabbit portal vein mediated by subtype 2 (designated P2Y purinoceptor). 
 
To date, it is obvious that it was a most fortunate historical accident that the 
pharmacological subdivision was created thus, as it happens to coincide with a 
fundamental division in molecular structure. The receptors originally identified as 
P2X receptors for their ,-mATP-responsiveness are now known to belong to a 
larger family of ionotropic ATP receptors. The other subclass of this family, 
originally recognised by preference for 2-MeSATP and being unaffected by 
,-mATP, actually comprises multiple subtypes that belong to the larger family of 
metabotropic or guanyl nucleotide binding protein (G protein) -coupled receptors. 
 
P2T and P2Z receptors 
 
One year after Burnstock and Kennedy's proposal, in 1986, two additional 
P2 receptor subtypes on platelets and mast cells (and lymphocytes) that did not 
seem to fit the P2X/P2Y subclassification were defined by Gordon (1986) and were 
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tentatively termed P2T and P2Z receptors, respectively. The platelet receptor being 
activated by ADP and blocked by ATP, was designated P2T because of its 
presence on thrombocytes and megakaryocytes (Born, 1962; Haslam and 
Cusack, 1981). For activation of the P2 receptor subtype present on mast cells 
and lymphocytes, designated P2Z (for alphabetical consistency) about 100 M of 
ATP was required (for activation of the other subtypes about 1 M of the most 
active agonists was sufficient), and it was shown by Cockroft and Gomperts 
(1979) that the agonist form inducing calcium-dependent histamine secretion was 
the tetrabasic acid ATP
4-. 
 
Pyrimidinoceptors, nucleotide receptors, P2U receptors 
 
A few years later, it became apparent that, similar to ATP, extracellular uracil 
nucleotides exert effects on many tissues and cells (Seifert and Schultz, 1989; 
O'Connor et al., 1991). Uridine  5'-triphosphate (UTP) was shown to induce 
endothelium-dependent relaxation and to stimulate prostacyclin (PGI2) production 
in various vascular beds. Although it was obvious that this effect was mediated via 
phosholipase C (PLC) -linked "purinoceptors" (as described for the classical 
P2Y purinoceptor), regarding the rank order of agonist potency, these responses 
could not be attributed to activation of P2Y purinoceptors. These observations led 
to the definition of a new receptor subtype characterised by the following rank 
order of agonist potency: UTP = ATP > ADP > ,-mATP, 2-MeSATP and termed 
nucleotide receptor (P2n) (Davidson et al., 1990; O'Connor et al., 1991). 
Subsequently, this receptor subtype was referred to as P2U receptor. However, in 
some systems UTP-sensitive receptors could be distinguished from ATP receptors 
on the basis of cross-desensitisation experiments, and a rank order of potency of 
UTP = uridine  5'-diphosphate (UDP) >> uridine-5'-monophosphate (UMP) 
= cytidine 5'-monophosphate (CMP) was established for this pyrimidine nucleotide 
receptor (pyrimidinoceptor) (von Kügelgen and Starke, 1990). 
 
P2S purinoceptor 
 
The existence of a P2 receptor - the P2S subtype - mediating contractile responses 
of guinea-pig ileal longitudinal smooth muscle (GPI), at which ,-mATP and 
2-MeSATP have been found to be equipotent, has been proposed but is still 
questioned (Wiklund and Gustafsson, 1988). Recent findings suggested the 
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existence of two types of P2 receptors mediating contraction of GPI. An 
,-mATP-sensitive P2 receptor situated somadendritically on cholinergic 
neurons, the stimulation of which causes ACh-mediated contraction via 
postjunctional muscarinic M3 receptors and another P2Y1-like receptor located 
postsynaptically on the smooth muscle (Kennedy and Humphrey, 1994; Czeche et 
al. ,1998b; Lambrecht et al., 1999). 
 
P2D and P4 receptors 
 
There are also hints that adenine dinucleotides (ApnA's; "n" indicating the number 
of phosphates between the two adenosine moieties) may have a role as 
neurotransmitters or neuromodulators (Pintor and Miras-Portugal, 1995a). The 
diadenosine polyphosphates Ap3A and Ap4A were found to be co-stored with 
other neurotransmitters in platelets and Ap4A, Ap5A as well as Ap6A were shown 
to be present in neurosecretory vesicles together with adenine nucleotides, ACh 
and catecholamines (Flogaard and Klenow, 1982; Rodriguez del Castillo et al., 
1988). In several tissues, ApnA's and ATP were shown to activate the same 
P2 receptor subtypes (see Miras-Portugal et al., 1998). 
 
On the basis of binding and displacement studies carried out in rat brain synaptic 
terminals with [
3H]Ap4A, the presence of high and medium affinity binding sites 
with Kd values in the nM and M range have been described. A displacement 
order of Ap4A > adenosine 5’-O-2-thiodiphosphate (ADPS) > ,-imido-
adenosine-5'-triphosphate (AMP-PNP) > ,-mATP >> 2-MeSATP which was 
distinct from the pharmacological profiles of the formerly described ATP receptors 
was observed for the high affinity binding site. Because of these features, a new 
subtype was proposed and has been termed P2D receptor (Pintor et al., 1993). 
Studying the intrasynaptosomal Ca
2+ increase evoked by Ap4A and Ap5A as well 
as ATP, ,-mATP and ADPS in rat midbrain synaptic terminals, the lack of 
inhibition of responses to the dinucleotides by suramin, the inability to 
cross-desensitise the polyphosphate responses with ATP or its non-hydrolysable 
analogues together with their additive responses indicated that adenine 
dinucleotides and ATP on the one hand and its analogues on the other hand act 
via different mechanisms and different receptors in this preparation. These 
receptors, only stimulated by diadenosine polyphosphates, were found in 
synaptosomes of mouse and guinea-pig as well and were designated dinucleotide 
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or P4 receptors (Pintor and Miras-Portugal, 1995a, 1995b). However, due to the 
close structural analogy between diadenosine polyphosphates and ATP it is 
necessary to be aware of difficulties in clearly identifying their specific 
physiological receptors and differentiate them from pharmacological actions on 
other nucleotide receptors. Another factor that should be taken into account is the 
presence of diadenosine polyphosphatases. These enzymes hydrolyse the ApnA's 
in an asymmetric way producing AMP and the corresponding Apn-1 nucleotide, the 
breakdown products being active neurotransmitting substances themselves (ATP, 
ADP) or subject to further breakdown by ecto-nucleotidases, generating 
adenosine as the final product (Mateo et al., 1997). 
 
P3 receptors 
 
A distinct P3 receptor that is activated by both nucleosides and adenine as well as 
pyrimidine nucleotides, and is antagonised by xanthines as well as ,-mATP has 
been proposed. P3 purinoceptors were originally reported to be located 
prejunctionally and to inhibit evoked NA release from sympathetic nerves in rat tail 
artery and ratVD (Shinozuka et al., 1988; Forsyth et al., 1991). They were 
activated by agonists with a potency order of 2-chloroadenosine (2-Cl-Ado) 
> ,-methylene ATP > ATP = adenosine. Evidence for the existence of receptors 
distinct from P1 and P2 purinoceptors came from several observations: first, the 
effects of both nucleosides and nucleotides on NA release were blocked by the 
P1  receptor antagonist 8-(p-sulphophenyl)  theophylline (8-SPT); second, the 
adenosine uptake inhibitor S-p-nitrobenzyl-6-thioguanosine (NBTG) potentiated, 
and adenosine deaminase blocked the effect of adenosine on NA overflow but 
didn't have any effect on the ability of the adenine nucleotides to inhibit NA 
overflow; third, in ratVD, inhibition of NA release by UTP was also inhibited by 
8-SPT. With regard to some more recent data on the inhibitory effect of 
nucleosides and nucleotides on NA overflow in rat and mouse vas deferens, an 
alternative explanation to the initial proposal of P3 receptors might be a mixture of 
effects mediated via two distinct prejunctional receptors; a P1 receptor sensitive to 
nucleosides and nucleotides, which is presumably of the A1 subtype, and a 
P2Y-like receptor activated solely by nucleotides (Kurz et al., 1993; von Kügelgen 
et al., 1994). Similar evidence for separate prejunctional A1 and P2 receptors has 
been obtained in rat and mouse atria and the rat iris (Fuder and Muth, 1993; von 
Kügelgen et al., 1995). 
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In radioligand binding studies with ratVD membrane preparations using the 
A1 receptor  antagonist  1,3-[
3H]-dipropyl-8-cyclopentylxanthine ([
3H]-DPCPX) as 
radioligand, nucleosides competed for [
3H]-DPCPX binding at two distinct sites, 
whereas nucleotides bound at a single site only. The latter site seemed to 
correspond with one of the two binding sites predicted by nucleoside competition 
binding. The identity of these two binding sites for  [
3H]-DPCPX in ratVD is not 
quite clear, one appeared to bind only nucleosides and is probably an adenosine 
A1 receptor, and the other binds both nucleosides and nucleotides and may most 
likely be a P3 receptor or a separate affinity state of the A1 receptor, respectively 
(Smith et al., 1997). However, this assumption needs further evaluation before the 
International Union of Pharmacology (IUPHAR) Receptor Nomenclature 
Committee will adopt a P3-category. 
 
In 1994, it was again Burnstock (Abbracchio and Burnstock, 1994) who proposed 
a new way of defining receptors responsive to nucleotides and established a 
revised nomenclature, which is still the basis for subclassification of P2 receptors. 
Based on the predicted structure and the signal transduction mechanism, 
P2 receptors were divided into two families: the P2X receptors being intrinsic ionic 
channels permeable to Na
+, K
+ and Ca
2+ (Benham and Tsien, 1987; Bean, 1992) 
and the P2Y receptor family belonging to the GTP-binding receptor family 
(Dubyak, 1991; O'Connor et al., 1991). A detailed analysis of literature led 
Abbracchio and Burnstock to the proposal that resting on different potency profiles 
of key agonists the P2Y receptor family comprises seven subtypes (named 
P2Y1-P2Y7) and the P2X receptor family consists of at least four P2X purinoceptor 
subclasses (P2X1-P2X4). In contrast to the general P2Y, P2X receptor subdivision, 
the further classification proposed by Abbracchio and Burnstock (1994) does not 
correspond with the current definition of P2X and P2Y receptor subtypes (see 
1.1.2.2.). 
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1.1.2.  Purinergic Receptors: Subclassification and nomenclature - current 
state 
 
1.1.2.1. P1/Adenosine  receptors 
 
Presynaptically or postsynaptically released ATP is hydrolysed extracellularly to 
adenosine, which itself is a potent signalling substance acting on adenosine 
P1  receptors. Furthermore, adenosine can be released (via carrier-mediated 
mechanisms) from neurons or from the activated postsynaptic cell (Zimmermann, 
1994). Biochemical evidence for the existence of at least two distinct adenosine 
receptors was provided by the demonstration that adenosine analogues inhibited, 
via A1 (Ri), or stimulated, via A2 (RA), AC activity in several mammalian cell types 
(van Calker et al., 1979; Londos et al., 1980). The effects of adenosine could be 
antagonised by methylxanthines and the order of potency of adenosine analogues 
was different for the two receptor subtypes (van Calker et al., 1979). The A1/A2/A3 
nomenclature is now generally in use (Fredholm et al., 1994, 1997, 1998). 
 
The adenosine receptor family comprises A1, A2A, A2B and A3 adenosine 
receptors, identified by convergent data from molecular, biochemical, and 
pharmacological studies, all of which couple to G proteins. Receptors from each of 
these four distinct subtypes have been cloned from a variety of species including 
human, rat, mouse, guinea-pig, dog, sheep and rabbit (see table 1.1., for review 
see Ralevic and Burnstock, 1998). 
 
A subclassification of the A1 receptor has been proposed which was based on the 
observation that affinities of a set of agonists and antagonists were higher in the 
rat and guinea-pig brain than in ratVD and GPI. The high-affinity receptors were 
suggested to be termed A1a and the low-affinity A1b receptors (Gustafsson et al. 
1990). However, there are no cloned equivalents for these putative subtypes and 
their existence remains equivocal. Additionally, an adenosine binding site in rat 
striatal membranes was suggested to be a novel "A4" adenosine receptor 
(Cornfield et al., 1992). Further studies revealed that the characteristics observed 
in experiments performed at 4 °C represent binding to a certain state of the 
A2A receptor (Luthin and Linden, 1995). 
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A further subclassification of A2 receptors introduced by Daly and colleagues 
(1983) was based on the recognition that adenosine-mediated stimulation of AC in 
rat brain was affected via distinct high affinity binding sites (restricted to striatal 
membranes) and low affinity binding sites (present throughout the brain). This 
subdivision was supported in a study which compared the high affinity striatal A2 
binding site with a low affinity A2 binding site in a human fibroblast cell line (Bruns 
et al. 1986). A2 receptors displaying a high affinity for the non-selective adenosine 
receptor agonist 5'-N-ethylcarboxamidoadenosine (NECA) were termed 
A2A receptors and those with low affinity were referred to as A2B receptors (Bruns 
et al., 1986). Final evidence came from the cloning of A2A and A2B receptors which 
show distinct pharmacological profiles in transfected cells (Maenhaut et al., 1990; 
Rivkees and Reppert, 1992; Stehle et al., 1992). 
 
A3, the fourth adenosine receptor subtype was identified relatively late in the 
history of P1 receptors with the cloning, expression and functional characterisation 
of a novel adenosine receptor from rat striatum (Zhou et al., 1992). 
 
Generally, adenosine receptor subtypes can be pharmacologically subdivided 
based on the concentration of the physiological agonist adenosine required for 
receptor stimulation; A1 and A2A receptors are "high affinity" adenosine receptors, 
which are activated by adenosine concentrations of 0.01 - 0.1 M, while the "low 
affinity" A2B and A3 receptors require concentrations of 1 - 10 M adenosine for 
activation. 
 
All P1 receptor agonists described so far are structural analogues of the 
endogenous ligand adenosine. Only minor modifications of the ribose part are 
permitted to retain adenosine receptor affinity and intrinsic activity. Modifications in 
the adenine moiety, including substitution at N
6 and C2-positions, yielded 
analogues with greater stability and higher potency than adenosine. Adenosine 
receptor antagonists can be divided structurally in xanthine and non-xanthine 
derivatives. In contrast to many non-xanthine derivatives, xanthine antagonists are 
well-defined in terms of structure-activity (for more detailed information, the reader 
is referred to the following reviews: Collis and Hourani, 1993; Coates et al. 1994; 
Feokistov and Biaggioni, 1996; Jacobson, 1996; Jacobson and Suzuki, 1996; 
Müller and Stein, 1996). 
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1.1.2.2. P2  receptors 
 
The division of P2 receptors into two main classes, the P2X receptor family of 
ligand-gated ion channels and the P2Y receptor family of G protein-coupled 
nucleotide receptors, according to Abbracchio's and Burnstock's proposal 
(Abbracchio and Burnstock, 1994), is now generally accepted (Fredholm et al., 
1997; Harden et al., 1998a; Humphreys et al., 1998). To date seven, mammalian 
P2X receptors, termed P2X1-7, and six P2Y receptors, P2Y1, P2Y2, P2Y4, P2Y6, 
P2Y11 and P2Y12 have been cloned, characterised pharmacologically and 
accepted as valid members of the P2 receptor family (von Kügelgen and Wetter, 
2000; Hollopeter et al., 2001; Khakh et al., 2001). 
 
The molecular cloning of DNA encoding P2 receptors has enabled the 
pharmacological selectivity of P2 receptors of defined amino acid sequence to be 
delineated. This development was particularly important because of the difficulties 
previously encountered in unambiguously resolving individual members of the 
P2  class of receptors in pharmacological studies with tissue preparations 
(Abbracchio and Burnstock, 1994). The existence of at least 14 native nucleotide 
receptor subtypes could not be clearly demonstrated in traditional pharmacological 
studies for a number of reasons: 
 
 First, the presence of ecto-enzymes that rapidly hydrolyse nucleoside 
triphosphates and diphosphates on the extracellular surface of most target 
cells, can greatly and selectively decrease the apparent P2 receptor potency of 
susceptible nucleotides under the conditions generally used (Kennedy and Leff, 
1995). This problem has been aggravated by the paucity of hydrolysis resistant 
agonists that can distinguish the various P2 receptor subtypes as well as by the 
unavailability of selective ecto-nucleotidases inhibitors. To date, 6-N,N-diethyl-
D-,-dibromomethylene ATP (ARL 67156, formerly known as FPL 67156) is 
the only compound displaying selectivity in favour of ecto-nucleotidases 
inhibition (cf. 1.1.5.7.) 
 A second factor is the common co-occurrence of several subtypes of P2X or 
P2Y, or of both classes, in a single cell or tissue; an overlap that often cannot 
be resolved in pharmacological measurements. Thus, studies of a response of 
a tissue to ATP are predictably compromised by (1) rapid conversion of ATP to 
ADP, which potentially acts on a different receptor subtype, and (2) conversion 
of ADP to AMP and finally adenosine, which itself can introduce a new set of 
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complications through activation of P1 receptors. To circumvent at least the 
latter problem, P1 receptor antagonists of reasonably high selectivity can be 
utilised to block the potential contribution of these receptors. 
 The third and probably most eminent problem is the lack of real discrimination 
of the pharmacological tools being available. Although some progress has been 
made in the development of subtype-selective agonists as well as potent 
subtype-selective antagonists in the last few years (see 1.1.3.), apart from a 
few exceptions there are neither agonists nor antagonists that discriminate 
adequately between the families of P2X and P2Y receptors, or between 
subtypes of receptors within each of these groups. This coincides with scarcity 
of high-affinity selective or non-selective antagonists which can be applied in 
radioligand-binding studies. 
 Rapid desensitisation is a typical feature of some P2X receptor subtypes, 
stimulation of which leading to inactivation of ATP-induced inward currents 
within ms. Hence, precautions such as single dose techniques, minimising the 
agonist contact time, and allowing sufficiently long dosage intervals have to be 
taken into consideration. 
 Species differences, occurring even among some of the cloned P2 receptor 
subtypes, display a further problem which seems to become more and more 
relevant. Studies on recombinant P2X4 and P2Y4 species orthologues revealed 
fundamental differences in agonist as well as antagonist sensitivities 
(cf. 1.1.2.2.1.1. and 1.1.2.2.2.1.). 
 
Most of these disadvantages also play a role in studies on the pharmacological 
properties of cloned P2 receptors in null cell lines. For example, hydrolysis of 
nucleotides remains a problem in studies with cultured cells, and 1321N1 human 
astrocytoma cells, which have been widely used for the expression and functional 
assay of cloned P2Y receptors, express ecto-nucleotidases that rapidly hydrolyse 
ATP and potentially hydrolyse UTP as well (Lazarowski et al., 1995, 1997b). In 
addition, a novel enzymatic activity was shown to be present on the extracellular 
surface of 1321N1 cells: nucleoside diphosphokinase, catalysing the transfer of 
the  -phosphate of nucleoside triphosphates to nucleoside diphosphates, can 
markedly contribute to the observed pharmacological activity of nucleoside di- and 
triphosphates (Nicholas et al., 1996b; Lazarowski et al., 1997a). Moreover, 
problems can occur due to the release of nucleotides from cells in response to 
medium changes or physical stimulation (Lazarowski et al., 1995); this includes 
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the elevation of basal levels of second messengers, such as inositol phosphates. 
This phenomenon is particularly important when studying cloned P2Y receptors 
expressed at high levels (Filtz et al., 1994; Parr et al., 1994; Lazarowski et al., 
1995), which may exhibit increased sensitivity to nucleotide-promoted activation of 
second messenger production due to receptor reserve. Conversely, 
desensitisation and downregulation of the P2 receptor promoted signalling 
response can potentially occur as a sequel of such activation, as shown for the 
P2X1 receptor present in HL-60 cells (Buell et al., 1996c). The modulatory effects 
of ions, reported for several recombinant homomeric P2X receptors, introduce a 
further set of complications for the interpretation of data obtained from studies 
using differential experimental protocols (North and Surprenant, 2000). Finally, 
nucleotide analogues that are not P2 receptor agonists may appear to be so by 
reducing the enzymatic breakdown of ATP (or UTP) released from cells. However, 
some of the above-mentioned problems can be circumvented: purification by high 
pressure liquid chromatography (HPLC) of nucleotides and their analogues prior 
to use of this molecules as well as nucleotide-modifying enzymes (e.g. hexokinase 
to convert nucleoside triphosphates in nucleoside diphosphates generating 
glucose-6-phosphate or apyrase to remove tri- and diphosphonucleotides from the 
extracellular medium under conditions where release of cellular nucleotides 
introduces problems) can be utilised to define precisely the pharmacological 
selectivity of a P2 receptor subtype (Nicholas et al., 1996b). 
 
The apparent mismatch of some pharmacological data obtained in biological 
tissues relating to the P2 receptor subtypes classified on the basis of molecular 
structure may be resolved in part by the development of agonists and antagonists, 
that selectively activate or block individual receptors without being susceptible to 
enzymatic breakdown or being inhibitors of nucleotide-degrading enzymes. 
 
1.1.2.2.1.  Ionotropic P2 receptors (P2X receptors) 
 
P2X receptors are a unique family of transmembrane proteins, found in a wide 
variety of cells, including smooth muscle cells, peripheral and central neurons, 
epithelial cells, and immune cells (Buell et al., 1996a). These receptors are rapidly 
activating (milliseconds) ligand-gated cationic channels with equal permeability to 
Na
+ and K
+, but higher permeability (four times for P2X1, P2X3, and 
P2X4 receptors, two times for P2X2 receptors) to Ca
2+ (Valera et al., 1994; Evans 
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et al., 1995, 1996; Lewis et al., 1995; Soto et al., 1996b; Garcia-Guzman et al., 
1997a). 
 
Structure, membrane topology and stoichiometry 
 
Despite the apparent functional similarities of P2X receptor responses to those of 
other ligand-gated channels such as the nicotinic or glutamate, P2X receptors 
display no obvious sequence homology with other channel families. P2X receptor 
subunits (ranging from 379 to 595 amino acids in length) are 26 - 47 % identical to 
one another at the amino acid level. All seven proteins have similar hydrophobicity 
profiles, with only two hydrophobic regions sufficiently long to span the membrane, 
suggesting that P2X receptors may have intracellular N- and C-termini, and two 
transmembrane domains separated by a large extracellular loop (Valera et al., 
1994; Brake et al., 1994; Surprenant et al., 1995). Native and artificially introduced 
glycosylation sites were used to confirm this topological model (Newboldt et al., 
1998; Torres et al., 1998a). Further evidence was provided by mutational studies 
on P2X subunits: those studies have demonstrated that sensitivity to ,-mATP 
can be exchanged between rP2X1 and rP2X2 by swapping the extracellular loop 
(Werner et al., 1996) and, moreover, the effects of the antagonists suramin and 
pyridoxalphosphate-6-azophenyl-2',4'-disulphonic acid (PPADS) can be modified 
by single point mutations of amino acid residues located in the putative 
extracellular loop (Buell et al., 1996b; Collo et al., 1996; Garcia-Guzman et al., 
1997a). 
 
Recent structure-function studies indicate, that the channel pore is lined by 
residues that include, at least in part, the second transmembrane domain 
(Rassendren et al., 1997a; Egan et al., 1998). 
 
The structural domains involved in desensitisation of P2X1 and P2X3 receptors 
have been localised by engineering chimeric constructs of rP2X1, rP2X3 and 
rP2X2  subunits. Desensitisation can be introduced in rP2X2 by replacing the 
putative transmembrane domains in combination with 11 - 15 amino acids towards 
the N- and C-terminal end with the equivalent rP2X1 or rP2X3 sequence (Werner 
et al., 1996). The mechanisms governing the desensitisation of P2X receptors are 
not completely understood although recent data indicates that its kinetics might be 
a regulated process. It has been proposed that Ca
2+, entering through P2X3, will 
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produce desensitisation through calcineurin-mediated dephosphorylation of 
N-terminal residues that are phosphorylated under resting conditions (King et al., 
1997a). 
 
Similar to other ion channel families, the seven P2X proteins that have been 
cloned are receptor subunits, not actual receptors, and functional receptors are 
believed to be formed by oligomeric assembly. Studies using recombinant 
expression of individual subunits provide evidence that in certain tissues the 
native P2X response could be due to homo-oligomeric receptors (e.g. the 
P2X1 receptor and the P2X receptor found in vas deferens) (Valera et al., 1994; 
Khakh et al., 1995b). On the other hand, a P2X receptor phenotype seen in adult 
dorsal root sensory neurons appears to result from hetero-oligomeric assembly of 
P2X2 and P2X3 subunits (Lewis et al., 1995; Cook et al., 1997; Vulchanova et al., 
1997). Additional evidence supporting the possible presence of hetero-oligomeric 
P2X  receptors comes from Northern blot, in situ hybridisation, and immuno-
cytochemical studies suggesting that cell populations in a variety of tissues may 
express multiple subunit genes (Collo et al., 1996, 1997; Vulchanova et al., 1997; 
Robertson, 1998; Xiang et al., 1998). 
 
A remaining question is that of the exact stoichiometry of P2X complexes. One 
piece of evidence, recently proposed, was based on a combination of cross-linking 
and blue native polyacrylamide gel electrophoresis (PAGE) analysis (Nicke et al., 
1998; Nicke, 1999). Cross-linked recombinant P2X receptors were shown to 
migrate predominantly as trimers. Similar results were obtained with blue native 
PAGE, a non-denaturating gel electrophoretic method. It was proposed that 
P2X receptors associate as trimers early during biosynthesis and that this trimeric 
association is the essential constituent of the receptor complex, the association of 
trimers into hexamers being also possible (Nicke et al., 1998; Stoop et al., 1999). 
 
The ability of P2X receptor subunits to form stable trimers (or multiples of trimers), 
in combination with the capacity of hetero-oligomeric assembly of at least some of 
the cloned subunits yields a large number of potentially existing native 
P2X receptors, 11 of which have been studied to date. 
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1.1.2.2.1.1.  Cloning of ionotropic P2 receptors 
 
The first two P2X receptor subunits were isolated from ratVD smooth muscle 
(rP2X1) (Valera et al., 1994) and rat pheochromocytoma PC12 cells (rP2X2, 
originally called P2XR1) (Brake et al., 1994) by expression cloning. Five additional 
members of the P2X family were subsequently cloned from rat tissues (rP2X3 to 
rP2X7) either by screening of diverse libraries, by polymerase chain 
reaction-techniques (PCR-techniques) or by using a combination of both (for 
review see Buell et al., 1996a; Soto et al., 1997). The molecular characterisation 
of P2X receptors has been further expanded with the cloning of various 
homologous human cDNAs (see Soto et al., 1997, and references therein). 
Heterologous expression of each of the single cDNAs in Xenopus laevis oocytes 
or mammalian cell lines results in ATP-induced cation-selective currents. 
However, the efficiency in forming a functional P2X receptor differs among the 
subunits; for the rP2X6  receptor, currents have been reported in only a small 
fraction of transfections into a human embryonic kidney cell line (HEK293 cells) 
(Collo et al., 1996; Soto et al., 1996b) and transiently transfected cell lines 
expressing rP2X5 produced currents that were 5  -  10 % of the peak currents 
detected with any other P2X subunit (Collo et al., 1996; Garcia-Guzman et al., 
1996). In a recent study, P2X6 receptor subunits failed to give ATP-induced 
currents when transfected into HEK293 cells, an effect that might be explained by 
their inability to form homo-oligomeric assemblies (Torres et al., 1999). Similar 
results were obtained when the cRNA coding for the P2X6 subunit was injected in 
Xenopus laevis oocytes; upon application of ATP (up to 500 M), no inward 
current was observed (Soto et al., 1996b; Lê et al., 1998; Khakh et al., 1999b). 
 
Recombinant P2X receptors can be divided into four major groups based on the 
three following criteria: relative effectiveness of ,-mATP, sensitivity to suramin 
and PPADS, and the rate of desensitisation (see table 1.2., Khakh et al., 2001). 
P2X1 and P2X3 subunits represent the first phenotype. Cells expressing these 
cDNAs are activated by ,-mATP and ATP, half-maximal concentrations are 
close to 1 M (Valera et al., 1994; Chen et al., 1995; Lewis et al., 1995; 
Garcia-Guzman et al., 1997b). 
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Table 1.2.  Summary of pharmacological characteristics of P2X receptor 
subtypes based on studies of recombinant homomers (taken from Humphrey et 
al., 1998). 
 
Group 1  Group 2  Group 3  Group 4 
,-mATP-sensitive 
rapidly desensitising 
 
suramin-sensitive 
,-mATP-insensitive
non desensitising 
 
suramin-sensitive 
,-mATP-insensitive
non desensitising 
 
suramin-insensitive 
,-mATP-insensitive
non desensitising 
pore forming 
suramin-sensitive 
P2X1 P2X2 P2X4 P2X7 
P2X3 P2X5 P2X6  
 
P2X1 receptor subunits have been cloned from ratVD, and human and mouse 
urinary bladder (Valera et al., 1994; Ralevic and Burnstock, 1998). When 
expressed in Xenopus oocytes or in HEK293 cells, rapidly desensitising (in 
hundreds of ms) inward currents were observed in response to the ATP 
analogues 2-MeSATP  ATP > ,-mATP >> ADP. In a recent paper, Bianchi and 
colleagues reported on 2',3'-O-(4-benzoylbenzoyl) ATP (BzATP), which is 
commonly in use as a P2X7/P2Z receptor agonist, to be a potent (nM) agonist at 
hP2X1, rP2X3 and hP2X3 receptors. The metabolically stable ADP analogue 
ADPS, previously described as a P2Y receptor agonist, was also shown to 
activate hP2X1 as well as rP2X3 and hP2X3 receptors in the micromolar range 
(Bianchi et al., 1999). Additionally, the activity of diadenosine polyphosphates 
(Ap2A - Ap6A) at recombinant P2X1 receptors was examined. Ap4A and Ap5A were 
found to be equipotent full agonists at the hP2X1 receptor, Ap6A acted as a partial 
agonist, and Ap2A as well as Ap3A were inactive (Bianchi et al., 1999). For the 
rP2X1 receptor, only Ap6A was a full agonist, both Ap4A and Ap5A were partial 
agonists, and Ap3A showed weak agonist activity (Wildman et al., 1999a). The 
P2  antagonists suramin and PPADS readily antagonise the agonist-evoked 
responses. P2X1 receptor mRNA is expressed in urinary bladder, smooth muscle 
layers of small arteries and arterioles, and vas deferens, lower levels have been 
detected in lung and spleen (Valera et al., 1994; Collo et al., 1996). P2X1 receptor 
mRNA is also present in dorsal root ganglia, trigeminal ganglia, coeliac ganglia, 
spinal cord, and rat brain (Valera et al., 1994; Collo et al., 1996). 
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The P2X3 receptor cloned from rat dorsal root ganglion (Chen et al., 1995; Lewis 
et al., 1995) shows only 43  % amino acid sequence homology with the 
P2X1  receptor. However, the rank order of agonist potency characterising 
homomeric hP2X3 and rP2X3 receptors is very similar to that obtained in studies 
with homomeric P2X1 receptors:  2-MeSATP   ATP   ,-mATP (Lewis et al., 
1995; Bianchi et al., 1999). As described for the P2X1 subtype, diadenosine 
polyphosphates exhibit agonist activity at human and rat P2X3 receptors as well. 
The hP2X3 is sensitive to activation by submicromolar concentrations of Ap4A, 
Ap5A and Ap6A, although all responses mediated by diadenosine polyphosphates 
are submaximal (Bianchi et al., 1999). In oocytes expressing rP2X3 receptors 
Ap4A, Ap5A and Ap6A were shown to be full agonists and more potent than ATP 
(Wildman et al., 1999a). Differences described for the agonistic potency of Ap3A 
at rP2X3, being rather inactive at rP2X3 expressed in 1321N1 human astrocytoma 
cells and, in contrast, a partial agonist, displaying higher potency than ATP at the 
rP2X3 expressed in Xenopus oocytes, may be determined by the different 
expression systems applied (Bianchi et al., 1999; Wildman et al., 1999a). In the 
continuous presence of agonist, the currents elicited by heterologously expressed 
P2X3 receptors decline rapidly. In contrast to P2X1 receptors (monoexponential 
decay; 	 = 100 - 300 ms) P2X3 receptor desensitisation kinetics are biexponential 
with decay constants of 50 ms and 1 s (Collo et al., 1996). The P2X3 receptor 
shows a restricted distribution; it is present in sensory neurons, and is absent in 
central nervous system neurons and smooth muscle (Chen et al., 1995; Lewis et 
al., 1995; Collo et al., 1996; Dunn et al., 2001). The human P2X3 receptor 
transcript has been detected in spinal cord and heart (Garcia-Guzman et al., 
1997b). 
 
The second and the third group comprise currents in cells expressing P2X2, P2X4, 
P2X5 and P2X6 receptors. In these cases, ATP activates the channel with an EC50 
of about 10 M (cf. exceptions described above for the P2X6 receptor) but 
,-mATP is ineffective even at concentrations of 100 - 300 M (Brake et al., 
1994; Evans et al., 1995; Buell et al., 1996b; Collo et al., 1996; Séguéla et al., 
1996; Soto et al., 1996a). These receptors can be further subdivided according to 
their antagonist sensitivity: P2X2 and P2X5 receptors are reversibly inhibited by 
suramin and PPADS (
 30 M), while P2X4 (and P2X6 receptors) are not blocked 
by these concentrations of the two antagonists. ATP evokes sustained currents at 
P2X2 (Brake et al., 1994; Evans et al., 1996) and P2X5 receptors (Collo et al., 
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1996; Garcia-Guzman et al., 1996) even during agonist applications lasting tens of 
seconds (Brake et al., 1994). P2X4 (and P2X6 receptors) show an intermediate 
phenotype, with about 60 % of the peak current remaining after a 2 s-application 
of ATP to transfected mammalian cells (Collo et al., 1996). 
 
ATP, 2-MeSATP and ATPS are approximately equipotent agonists at the 
recombinant P2X2 receptor, whereas ,-mATP and ,-mATP are inactive either 
as agonists or antagonists (Brake et al., 1994). In contrast to P2X1 and 
P2X3 receptors the rP2X2 receptor when expressed in 1321N1 cells is insensitive 
to activation by diadenosine polyphosphates (Bianchi et al., 1999), although Ap4A 
was described to exhibit agonist activity at rP2X2 receptors expressed in Xenopus 
oocytes (Pintor et al., 1996; Wildman et al., 1999a). P2X2 receptor mRNA is 
present in bladder, brain, spinal cord, superior cervical ganglia, adrenal medulla, 
intestine, and vas deferens, with highest levels found in the pituitary gland and vas 
deferens (Brake et al., 1994). Immunohistochemical detection shows a 
widespread distribution of the P2X2 receptor in brain and spinal cord (Vulchanova 
et al., 1996). Studies on the genomic organisation of the rP2X2 receptor revealed 
a large number of exon-intron boundaries present in the coding region, suggesting 
the existence of several subunit isoforms produced by alternative splicing (Brändle 
et al., 1997). Accordingly, up to six different splice variants of the rat 
P2X2 receptor have been identified (Simon et al., 1997; Koshimizu et al., 1998). 
The first variant, now termed P2X2(b), has a 69 amino acid deletion of the 
C-terminus, expresses in the nervous system at least as abundantly as the original 
P2X2  subunit (distinguished by the terminology P2X2(a)), and is able to form 
homo-oligomeric functional channels, as was shown by its expression in Xenopus 
oocytes and mammalian cells (Simon et al., 1997). The P2X2(b) receptor is equally 
sensitive to agonists - the only difference in properties detected between this short 
and the P2X2(a) long form is an increased, intermediate rate of desensitisation 
(Simon et al., 1997). Alternative splicing also occurs in the TM1 region of the 
P2X2  receptor, generating two additional isoforms, termed p2x2(c) and p2x2(d), 
respectively. Although functional expression of these two isoforms has not yet 
been achieved (denoted by the lower case letters), mRNA for the p2x2(c) is present 
in many structures in the nervous system, whereas the transcript for the p2x2(d) 
variant has only been found in the nodose ganglion (Simon et al., 1997). 
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The P2X5 receptor was cloned from rat coeliac ganglia and heart (Collo et al., 
1996; Garcia-Guzman et al., 1996). Human homologues of the P2X5 receptor 
have tentatively been identified (Genbank: U49395/6). However, the full sequence 
of the hP2X5 receptor has yet to be confirmed (Lê et al., 1997). The 
rP2X5  receptor is able to form a functional homo-oligomeric channel and has 
pharmacological properties in terms of agonist potency (ATPS   ATP 
= 2-MeSATP >> ADP), antagonist sensitivity, and desensitisation which are very 
similar to the P2X2 channel, when both are expressed in HEK293 cells (Collo et 
al., 1996). A major difference to the other known P2X receptor subtypes is that the 
agonist-evoked peak current obtained for the P2X5 homo-oligomer is always very 
small, being 10-fold less than that of any other recombinant P2X subtype 
expressed in HEK293 cells (Collo et al., 1996). Rat P2X5 subunit transcripts have 
been identified in brain, heart, spinal cord and adrenal medulla, as well as thymus 
and lymphocytes (Garcia-Guzman et al., 1996; Lê et al., 1997; Bogdanov et al., 
1998a).  In situ hybridisation shows P2X5 mRNA in motoneurons of the ventral 
horn of the spinal cord. With the exception of trigeminal mesencephalic nucleus 
neurons, the brain does not express P2X5 mRNA (Collo et al., 1996). Further 
sequence analysis of the recently identified P2X subunit from chick skeletal 
muscle, which was tentatively called the chick P2X8 subunit because of its unique 
functional properties and its 59 % sequence homology to rat and human 
P2X5 subunits (Bo et al., 2000), indicates that it is a species homologue of P2X5. 
 
The main P2X receptors detected in adult rat central nervous system (CNS) by in 
situ hybridisation are P2X4 (Bo et al., 1995; Séguéla et al., 1996; Buell et al., 
1996b; Soto et al., 1996a) and P2X6 (Collo et al., 1996; Soto et al., 1996b), 
showing an overlapping distribution in many regions of the brain. This distribution 
pattern is not present in peripheral tissues: rP2X6 was not detected in RNA 
isolated from blood vessels and vas deferens (Soto et al., 1996b) where rP2X4 is 
present (Soto et al., 1996a). P2X4 receptors were originally cloned from rat brain 
(Bo et al., 1995), and subsequently, both human (Garcia-Guzman et al., 1997a) 
and murine orthologues (mP2X4) have been isolated (Townsend-Nicholson et al., 
1999; Simon et al., 1999). Comparing their pharmacological properties, 
differences occurred, especially with respect to antagonist sensitivities. Generally, 
the rank order of agonist potency characterising P2X4 receptors was shown to be 
similar for rat and human P2X4 receptors expressed in Xenopus oocytes (Soto et 
al., 1996a; Garcia-Guzman et al., 1997a): ATP  2-MeSATP  CTP  dATP; 
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purine analogues other than ATP exhibited partial agonistic activity at the 
hP2X4  receptor (Bianchi et al., 1999). AP4A, the most potent member of the 
diadenosine polyphosphate family, also acts as a partial agonist at human as well 
as rat P2X4 receptors (Bianchi et al., 1999; Wildman et al., 1999a). In a recent 
paper, a comparison of the mouse, human and rat orthologues of the 
P2X4  receptor was performed under identical experimental conditions using 
HEK293 cells (Jones et al., 2000). In this study, the potency of ATP was shown to 
be similar at the three species orthologues. In contrast, ,-mATP acted as a 
partial agonist at human and mouse P2X4, but was found to block ATP-induced 
responses at rP2X4 (Jones et al., 2000). The rP2X4 receptor was originally 
described to be insensitive to the classical P2 receptor antagonists suramin and 
PPADS (Bo et al., 1995; Buell et al., 1996b). Subsequent studies revealed that all 
P2X4 orthologues were relatively suramin-insensitive, compared to P2X1, P2X2 
and P2X3 subunits (Soto et al., 1996a; Garcia-Guzman et al., 1997a; Bianchi et 
al., 1999; Jones et al., 2000); the most remarkable pharmacological difference 
between hP2X4 and mP2X4, and the rP2X4 receptor concerns the antagonistic 
potency of PPADS. Mouse and human receptors were shown to be sensitive to 
PPADS when pre-incubated for several minutes, the rat receptor however, 
exhibited very low sensitivity to PPADS (Soto et al., 1996a; Garcia-Guzman et al., 
1997a; Jones et al., 2000). Interestingly, a single point mutation that provides the 
rat receptor with lysine, instead of glutamate (Glu
249) at the position equivalent to 
that found in the rP2X1 and rP2X2 receptors restores the ability of PPADS to 
produce slowly reversible inhibition, which seems to be due to the ability of 
PPADS to form a Schiff's base by virtue of its aldehyde moiety (Buell et al., 
1996b). Another interesting feature recently demonstrated for P2X4 receptors is a 
change in permeability of the ionic channel during ATP applications continued for 
several seconds. Causing an "activation-history-dependent" increase in 
permeability, and allowing the passage of fluorescent cations such as the 
relatively large molecule YO-PRO-1 (Khakh et al., 1999a; Virginio et al., 1999). 
Those changes in cation permeability in response to ATP application were 
previously thought to be unique for P2X7 receptors (Surprenant et al., 1996), but 
have now been demonstrated for P2X4 as well as P2X2 channels. 
 
The P2X6 clone was isolated from rat brain cDNA libraries (Collo et al., 1996; Soto 
et al., 1996b). The original pharmacological characterisation of rP2X6, based on 
observations from a small fraction of transfections into HEK293 cells (Collo et al., 
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1996), seems to be controversial, especially on the basis of recent findings, 
indicating that P2X6 subunits are not capable of forming functional homomeric 
receptors when expressed in HEK293 cells as well as in Xenopus oocytes (Soto 
et al., 1996b; Torres et al., 1999; Khakh et al., 1999b). However, the P2X6 mRNA 
was found to be widely expressed in both the CNS and in peripheral tissues (Collo 
et al., 1996; Soto et al., 1996b). 
 
The P2X7 receptor, formerly classified as the P2Z subtype, is the only 
representative of the fourth group of P2X receptors (see table 1.2.). 
Electrophysiological experiments in HEK293 cells transfected with the rat or 
human P2X7 receptor show that brief application of ATP activates an inward 
cation current (Surprenant et al., 1996; Rassendren et al., 1997b). Key properties 
of these currents are little rectification, little desensitisation, strong potentiation by 
reducing the concentration of extracellular Ca
2+ and/or Mg
2+ (reviewed by North 
and Surprenant, 2000), and relative insensitivity to ATP (300 M) as compared to 
BzATP (3 - 30 M). It was particularly the last two of these properties that 
suggested that the P2X7 receptor might correspond to the P2Z receptor 
(Surprenant et al., 1996); this interpretation was strongly supported by the findings 
that activation of P2X7 receptors allowed the uptake of YO-PRO-1 into transfected 
HEK293 cells, and that prolonged exposure to agonists led to cytolysis. Similarly 
at P2Z receptors, first described in rat mast cells (Cockroft and Gomperts, 1979) 
but also present in immune cells (Surprenant et al., 1996; Di Virgilio et al., 1996), 
high concentrations of ATP led to membrane permeabilisation. There are 
differences between the properties of the rat and human P2X7 receptors: 
activation of hP2X7 requires higher agonist concentrations, inward currents decline 
more quickly when the agonist is removed, and YO-PRO-1 uptake is less for the 
human compared to the rat receptor under otherwise comparable conditions 
(Rassendren et al., 1997b). At rat receptors, currents evoked by BzATP are 
antagonised only poorly by suramin, PPADS and 2',3'-O-(2',4',6')-trinitrophenyl-
ATP (TNP-ATP), and irreversibly blocked by 2',3'-dialdehyde-ATP (oxoATP) after 
pre-incubation for 1  -  2  h (Surprenant et al., 1996; Virginio et al., 1998). The 
calmodulin inhibitor calmidazolium potently inhibits BzATP activated currents in 
HEK293 cells expressing P2X7 receptors without affecting the YO-PRO-1 uptake 
(Virginio et al., 1997). The isoquinolines 1-[N,O-bis(5-isoquinolinesufonyl)-N-
methyl-L-tyrosyl]-4-phenylpiperazine (KN-62) and N-[1-[N-methyl-p-(5-
isoquinolinesulphonyl)benzyl]-2-(4-phenylpiperazine)ethyl]-5-isoquinolinesulphon-
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amide (KN-04) inhibit currents evoked by BzATP in HEK293 cells expressing 
hP2X7, but not in those expressing the rat receptors (Humphreys et al., 1998); a 
similar species selectivity has first been shown for the respective native 
P2Z receptors (Gargett and Wiley, 1997). The P2X7 subunit has a C-terminal tail 
approximately 200 amino acids longer than in any other of the known 
P2X subunits. Mutagenesis experiments have shown that this long C-terminal tail 
is involved in the formation of the large pore, though it does not affect the function 
as an ATP-gated non-selective ion channel (Surprenant et al., 1996). However, 
recent data, describing pore dilation of P2X2 and P2X4 receptors after prolonged 
exposure to ATP might indicate that the C-terminal domain is not directly involved 
in the initial dilation of the ion channel (Virginio et al., 1999). The P2X7 has a much 
wider distribution than has been previously expected, mRNA for this subtype being 
not only present in macrophages and other related immune cells, but in heart, 
liver, pancreas, brain, spinal cord, skeletal muscle, lung, and spleen (Surprenant 
et al., 1996; Rassendren et al., 1997b). In the brain the P2X7 transcript appears to 
be present on ependyma and microglia, but not in neurons (Collo et al., 1997). 
 
Like other transmitter-gated ion channels P2X receptors are sensitive to a number 
of endogenous agents, including Zn
2+, Cu
2+, H
+, Mg
2+ and Ca
2+ (for review see 
North and Surprenant, 2000) as well as other neurotransmitters or neuro-
modulators (Hu and Li, 1996; Wildman et al., 1997). Differential effects of such 
modulating agents may provide a simple means to discriminate among 
recombinant P2X receptor subtypes as well as to characterise P2X receptors in 
native tissues in the absence of subtype-selective antagonists. Effects of H
+ and 
Zn
2+ on recombinant rP2X1-4 are summarised in table 1.3. (see Wildman et al., 
1999c). P2X2 receptors have a unique phenotype with respect to ions. Thus, they 
are the only P2X receptor subtype at which the response to ATP is increased by 
acidification of the extracellular solution (King et al., 1997b; Stoop et al., 1997; 
Ding and Sachs, 1999). In contrast, agonist potency is decreased at P2X1, P2X3 
(Wildman et al., 1999c) and P2X4 (Wildman et al., 1999b) in the presence of 
increasing concentrations of H
+. ATP-induced currents are potentiated by both 
Zn
2+ and Cu
2+ at P2X2 receptors (Wildman et al., 1998; Xiong et al., 1999), 
allowing P2X2 receptors to be distinguished from P2X4 receptors, which are less 
sensitive to Cu
2+ (Xiong et al., 1999). At P2X1 receptors the potency of ATP is 
decreased in the presence of Zn
2+, whereas at P2X3 the actions of Zn
2+ are 
complex: ATP-responses are potentiated when Zn
2+ is co-applied with ATP, 
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pre-incubation of Zn
2+ results in a concentration-dependent potentiation followed 
by inhibition (Wildman et al., 1999c); the same effect occurs at P2X2 receptors, 
although the magnitude of the Zn
2+ effect is much greater (Wildman et al., 1998). 
 
Table 1.3.  Modulation of recombinant rP2X1-4 by H
+ and Zn
2+ (taken from 
Wildman et al., 1999c) 
 
 rP2X1 rP2X2 rP2X3 rP2X4 
H
+ effect  ATP potency  
ATP efficacy  
time independent 
ATP potency  
ATP efficacy  
time independent
ATP potency  
ATP efficacy  
time independent 
ATP potency  
ATP efficacy  
time independent
Zn
2+ effect  ATP potency  
ATP efficacy  
time dependent 
ATP potency   
ATP efficacy  
time dependent 
ATP potency   
ATP efficacy   
time dependent 
ATP potency  
ATP efficacy  
time independent
H
+ & Zn
2+ 
combined 
ATP potency  
ATP efficacy  
effects additive 
ATP potency  
ATP efficacy  
H
+ effect 
ATP potency   
ATP efficacy   
Zn
2+ effect 
ATP potency  
ATP efficacy  
effects additive 
Symbols: , increase; , decrease;  no change;  , bi-directional changes, dependent 
on incubation time;  , no change initially, but a decrease with prolonged incubation. 
 
1.1.2.2.1.2. Heteromeric ionotropic P2 receptors 
 
The cloning of ATP receptors and their functional expression has proven 
extremely useful in elucidating the basic properties of these proteins and for 
providing a template for further study of native P2 receptors. With the molecular 
identification of seven P2X subunits, understanding of the biophysical and 
pharmacological properties of these channels has considerably increased. 
However, discrepancies between heterologously expressed homo-oligomeric 
P2X  subunits and electrophysiological recordings from neuronal preparations 
likely reflect the existence of native heteromeric phenotypes of P2X receptors. 
Moreover, results from Northern blots and in situ hybridisation data have indicated 
that the six neuronal P2X subunit genes are transcribed in specific but overlapping 
populations in the peripheral nervous system as well as the CNS, again 
suggesting that P2X receptors might co-assemble into heteromultimeric channels. 
Almost all known ionotropic receptors exist as hetero-oligomers (for review see 
Barnard, 1996), in which different subunits associate to generate channels with 
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unique functional properties, allowing for diversity in signalling. The subunit 
composition of heteromeric P2X receptors is not known. However, using 
epitope-tagged constructs, physical associations can be shown between some 
pairs of P2X subunits in heterologous expression systems (Radford et al., 1997; 
Lê et al., 1998, 1999; Torres et al., 1999). These co-immunoprecipitation studies 
revealed that the P2X7 subunit is unlikely to assemble with other P2X subunit, 
whereas others such as P2X2 and P2X5 subunits will readily heteroplymerise with 
most members of the P2X family (see table 1.4.). 
 
Of those pairs that are now known to co-immunoprecipitate, some have been 
studied functionally after co-expression. The non-desensitising response to 
,-mATP observed in sensory neurons (Khakh et al., 1995a; Lewis et al., 1995; 
Cook et al., 1997) can be reproduced in HEK293 cells by co-expression of P2X2 
and P2X3 receptor cDNA; because this phenotype could not be accounted for 
readily by any simple mixing of channels with P2X2 and P2X3 properties, it was 
concluded that heteromeric channels must be formed (Lewis et al., 1995). This 
hypothesis was supported by the observation of a high level of co-localisation of 
P2X2- and P2X3-immunoreactivity in rat nodose and dorsal root ganglia 
(Vulchanova et al., 1997). Direct evidence for the formation of a P2X2P2X3 
heteromer came from a study showing that in cells co-infected with P2X2 and 
P2X3 receptors, the two proteins can be cross-immunoprecipitated with antibodies 
specific for either of the epitope tags introduced at the C-terminus of the proteins 
(Radford et al., 1997). The heteromeric P2X2P2X3 receptor shares properties of 
P2X3 with respect to activation by nucleotide agonists. The rank order of potency 
of agonists is comparable to the human and rat P2X3 receptors (Lewis et al., 
1995; Bianchi et al., 1999). In contrast to their activity at hP2X3 , ApnA's were 
significantly less potent as P2X2P2X3 agonists (Bianchi et al., 1999). Suramin and 
PPADS readily antagonise P2X2P2X3-mediated currents (Lewis et al., 1995; 
Bianchi et al., 1999). The heteromeric receptor is also very sensitive to 
8,8'-(carbonylbis(imino-3,1-phenylenecarbonylimino)) bis (1,3,5-naphthalene-trisul-
phonic acid) (NF023) and to TNP-ATP, implying that for these antagonists, the 
presence of the P2X3 subunit is sufficient to generate high sensitivity (Soto et al., 
1999; Virginio et al., 1998). The effect of pH-changes, however, is similar to that 
seen for homomeric P2X2 receptors (Evans et al., 1996). 
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P2X4 and P2X6 subunits are extensively co-expressed throughout the CNS (Collo 
et al., 1996), and there is evidence for their heteropolymerisation in Xenopus 
oocytes (Lê et al., 1998). The co-injected oocytes were slightly more sensitive to 
2-MeSATP and ,-mATP than were oocytes injected only with the P2X4 subunit 
(Lê et al., 1998; Khakh et al., 1999b); there was no difference in the effect of zinc 
or protons between heteromeric P2X4P2X6 and homomeric P2X4 (Lê et al., 1998). 
The antagonistic potency of suramin and PPADS is slightly higher at the 
P2X4P2X6 heteromer than at homomeric P2X4. Reactive blue 2 (RB2), which was 
shown to potentiate P2X4 receptor activity, is an antagonist at the P2X4P2X6 
heteromer (Lê et al., 1998). However, in these experiments co-injected oocytes 
might express both P2X4 homomers and P2X4P2X6 heteromers which are both 
activated by ATP, a fact that complicates the interpretation of antagonist 
sensitivities. Therefore, it remains unclear to what extent this combination can 
account for the response by many central neurons (Lê et al., 1998). 
 
Results from in  situ hybridisation, PCR/cloning analysis, and immuno-
cytochemistry experiments have implicated the co-existence of P2X1 and 
P2X5 receptors in heart (Bogdanov et al., 1998a) and spinal cord tissue (Collo et 
al., 1996). When Xenopus oocytes were co-injected with P2X1 and P2X5 subunits, 
a slowly desensitising response induced by ,-mATP was observed, whereas 
homomeric P2X5 receptors are almost insensitive to this agonist and homomeric 
P2X1 receptors desensitise strongly in the first second of agonist application (Lê et 
al., 1999). Similar results were obtained from co-injection of HEK293 cells with the 
cDNAs encoding for the P2X1 and P2X5 isoforms (Torres et al., 1998b; Haines et 
al., 1999), where biphasic inward currents, consisting of a fast peak current that 
quickly diminishes to a sustained plateau, were observed in response to 
ATP  2-MeSATP  ATPS  ,-mATP  ADP (Haines et al., 1999). In the same 
study using ATP as agonist, the P2X1P2X5 heteromer was shown to be as 
sensitive to the antagonists suramin and PPADS as the respective homomeric 
P2X1 and P2X5 receptors, but markedly less sensitive to TNP-ATP than 
homomeric P2X1 receptors. In contrast, in oocytes co-injected with P2X1 and 
P2X5, the antagonist TNP-ATP has an inhibitory effect on ,-mATP-induced 
currents similar to that observed at the P2X1 receptor in the same study (Lê et al., 
1999). Whether these differences are due to different expression systems, the use 
of different agonists or differences in the interpretation and analysis of the currents 
(peak vs. plateau) remains to be determined. 
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Almost recently co-expression of P2X2 and P2X6 receptor subtypes which are 
present in rat central nervous system (CNS) and frequently co-localise in the same 
brainstem nuclei resulted in a heteromeric rP2X2P2X6 receptor which showed a 
significantly different phenotype from the wildtype rP2X2 receptor (King et al., 
2000). Differences included reduction in agonist potencies, a biphasic ATP-
evoked inward current, and modulation of channel activity by H
+. The potentiating 
effect of Zn
2+ on ATP responses was similar to that observed at rP2X2, whereas 
the pH-dependent blocking activity of suramin was changed at this heteromeric 
receptor (King et al., 2000). 
 
Table 1.4.  Summary of observed P2X-subunit co-assembly (taken from Torres 
et al., 1999) 
 
 P2X1 P2X2 P2X3 P2X4 P2X5 P2X6 P2X7 
P2X1  + + + - + + - 
P2X2    + + - + + - 
P2X3     + - + - - 
P2X4        + + + - 
P2X5       +  +  - 
P2X6       -  - 
P2X7         +  
 
Co-immunoprecipitation studies (Torres et al., 1999) suggest the existence of 
further heteromeric receptors. Thus, the lack of novel phenotypes does not 
necessarily mean that two subunits are not interacting to form a hetero-oligomeric 
complex, as was originally anticipated from the study of Lewis and colleagues 
(1995) for the combinations P2X1P2X2, P2X1P2X4, and P2X3P2X4. An alternative 
explanation is that when two receptor subunits participate to form a complex, one 
can dominate the phenotype of the resulting channel, and thus, a phenotype 
resembling one of the respective homomers is observed. 
 
1.1.2.2.1.3. Native ionotropic P2 receptors 
 
ATP-gated ion channels have been studied in a broad range of cell types including 
smooth muscle, cardiac muscle, platelets, antigen-presenting immune cells, 
epithelial cells, and peripheral and central neurons (for review see Ralevic and 
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Burnstock, 1998; Lambrecht, 2000). Three different phenotypes can be observed 
based on the relative effectiveness of ATP analogues, and biophysical 
characteristics of the ionic current of native P2X receptors (table 1.5.). Usually 
selective antagonism is the best way to discriminate among receptors in native 
tissues, but the limited arsenal of compounds currently available has hampered 
this approach (see 1.1.3.2.). Comparative studies of agonist potency should 
ideally be performed in the absence of metabolism, which was not possible for 
many studies on native P2 receptors as selective, potent inhibitors of 
ecto-nucleotidases on the one hand, and enzymatically stable agonists on the 
other hand were not available. Recent studies show that potencies of ATP and 
2-MeSATP are decreased markedly by breakdown and that, when this is 
prevented, e.g. by the use of isolated cells, both agonists are equipotent or even 
more potent than ,-mATP at native P2X receptors (Humphrey et al., 1995; 
Kennedy and Leff, 1995; Khakh et al., 1995b). Therefore, in the absence of 
nucleotide metabolising enzymes, the original rank order of agonist potency of 
,-mATP >> 2-MeSATP   ATP characterising smooth muscle P2X receptors, 
needed to be redefined. Thus, it was suggested that 2-MeSATP  ATP 
 ,-mATP with activity at high nanomolar and low micromolar concentrations 
and small differences in their potency, is a more accurate description of the 
pharmacological properties of P2X receptors in native tissues (Kennedy and Leff, 
1995). 
 
Accordingly, the first of the three groups of native receptors is represented by 
response of smooth muscle, cardiac muscle, platelets and sensory neurons of 
nodose and dorsal root ganglia (reviewed by Evans and Surprenant, 1996; Ralevic 
and Burnstock, 1998; MacKenzie et al., 1999). In these tissues, ,-mATP is 
about equipotent to ATP itself, and concentrations producing halfmaximal effects 
are in the range of 1 - 3 M. The currents evoked by these agonists show inward 
rectification, but they fall into two subgroups depending on the degree to which 
they decline during continued agonist application. In smooth muscle cells and 
platelets such desensitisation is profound; the time constant of desensitisation is 
typically 100 - 300 ms, and largely independent of the concentration of agonist 
(Evans and Kennedy, 1994; Khakh et al., 1995b). These pharmacological 
properties are similar to those observed for recombinant P2X1 receptors 
expressed in heterologous systems (cf. 1.1.2.2.1.1.) and therefore provide further 
evidence for smooth muscle P2X being the native counterpart of homomeric 
P2X1 receptors. Currents in neonatal sensory neurons also desensitise, exhibiting 
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biexponential kinetics with decay constants of 50 ms (fast component) and 1 s 
(slow component) most similar to those observed at recombinant P2X3 receptors 
(cf. 1.1.2.2.1.1.); as described for P2X3 homomers desensitisation is strongly 
dependent on the agonist concentration. In contrast, currents evoked by ATP or 
,-mATP in adult rat sensory neurons or guinea-pig coeliac ganglion cells show 
little or no desensitisation (Khakh et al., 1995a), a pharmacological profile that 
does not correspond to any of the homomeric P2X receptors, but was obtained 
after co-expression of P2X2 and P2X3 receptors in HEK293 cells (see 1.1.2.2.1.2.; 
Lewis et al., 1995). 
 
Table 1.5.  Proposed subtypes of P2X receptors contributing to functional 
channels in native tissue (for references see text). 
 
Recombinant Phenotype  Native 
P2X1  ,-mATP-sensitive, 
concentration-independent desensitisation
smooth muscle 
P2X3  ,-mATP-sensitive, 
concentration-dependent desensitisation 
neonatal sensory 
ganglia 
P2X2P2X3  ,-mATP-sensitive, 
non-desensitising 
adult sensory ganglia
P2X2  ,-mATP-insensitive, 
non-desensitising 
PC12 cells, SCG, 
submucosal ganglia 
P2X4  ,-mATP-insensitive, 
non-desensitising, 
suramin-, PPADS-insensitive 
salivary gland 
 
The second group of tissues comprises those where the action of ATP is not 
mimicked by ,-mATP. These ,-mATP-insensitive receptors are present in a 
diverse range of cells including PC12 cells (Nakazawa et al., 1991), superior 
cervical ganglion neurons (Khakh et al., 1995a), submucosal enteric neurons 
(Barajas-Lopez, 1994), outer hair cells of the cochlea (Raybould and Housley, 
1997), nucleus tractus solitarius neurons (Ueno et al., 1992), ciliary ganglion (Sun 
and Stainley, 1996), and epithelial cells including the submandibular gland (Buell 
et  al., 1996b). The effective concentrations of ATP at these receptors with 
EC50 values typically 3 - 30 M tend to be higher than those at the first class. The 
currents do not desensitise much during agonist applications of several seconds, 
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and repeated applications evoke currents with relatively constant peak amplitude. 
Within this group, the receptors can be further distinguished by their sensitivity to 
PPADS and suramin. These receptors correspond well in their pharmacological 
properties to recombinant P2X2 (suramin-, PPADS-sensitive) and P2X4 receptors 
(largely suramin-, PPADS-insensitive; cf. 1.1.2.2.1.1.). 
 
The third main phenotype, the membrane permeabilising P2Z receptor has been 
already discussed together with its correlate, the recombinant P2X7 receptor 
(see 1.1.2.2.1.1.). 
 
1.1.2.2.2.  Metabotropic P2 receptors (P2Y receptors) 
 
P2Y receptors couple to heterotrimeric G proteins which in turn activate 
intracellular second messenger systems (mostly PLC, but also PLA2, PLD and 
AC) to alter the physiological function of excitable and non-excitable cells. So far, 
the P2Y receptor family is composed of nine cloned and functionally defined 
subtypes, six of which (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, and P2Y12) are present in 
human tissues and are included in the P2Y receptor family by the NC-IUPHAR 
Committee (Fredholm et al., 1997; Harden et al., 1998a; for review see: Communi 
and Boeynaems, 1997; King et al., 1998; Ralevic and Burnstock, 1998; 
von Kügelgen and Wetter, 2000; Hollopeter et al., 2001). The use of lower case 
was recommended for mammalian orphan receptors or functional non-mammalian 
P2 receptors without a mammalian orthologue, e.g. cp2y3 for the G-pro-
tein-coupled receptor cloned from chick. The first letter indicates species 
(h,  human; c, chick; t, turkey; b, bovine; m, mouse; r, rat; x, Xenopus laevis). 
P2Y receptors can be subdivided based on their agonist profiles: P2Y1, P2Y11 and 
P2Y12  receptors are selectively activated by adenine nucleotides, whereas all 
other P2Y receptors (except P2Y6) display a weak selectivity: uracil nucleotides as 
well as adenine nucleotides act as agonists on P2Y2, rP2Y4, p2y3, tp2y and p2y8. 
Additionally, P2Y1, P2Y12, P2Y6, and p2y3 receptors show a preference for 
nucleoside diphosphates and can therefore be distinguished from the tri-
phosphate-preferring P2Y2, P2Y4, P2Y11, tp2y and p2y8 receptors (see table 1.6.). 
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1.1.2.2.2.1.  Cloning of metabotropic P2 receptors 
 
The final removal of all earlier doubts concerning the existence of P2 receptors 
demanded the cloning of their genes. In 1993, the cDNA encoding for a 
heptahelical protein was isolated from chick brain and, following expression in 
Xenopus oocytes, was shown to be activated by 2-MeSATP  ATP > ADP; UTP, 
,-mATP, and ,-mATP were inactive (see table 1.6.). Responses to ATP and 
2-MeSATP were antagonised by suramin and RB2 (Webb et al., 1993; Barnard et 
al., 1994). Activation of this receptor, termed P2Y1, resulted in 
inositol 1,4,5-triphosphate  (IP3) formation (via PLC) (Simon et al., 1995). 
Subsequently, orthologues of the cP2Y1 receptor have been cloned from turkey 
(Filtz et al., 1994), rat (Tokuyama et al., 1995; Pacaud et al., 1996), mouse 
(Tokuyama et al., 1995), bovine (Henderson et al., 1995) and human tissues 
(Léon et al., 1995, 1997; Ayyanathan et al., 1996; Janssens et al. 1996; Schachter 
et al., 1996). Characteristically, the P2Y1 receptor is strongly activated by 
2-methylthio-ADP (2-MeSADP), 2-MeSATP, ADP and ADPS, sensitivity to ATP 
seems to be variable, even among the cloned orthologues of the P2Y1 receptor 
(Webb et al., 1993, 1994; Simon et al., 1995; Henderson et al., 1995; see King et 
al., 1998). Moreover, investigating the purity of commercially available ATP and 
2-MeSATP, contamination of solutions with about 10 % nucleoside diphosphates 
were observed, and after removing contaminating ADP enzymatically (by creatine 
phosphate/creatine phosphokinase) or by HPLC, both triphosphates appeared to 
be competitive antagonists rather than agonists at rP2Y1 and hP2Y1 (Hechler et 
al., 1998c; Léon et al., 1997). However, it remains to be clarified, whether these 
differences in the relative potency found for ATP and ADP are due to inherent 
differences in receptor structure or caused by different experimental protocols 
(Palmer et al., 1998; Dixon, 2000). 
 
The first cloned P2Y2 receptor was from mouse NG108-15 neuroblastoma cells. 
UTP and ATP were full and equipotent agonists at mP2Y2, whereas ATPS was 
less potent, and 2-MeSATP as well as ,-mATP were reported to act as weak 
partial agonists (Lustig et al., 1993). This agonist rank order of potency was 
confirmed and extended for the subsequently cloned hP2Y2 (Parr et al., 1994). 
ATP and UTP as well as the stable UTP analogue UTPS were found to be 
equipotent, full agonists while 2-MeSATP and ,-mATP were only weakly active 
(Parr et al., 1994, Lazarowski et al., 1996). In a further study, the polyphosphate 
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Ap4A was shown to be a potent agonist at hP2Y2 stably expressed in 1321N1 
human astrocytoma cells (Lazarowski et al., 1995). Although agonist activity at 
recombinant P2Y2 receptors has been extensively studied, only little attention has 
been paid to the blocking activity of P2 receptor antagonists. Charlton and 
colleagues (1996) have shown that suramin weakly antagonises hP2Y2 receptors, 
whereas PPADS had no effect on UTP responses. These findings were confirmed 
in a recent study by Janssens and co-workers (1999), who identified RB2 as the 
most potent antagonist at hP2Y2. 
 
The P2Y4 receptor, originally believed to be identical with the native 
pyrimidinoceptor, was cloned from human genomic DNA libraries (Communi et al., 
1995; Nguyen et al., 1995). The hP2Y4 is highly selective for UTP, whereas purine 
nucleotides (ATP, ADP) appeared to be either weak partial agonists or ineffective. 
Using purified ATP, Nicholas and co-workers reported that ATP is a full agonist at 
hP2Y4, although 50 times less potent than UTP (Nicholas et al., 1996a, 1996b; 
Harper et al., 1998). Recently, an orthologue (83 % identity) of the hP2Y4 has 
been cloned from a rat genomic library. When expressed in Xenopus oocytes, the 
pharmacological profile of rP2Y4 is consistent with P2U receptors, UTP and ATP 
were equipotent and equiactive agonists (Bogdanov et al., 1998b), as well as with 
that of the newly cloned turkey receptor tp2y (Boyer et al., 1997). The new form of 
P2U-like receptor represented by rP2Y4 can be distinguished from P2Y2 on the 
basis of agonist potency profiles (Nicholas et al., 1996a, 1996b), and antagonist 
profiles, in that rP2Y4 is blocked by RB2 but is not antagonised by suramin 
(Bogdanov et al., 1998b). Additional studies comparing human and rat P2Y4 
revealed that in contrast to previous observations, ATP acts as an antagonist 
displaying moderate potency at hP2Y4 receptors (Kennedy et al., 2000). Results 
obtained for the rat orthologue were confirmed, ATP and UTP, both being potent 
agonists, and extended to other nucleoside triphosphates including inosine 5'-tri-
phosphate (ITP), guanosine 5'-triphosphate (GTP), cytosine 5'-phosphate and 
xanthosine 5'-triphosphate (XTP), acting as rP2Y4 agonists, as well (Kennedy et 
al., 2000). Agonist action of those naturally occurring nucleoside triphosphates on 
tp2y (Boyer et al., 2000) as well as on xp2y (cloned from Xenopus laevis, 
sometimes referred to as p2y8) (Bogdanov et al., 1997) led to the suggestion that 
these receptors may represent species homologues of the mammalian 
P2Y4 receptor (Boeynaems et al., 2000; Boyer et al., 2000; Kennedy et al., 2000). 
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Species orthologues of the uridine nucleotide-preferring receptor P2Y6 have been 
cloned from rat and human (Chang et al., 1995; Communi et al., 1996). The 
human receptor is most potently activated by UDP, and to a lesser extent by UTP, 
ADP and 2-MeSATP, whereas ATP is only a weak partial agonist (Communi et al., 
1996). The more widespread distribution of the P2Y6 receptor, compared to the 
P2Y4 receptor, suggests that this receptor is more likely to account for 
endogenous uridine nucleotide-specific responses. 
 
The P2Y11 receptor cloned from human placenta, was shown to be coupled to the 
stimulation of both the phosphoinositide and adenylyl cyclase pathways and 
therefore being unique among the P2Y receptor subtypes cloned so far (Communi 
et al., 1997; Kennedy et al., 1999). P2Y11 receptors are potently activated by 
ATPS, BzATP, ATP and 2-MeSATP, while the dinucleotide derivatives ADP and 
2-MeSADP display very weak or, as well as UTP, UDP, AMP and adenosine no 
agonist activity at all (Communi et al., 1997). In a recent study, the ATP derivative 
AR-C67085 (2-propylthio-,-dichloromethylene-ATP, formerly FPL 67085, 
syn. ARL 67085), a potent inhibitor of ADP-induced platelet aggregation 
(Humphries et al., 1995a), was shown to be the most potent agonist at 
hP2Y11 receptors (Communi et al., 1999). Suramin and RB2 acted as antagonists, 
whereas PPADS was completely inactive at P2Y11 receptors expressed in 1321N1 
astrocytoma cells as well as in chinese hamster ovary cells (CHO-K1 cells) 
(Communi et al., 1999). It was concluded from the authors, that the 
pharmacological profile of the P2Y11 receptor is very similar to the cyclic 
AMP-coupled P2Y receptor mediating granulocytic differentiation of the HL-60 
promyelocytic leukaemia cells (Jiang et al., 1997; Conigrave et al., 1998) and that 
this receptor is likely to be of the P2Y11 subtype (Communi et al., 1999). 
 
Six additional G protein-coupled receptors have been proposed to be members of 
the P2Y receptor family. The p2y3 receptor is a P2Y receptor originally cloned 
from a chick brain cDNA library (Webb et al., 1996a). The relatively high amino 
acid sequence identity between the chick p2y3 and mammalian P2Y6 receptors 
(65 %) and their similar pharmacological profile, both being potently activated by 
UDP, indicate that the p2y3 is likely to be the avian homologue of the mammalian 
P2Y6 receptor (Li et al., 1998). 
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The proposed p2y5 receptor (Webb et al., 1996b) was originally cloned from 
activated chick T-lymphocytes as an orphan receptor designated 6H1 receptor 
(Kaplan et al., 1993), and the human p2y7 receptor was cloned from a human 
erythroleukemia cell line (Akbar et al., 1996). Both of these G protein-coupled 
receptors were suggested to be members of the P2Y receptor family largely on 
the basis of binding studies using [
35S]dATPS, which was subsequently shown 
not to be a general radioligand for P2Y receptors (Schachter and Harden, 1997). 
Moreover, these receptors exhibit predicted amino acid sequences that are only 
28  - 32 % identical to that of known P2Y receptors, and nucleotide-promoted 
second messenger signalling was not observed after expression of either of these 
G protein-coupled receptors (Herold et al., 1997; Li et al., 1997; Yokomizo et al., 
1997). The protein originally referred to as the p2y7 receptor has been recently 
reported to be a receptor for leukotrienes (Yokomizo et al., 1997). 
 
A P2Y receptor cloned from Xenopus neural plate, was shown to be activated 
equipotently by purine and pyrimidine nucleoside triphosphates and was 
tentatively named P2Y8 (Bogdanov et al., 1997). As a mammalian homologue of 
this receptor has not been identified, its inclusion as a distinct subtype of the 
P2Y receptor family does not seem appropriate. Recent studies, however, indicate 
that based on pharmacological data and a relatively high sequence identity, xp2y8 
might represent a species homologue of the mammalian P2Y4 (Boeynaems et al., 
2000; Boyer et al., 2000; Kennedy et al., 2000). 
 
Additionally, two sequences (P2Y9, P2Y10) related to the p2y5 receptor have been 
submitted to the GenBank/EMBL Data Bank. The P2Y9 sequence is identical to 
that recently published under the name p2y5-like (Janssens et al., 1997). 
However, as for the p2y5 receptor, there is no functional evidence that these 
proteins are nucleotide receptors (Janssens et al., 1997; Schachter and Harden, 
1997). 
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1.1.2.2.2.2. Native metabotropic P2 receptors 
 
Before the cloning of the first P2Y receptor cDNA's, agonist studies in mammalian 
tissues indicated that at least three separate metabotropic P2 receptor 
phenotypes exist (see 1.1.1., table 1.7.): G protein-coupled receptors activated 
preferentially by adenine nucleotides (P2Y, P2T, P2D), metabotropic P2 receptors 
activated preferentially by uridine nucleotides (pyrimidinoceptor) and receptors 
activated equally by adenine and uridine nucleotides (P2U). Some confusion in the 
literature was caused by the identification of P2U receptors (O'Connor et al., 
1991), because they were often loosely termed "pyrimidinoceptors" and separate 
identity of these and receptors activated preferentially by UTP or UDP (ATP being 
weakly active or inactive) was often indistinct (Seifert and Schultz, 1989; 
cf. 1.1.1.). 
 
P2Y receptors were originally identified as receptors that mediate relaxation of the 
GPTC and the longitudinal layer of the rabbit portal vein, and release of relaxing 
substances from rat and pig arterial endothelial cells (Burnstock and Kennedy, 
1985). Currently, the native P2Y receptor is characterised by a high agonistic 
potency of alkylthio-ATP derivatives (e.g. 2-MeSATP, 2-MeSADP) and adenosine 
phosphorothioates (ATPS, ADPS). ATP and ADP are usually equiactive, yet 
less potent than the above, while methylene-phosphonate ATP derivatives 
(,-mATP, ,-mATP) as well as pyrimidine nucleotides are either considerably 
less potent or inactive (Cusack, 1993; Abbrachio and Burnstock, 1994). 
P2Y receptor-mediated responses have been demonstrated in variety of tissues 
and cells (for review see: Dubyak and El-Motassim, 1993; Abbracchio and 
Burnstock, 1994; Boarder et al. 1995; Ralevic and Burnstock, 1998). At present, 
the correspondence between the recombinant P2Y1 receptor and the native 
P2Y receptor is controversial (Abbracchio and Burnstock, 1998; King et al., 1998). 
Moreover, a heterogeneity within pharmacologically characterised P2Y receptor-
mediated responses is still under discussion (see Ralevic and Burnstock, 1998; 
Lambrecht et al., 1999). Coupling of endogenous P2Y receptors to different signal 
transduction pathways, as described for the PLC-coupled P2Y receptors on turkey 
erythrocytes and AC-linked P2Y receptors present on rat C6-2B glioma cells 
(Boyer et al. 1994, 1996b), differences in the relative potencies of ATP and ADP 
(see Ralevic and Burnstock, 1998) and analogues of ATP (Fischer et al., 1993; 
Boyer et al., 1995) as well as differences in both, antagonistic properties and 
potency of PPADS on P2Y receptor-mediated responses (Boyer et al., 1994; 
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Ziganshin et al., 1994b; Windscheif et al., 1995; Ralevic and Burnstock, 1996; 
Schachter et al., 1996; Lambrecht et al., 1999) are in favour of a further 
subdivision of this receptor. The fact, that differences in agonist and antagonist 
potencies occur, even among the cloned orthologues of the P2Y1 receptor (Boyer 
et al., 1996a; see section 1.1.2.2.2.1.) may, on the other hand, account for these 
differences being determined by small structural variations as indicated by 
sequence homology of 83 % between tP2Y1 and hP2Y1 (Ayyanathan et al., 1996). 
However, a contribution of P2 receptors that have not yet been cloned to 
P2Y receptor-mediated responses in native tissues cannot be excluded. 
 
Native P2U receptors, mediating for example PGI2 release and endo-
thelial-dependent relaxation in a variety of vascular preparations and an increase 
in Cl
- secretion in human airway epithelia, were found to have no preference for 
either adenine- or uridine-triphosphates, with both ATP and UTP being equiactive 
agonists, UTPS and ATPS equally potent, while 2-MeSATP, ADPS, ,-mATP, 
ADP and UDP are significantly less potent or inactive (O'Connor et al., 1991; 
Cusack, 1993; Boarder et al., 1995; Ralevic and Burnstock, 1998; King et al., 
1998). As for P2Y1 receptors and endogenous P2Y receptors there is controversy 
about the P2Y2 receptor being the sole equivalent of the P2U receptor. The fact 
that P2U receptors are either sensitive or insensitive to suramin and PPADS (for 
review see Ralevic and Burnstock, 1998) may indicate that native P2U receptors 
which are equieffectively activated by UTP and ATP display a heterogeneous 
receptor population. In fact, comparing the agonist potencies for recombinant 
rP2Y2 and rP2Y4, UTP and ATP being equieffective, full agonists at both receptor 
subtypes, these receptors are two structurally distinct forms of the P2U receptor 
(Chen et al., 1996; Bogdanov et al., 1998b). Sensitivity to suramin, shown for the 
human orthologue of rP2Y2 and the fact that rP2Y4 is insensitive to suramin 
indicate, that P2U receptors can be differentiated by their susceptibility to 
blockade by suramin. 
 
In some tissues a native P2 receptor, believed to be a uridine nucleotide-selective 
receptor, could be distinguished from receptors activated by ATP (see 1.1.1., 
Seifert and Schultz, 1989; von Kügelgen and Starke, 1990). These receptors, 
termed pyrimidinoceptors, may represent a heterogeneous population as well. The 
P2 receptor in HL-60 cells is highly selective for UTP, UDP acts as a weak partial 
agonist, whereas the PLC-coupled P2 receptor in C6-2B rat glioma cells is highly 
39 1. Introduction and Aim of the Thesis 
selective for UDP, while UTP is much less potent (Lazarowski and Harden, 1994). 
Furthermore, a uridine nucleotide receptor activated by UTP and UDP but not by 
ATP has been described in neurons of the rat superior cervical ganglion (SCG) 
(Boehm et al., 1995; Connolly, 1995; Connolly and Harrison, 1995; von Kügelgen 
et al., 1997). Whether these receptors find their counterparts within the cloned 
uridine nucleotide-selective mammalian P2Y receptor subtypes (hP2Y4 and P2Y6) 
is far from clear (for review see: Ralevic and Burnstock, 1998; Communi et al., 
1998; King et al., 1998; Communi and Boeynaems, 1997). 
 
Exposure of platelets to ADP results in an increase in intracellular calcium, rapid 
calcium influx, PLC activation, and in an inhibition of stimulated AC. ADP causes 
platelets to change shape and activates fibrinogen receptors, leading to platelet 
aggregation (Hourani and Hall, 1994; Gachet et al., 1997; Kunapuli, 1998a, 
1998b). All the physiological and intracellular signalling events triggered by ADP in 
platelets were initially attributed to a single cell surface receptor, termed P2T 
(Gordon, 1986). Subsequently, the presence of P2X1 receptors on platelets 
(MacKenzie et al., 1996), and the identification of mRNA encoding for the 
P2Y1  receptor in platelets together with the observation, that ATP acts as an 
antagonist, when this P2Y1 receptor is expressed in Jurkat cells (Léon et al., 1997) 
led to the proposal of a two receptor model, in which P2Y1 receptors coupled to 
Gi, cause inhibition of AC, and the P2X1 receptor is the receptor mediating rapid 
calcium influx and shape change (Gachet et al., 1997). Based on the observation 
that 2-propylthio-d-,-difluoromethylene ATP (ARC 66096MX; formerly 
FPL 66096), a potent inhibitor of ADP-induced platelet aggregation (Humphries 
et al., 1994) blocks ADP-induced inhibition of AC, but fails to inhibit ADP-mediated 
intracellular calcium increases, a three receptor model was proposed (Daniel et 
al., 1998): one receptor coupled to inhibition of stimulated AC, designated P2TAC 
by the authors, alternatively termed P2YADP; a second receptor coupled to 
mobilisation of calcium from intracellular stores through activation of PLC and IP3 
formation, designated P2TPLC, identical with the P2Y1 receptor; and the third, an 
ionotropic P2X1 receptor mediating rapid calcium influx. Thus, the concept of the 
"P2T"  receptor was resolved into three P2 receptor subtypes (Hechler et al., 
1998b; Jin et al., 1998; Kunapuli et al., 1998a). Inhibition of platelet aggregation 
by the thienopyridine clopidogrel (Plavix
) was reported to be due to the blockade 
of P2TAC receptors (Hechler et al., 1998a) which seem to act in concert with the 
PLC-coupled P2Y1 receptors to mediate ADP-induced platelet aggregation (Jin et 
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al., 1998; Jin and Kunapuli, 1998; Kunapuli et al., 1998a). P2Y1 receptor activation 
causes a rapid and transient aggregation, whereas the extent of sustained 
aggregation seems to be determined by the level of P2TAC receptor occupancy 
(Boeynaems et al., 2000; Jarvis et al., 2000). The function of P2X1 receptors, 
mediating rapid entry of extracellular calcium, remains to be elucidated. 
 
Although the physiological function of the P2TAC has been extensively studied, the 
molecular identity of the Gi-linked receptor was elusive until very recently. 
Displaying only 19 % identity to the P2Y1 receptor and being most closely related 
to the UDP-glucose receptor (44 % identity) it is conceivable that many effort in 
cloning of the now termed P2Y12 receptor was without success. However, there is 
convincing evidence that the recently cloned P2Y12 receptor is equivalent to the 
P2TAC  receptor (Hollopeter et al., 2001). 
 
1.1.3.  P2 receptor ligands 
 
Despite the progress that has been made in the P2 receptor field by cloning and, 
as far as possible, pharmacological characterisation of recombinant P2X and 
P2Y  receptor subtypes, the development of selective ligands for this receptor 
class lags far behind most other receptor families. The cloned receptors became 
available for pharmacological studies only very recently and therefore 
structure-activity relationship (SAR) studies were performed most thoroughly in 
classical smooth muscle preparations. In many instances the selectivity and 
efficacy of a certain compound differed depending on the tissue used and the 
experimental protocol applied, thus providing a confusing picture for the 
development of SAR's for the various P2 receptor subtypes. Nevertheless, some 
principle suggestions of SAR's established for P2 receptor ligands which were 
based on studies on native smooth muscle P2X and P2Y receptors have been 
confirmed in recent studies using assays with apparently defined P2 receptor 
subtypes. 
 
1.1.3.1. Agonists 
 
With the exception of a novel series of recently described theobromine and 
theophylline analogues (Fischer et al., 1999b), all known agonist ligands for the 
P2  receptor family are essentially variations on the purine nucleotide 
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pharmacophore (figure 1.1.). Generally, ATP is the most potent native nucleotide 
at P2X receptors, whereas at various subtypes of P2Y receptors UTP, and/or ADP 
and UDP may serve as agonists (see 1.1.2.). Dozens of ATP analogues with 
modifications at the triphosphate, ribose 2' or 3', purine C-2 or C-8, or at the purine 
N
6 positions have been synthesised and their pharmacological profile reported in 
functional assays (for reviews see Cusack, 1993; Fischer et al., 1993; Burnstock 
et al., 1994; Jacobson and Suzuki, 1996; Jacobson et al., 1998a; Ralevic and 
Burnstock, 1998). In general, substitution at the C-2 position led to enhancement 
of potency, and modifications of the triphosphate group generated compounds 
displaying increased enzymatic stability. 
 
Triphosphate modifications 
 
Modification of the triphosphate group by replacement of the bridging oxygen 
atoms with methylene units or of the charged oxygen atoms with sulphur resulted 
in some cases in potent analogues having stability towards ecto-nucleotidases. 
,-mATP, in particular is noteworthy for its potency at native P2X receptors 
(Cusack, 1993; Burnstock et al., 1994) and its selectivity for recombinant 
homomeric P2X1 and P2X3 receptors as well as P2X2P2X3 and P2X1P2X5 
heteromers (Ralevic and Burnstock, 1998; Haines et al., 1999). To date, there is 
no evidence that ,-mATP activates P2Y receptors to any degree (Yu 
et al., 1999). 
 
Replacement of D-ribose by L-ribose in the group of methylenephosphonate 
analogues generates selective agonists for the P2X receptor family (Cusack, 
1993). One of these compounds, L-,-mATP, proved to be a useful agonist for 
the differentiation of P2X1 receptor-mediated responses from those elicited via 
other P2X receptor subtypes. It potently activates native smooth muscle P2X 
(Cusack, 1993; Trezise et al., 1995) and recombinant P2X1 receptors (Evans et 
al., 1995), but, in contrast, was found to be inactive at native ,-mATP-sensitive 
and ,-mATP-insensitive P2X receptors in neuronal preparations (Evans et al., 
1995; Trezise et al., 1995; Rae et al., 1998) as well as at recombinant P2X2 
(Evans et al., 1995) and P2X4 receptors (Buell et al., 1996b). Furthermore, 
L-,-mATP is inactive on P2Y receptors mediating relaxation of GPTC and on 
native and recombinant P2Y receptors present in chick brain (Hourani et al., 1985; 
Cusack, 1993; Simon et al., 1995). 
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A thio-substitution at the terminal phosphate also provides stability to 
ecto-nucleotidases activity (Cusack, 1993), leading to such analogues as ATPS 
and ADPS, both of which have been explored as radioligands for P2 receptors. 
ATPS is a potent agonist at recombinant homomeric P2X1-6, heteromeric 
P2X2P2X3, and P2X1P2X5 receptors (Collo et al., 1996; Bianchi et al., 1999; 
Haines et al., 1999) as well as at recombinant P2Y1, P2Y2 and P2Y11 receptors 
(Erb et al., 1993; Schachter et al., 1996; Sromek and Harden, 1998; Communi et 
al., 1999). It is only weakly active at P2X7 receptors (Bianchi et al., 1999), and acts 
as a weak partial agonist at P2Y4 and P2Y6 receptors (Chang et al., 1995; 
Bogdanov et al., 1998b). ATPS is almost equipotent to ATP in eliciting relaxation 
of GPTC and IP3 formation in turkey erythrocyte membranes both mediated via 
P2Y receptors, and is more potent than ATP at P2X receptors present in 
guinea-pig urinary bladder and vas deferens (Burnstock et al., 1994). The 
phosphorothioate compound ADPS displayed preference for the P2Y receptor 
subtype in functional experiments, being markedly more potent than ATP and 
ADP in the turkey erythrocyte model (Burnstock et al., 1994) and equipotent to 
ATP in eliciting relaxation of GPTC as well as contraction of guinea-pig vas 
deferens and urinary bladder (Cusack, 1993; Burnstock et al., 1994). It is more 
potent than ATP at recombinant hP2Y1, tP2Y1 (Filtz et al., 1994; Schachter et al., 
1996), at the P2Y receptor coupled to inhibition of AC in rat C6-2B glioma cells 
(Filtz et al., 1994), displayed partial agonistic activity at the recombinant 
rP2Y6 receptor and is a full agonist at its avian orthologue, the chick p2y3 receptor 
(Chang et al., 1995; Li et al., 1998). At recombinant P2Y11 receptors ATP is 
slightly more potent than ADPS (Communi et al., 1999). Agonistic action of 
ADPS was also described at recombinant hP2X1, hP2X3 and rP2X3 as well as at 
hP2X4 receptors, although in comparison to ATP, its potency was at least 10 times 
lower (Bianchi et al., 1999). ADPS was shown to be inactive as an agonist at 
recombinant hP2X4 and hP2X7 monomers, the P2X2P2X3 heteromer (Bianchi et 
al., 1999), recombinant tp2y  receptors (Boyer et al., 1997), and native 
P2U receptors mediating activation of human neutrophils (Cusack, 1993). 
 
Uri et al. (1994) reported that various negatively charged amino acid derivatives of 
adenosine (at the 5'-hydroxyl groups) acted as weak agonists at the PLC-linked 
P2 receptors on C6-2B glioma cells, demonstrating that the triphosphate group 
could be replaced by a non-phosphate moiety. 
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Ribose modifications 
 
The potency and selectivity of nucleotide analogues are highly dependent on the 
2'- and 3'-ribose substituents (Burnstock et al., 1994; Martin et al., 1995). 
Generally, removal of either free hydroxyl group resulted in a decrease in potency 
for P2Y receptors, with the exception of 3'-amino-3'-deoxy ATP which was more 
potent than ATP at P2Y receptors in turkey erythrocytes. Activities at 
P2X receptors decreased or remained unchanged by ribose substitutions, except 
for 3'-benzylamino-3'-deoxy ATP, which was markedly more potent than ATP in 
guinea-pig vas deferens and urinary bladder and either inactive or a weak agonist 
in P2Y-systems, thereby displaying selectivity for native P2X receptors (Burnstock 
et al., 1994). Bulky ether substituents placed at the 2'-position of ,-mATP greatly 
diminished activity, whereas a p-methoxybenzyl ether at the 3'-position, resulted in 
the same potency and efficacy as ,-mATP at P2X receptors (Martin et al., 1995). 
As described for L-,-mATP, replacement of the D-ribose by L-ribose can 
generate agonists selective for the P2X receptor subtype present in smooth 
muscle. 
 
Adenine modifications 
 
Numerous nucleotides related to either ATP or ,-mATP but modified on the 
adenine base have been synthesised. These include substitutions at the purine 
C-2 position, at the exocyclic N
6 position, and at the C-8 position. 
 
2-MeSATP is a highly potent P2 receptor agonist. Previously, it was thought to be 
selective for P2Y receptors; however, its relatively weak activity at native 
P2X receptors was later shown to be due to its breakdown by ecto-nucleotidases 
(Kennedy and Leff, 1995). Besides its agonistic action at several P2 receptor 
subtypes in tissue preparations, 2-MeSATP is equipotent to ATP at recombinant 
P2X1-3 and slightly less potent than ATP at recombinant P2X4 homomers, as well 
as at the P2X2P2X3 heteromer (Bianchi et al., 1999). Activation of members of the 
P2Y receptor family was reported for P2Y1 (see comments in 1.1.2.2.2.1.), P2Y6 
(Chang et al., 1995) and P2Y11 (Communi et al., 1999), and rP2Y4 receptors 
(Bogdanov et al., 1998b). In contrast, 2-MeSATP was found to be inactive at 
human P2Y4 (Communi et al., 1995) and mouse and human P2Y2 receptors 
(Lustig et al., 1993; Lazarowski et al., 1995). Congeners of 2-MeSATP were 
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synthesised as probes for P2 receptors (Fischer et al., 1993). Chain elongation at 
this site preserved high potency at P2Y receptors, thus proving that this position 
within the receptor protein has tolerance for structural variations of the ligand 
(Fischer et al., 1993). The addition of a thioether chain at the 2-position increased 
potency not only for 5'-triphosphate derivatives but also for di- and mono-
phosphates. Those monophosphate analogues had considerable agonistic 
potencies at the turkey erythrocyte P2Y receptor and the AC-linked P2Y receptor 
present in C6-2B glioma cells, at which AMP itself is inactive. However, those 
derivatives were generally several orders of magnitude less potent than their 
corresponding 2-thioether triphosphates (Fischer et al., 1993; Boyer et al., 1996b). 
A further benefit of the presence of a long chain thioether group at the 2-position 
is the increased stability of the triphosphate group at the 5'-position (Zimmet et al., 
1993; Fischer et al., 1999a). Recently, a series of 2-thioether 5'-O-(1-thio-
triphosphate) adenosine derivatives have been introduced as P2Y1 receptor 
agonists, the 2-hexylthio-ATPS isomers displayed apparent affinities in the 
nanomolar range and increased stability towards ecto-nucleotidases (Fischer et 
al., 1999a). 
 
In general, modifications of the ATP purine nucleus at the C-8 or N
6 position were 
not well-tolerated by smooth muscle P2X receptors as well as native 
P2Y receptors. 8-Bromo ATP, which was originally claimed to be active at urinary 
bladder P2X receptors (Welford et al., 1987), was inactive at vas deferens and at 
vascular P2Y receptors (Burnstock et al., 1994). However, N
6-methyl ATP was 
equipotent to ATP at GPTC P2Y receptors and inactive in vascular smooth muscle 
and P2X preparations (Fischer et al., 1993). The N
6 position does not 
accommodate as wide a range of substituents as does the 2-position. 
Substituents larger than methyl as well as substitution at the N
6 position with 
dimethyl abolished potency at P2X as well as P2Y receptors (Burnstock et al., 
1994; Boyer et al., 1996b). 
 
 
 
 
 
 
Fig. 1.1.  Chemical structure of principle P2 receptor agonists (see page 46). 
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1.1.3.2. Antagonists 
 
Almost all P2 receptor antagonists, including suramin (figure 1.5.), PPADS and 
RB2 (figure 1.2.), share a common polyaromatic, polysulphonated skeleton. Most 
of these antagonists have suffered from a serious lack of specificity for the 
P2  receptor family, selectivity for certain P2 receptor subtypes and potency in 
blocking P2 receptor-mediated responses. 
 
Histochemical dyes 
 
Among the histochemical dyes displaying P2 receptor-blocking properties are 
evans blue, RB2, trypan blue and reactive red 2 (figure 1.2.). Evans blue and 
trypan blue differ only in the position of the sulphonate residues at the 
naphthalene rings. Both compounds were found to be relatively potent antagonists 
at the P2X  receptor subtype present in ratVD (Bültmann and Starke, 1993; 
Bültmann et al., 1994; Khakh et al., 1994). However, they display different 
selectivities in terms of ecto-nucleotidases inhibition and inhibition of 
P2Y receptor-mediated relaxation of GPTC; evans blue being a potent inhibitor of 
ATP breakdown in vas deferens tissue, and trypan blue, in contrast, more 
effective in blocking P2Y receptors present in GPTC (Bültmann et al., 1995; 
Bültmann et al., 1996a). SAR studies performed with a series of evans blue and 
trypan blue derivatives confirmed the importance of the substitution pattern of the 
naphthalene rings for the antagonistic potency of trypan blue derivatives at GPTC 
P2Y receptors as well as for the selectivity of evans blue derivatives for ratVD 
P2X receptors (Wittenburg et al., 1996). 
 
Reactive red 2 was introduced as a highly potent competitive, slightly 
P2Y receptor-selective (GPTC) antagonist. However, potent but non-competitive 
antagonism at ratVD P2X receptors as well as its property to potently inhibit ATP 
breakdown in ratVD limit its usefulness (Bültmann and Starke, 1995). RB2 (syn. 
basilen blue E-3G), which is a mixture of meta- and para-sulphonic acid isomers 
(and cibacron blue 3GA the respective ortho-isomer) was reported to act as a 
potent competitive P2Y antagonist in particular at the AC-coupled P2Y receptors 
of C6-2B glioma cells (Boyer et al., 1994). Among the recombinant receptors 
P2X1, P2X2 and P2X4, as well as P2Y1, p2y3, P2Y4, P2Y6 and P2Y11 have been 
shown to be sensitive to either cibacron blue 3GA or RB2 (Brake et al., 1994; 
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Simon et al., 1995; Chang et al., 1995; Communi et al., 1996, 1999; Michel et al., 
1996; Seguéla et al., 1996; Webb et al., 1996a). Although both compounds were 
often considered as P2Y-selective antagonists, studying the effect of a series of 
RB2 derivatives Tuluc and colleagues (1998) reported them to be equipotent 
antagonists at ratVD P2X and GPTC P2Y receptors. 
 
The anion transport inhibitor 4,4'-diisothiocyanatostilbene-2,2'-disulphonate (DIDS; 
figure 1.2.) was initially used to block P2Z receptor-mediated responses, and was 
subsequently shown to act as a non-competitive, slowly reversible antagonist 
selective for ratVD P2X receptors versus GPTC P2Y receptors, and to inhibit ATP 
breakdown by ecto-nucleotidases present in ratVD (Bültmann and Starke, 1994a; 
Bültmann et al., 1996b). DIDS discriminates between subtypes of recombinant 
P2X receptors, being a potent inhibitor at rat P2X1 receptors, but 100-fold less 
effective P2X2 receptors (Evans et al., 1995). Evaluation of a series of DIDS 
analogues revealed that the isothiocyanato residues, which may react with amines 
to form thioureas, are essential for the interaction of these compounds with 
P2 receptors (Bültmann et al., 1996b). None of the smaller derivatives was more 
potent than the parent compound in blocking ratVD P2X receptors, moreover, 
some structural variations led to a loss of selectivity for the P2X receptor subtype 
(Bültmann et al., 1996b). 
 
Pyridoxal phosphate derivatives 
 
A diazo derivative of the coenzyme pyridoxal phosphate, PPADS (figure 1.2.), 
which was shown to be an antagonist at rabbit vas deferens P2X receptors and 
therefore introduced as P2X-selective compound, is one of the most important 
and most commonly used P2 receptor antagonists (Lambrecht et al., 1992; for 
review see Lambrecht, 2000). PPADS has been examined in a wide range of 
tissues (Lambrecht, 1996; Lambrecht et al., 1996a) and cells, displaying inhibitory 
potency at recombinant homomeric P2X1, P2X2, P2X3 and P2X5, heteromeric 
P2X2P2X3 and P2X1P2X5 and P2Y1 receptors, but being weak or ineffective at 
homomeric P2X4, P2X6 and P2X7, heteromeric P2X4P2X6 and P2Y2, P2Y4, P2Y6 
and P2Y11 (Lewis et al., 1995; Soto et al., 1997; Harden et al., 1998b; Lê et al., 
1998; Ralevic and Burnstock, 1998; Communi et al., 1999). On the basis of these 
observations, the original characterisation of PPADS as a selective antagonist for 
smooth muscle P2X receptors has to be discarded, however, it is still a very useful 
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tool for P2 receptor characterisation, in being selective for certain P2X receptor 
subtypes as well as for the P2Y1 receptor. The applicability of PPADS, when used 
at concentrations  10 M is limited by some non-P2 receptor actions; as 
described for other P2 receptor antagonists, ATP breakdown is inhibited by 
PPADS (Windscheif et al., 1995; Heine et al., 1999; Lambrecht et al., 2000b). 
Moreover, antagonistic effects of PPADS (100 M) have been reported at 
5-HT3  receptors and at nicotinic receptors (Hussy et al., 1994; Khakh et al., 
1995a). The pseudo-irreversible nature of antagonism displayed by PPADS at 
native P2X receptors present in several smooth muscle preparations, including the 
rabbit, guinea-pig and rat vas deferens (Lambrecht et al., 1992, 1996a, 2000b) 
and rat mesenteric arterial bed (Windscheif et al., 1994) as well as the slow 
reversibility of its blocking effects on recombinant P2X1, P2X2 and P2X5 receptors 
introduce further restraints (Evans et al., 1995; Collo et al., 1996). 
 
An isomer of PPADS, pyridoxalphosphate-6-azophenyl-2',5'-disulphonic acid 
(iso PPADS), was shown to be a slowly-equilibrating and slowly-reversible P2X 
antagonist with potency almost similar to PPADS. Pyridoxalphosphate itself, is a 
non-selective P2 receptor antagonist, being about 10-fold less potent than PPADS 
(Lambrecht et al., 1996a; Ralevic and Burnstock, 1998). 
 
Of the numerous PPADS analogues investigated so far (Windscheif et al., 1995; 
Lambrecht et al., 1996a; Jacobson et al., 1998b; Kim et al., 1998; Kim et al., 
2001), two derivatives, cyclic pyridoxine-
4,5-monophosphate-6-phenylazo-
2',5'-disulphonate (MRS 2220; figure  1.2.) and pyridoxal-5'-phosphate-6-
(2'-naphthylazo-6'-nitro-4',8'-disulphonate) (PPNDS; figure 1.2.) exhibit 
advantages both in terms of subtype selectivity, and PPNDS also in terms of 
antagonistic potency. MRS 2220 was reported to act as a reversible and 
surmountable antagonist at recombinant P2X1 receptors, being 5-fold less potent 
at recombinant P2X3, and without effect at P2X2, P2X4 and P2Y1,2,4,6 (Jacobson et 
al., 1998b). However, the P2X1 receptor-blocking potency of MRS 2220 is 100-fold 
less compared to PPADS. MRS 2220 is particularly interesting because it is the 
first PPADS analogue that, although lacking the aldehyde group, preserved the 
P2X receptor-blocking potency. Thus, the Schiff's base formation (Buell et al., 
1996b) between ligand and receptor is not necessarily required for recognition of 
pyridoxalphosphate derivatives. 
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The naphthylazo derivative PPNDS was found to be more potent than PPADS at 
native P2X receptors in ratVD as well as at recombinant P2X1 receptors 
(Lambrecht et al., 2000c). PPNDS was shown to act as a specific, and 
P2X1 receptor-selective antagonist, being markedly less potent at P2Y receptors 
of GPI, exhibiting only weak inhibitory potency on ecto-nucleotidases, and being 
without significant effects on several receptor classes, including 1A, A1, A2B, H1, 
and M3 (Lambrecht et al., 2000c). 
 
The heteromeric bivalent ligand 6-[(4,6,8-trisulpho-1-naphthyl)iminocarbonyl-1,3-
(4-methylphenylene)- iminocarbonyl-1,3- phenylene-azo] -pyridoxal-5'-phosphate 
(SB9; figure 1.2.) comprising pyridoxal-5'-phosphate, a diazo group as spacer and 
as second pharmacophore, the monomer of suramin, has been found to be a 
potent antagonist selective for P2Y receptors present in guinea-pig ileal smooth 
muscle preparation (Lambrecht et al., 2000b). Inhibitory potency of SB9 at rat vas 
deferens P2X receptors is about 10-fold lower. Therefore, the compound displays 
unique properties among the pyridoxal-5'-phosphate and suramin analogues 
reported to date, which are either non-selective P2 or P2X receptor-preferring 
antagonists (Lambrecht et al., 2000b). 
 
Nucleotide derivatives 
 
Trinitrophenyl (TNP) -substituted nucleotides have been introduced as potent 
antagonists, displaying selectivity for homomeric P2X1, P2X3 and heteromeric 
P2X2P2X3 receptors (Virginio et al., 1998). TNP-ATP (figure 1.2.) was reported to 
be markedly less effective as an antagonist in cells expressing homomeric P2X2, 
P2X4, or P2X7 receptors, however, effects of the TNP-nucleotides on P2Y receptor 
subtypes as well as on other receptor classes have not been examined, so far. 
When CRC's were constructed using either ATP or ,-mATP as agonist in cells 
expressing P2X3 receptors the antagonism of TNP-ATP was insurmountable, 
indicating that the compound acts as non-competitive probably allosteric 
antagonist (Virginio et al, 1998). Non-competitive antagonism was also observed 
for TNP-ATP at rat mesenteric artery P2X receptors. Surprisingly, compared to 
results obtained from the dissociated smooth muscle cells, the potency of 
TNP-ATP was markedly reduced in the whole tissue experiments. (Lewis et al., 
1998). This might reflect the breakdown of TNP-ATP by ecto-nucleotidases; as 
shown in the original study, the breakdown product TNP-adenosine was without 
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any effect on P2X receptors (Virginio et al., 1998). Thus, although TNP-ATP is a 
potent antagonist, it is of limited use in whole tissue assays. 
 
Diinosine pentaphosphate (Ip5I) is a potent antagonist of the tentative P4 receptor 
present in rat brain synaptic terminals (Pintor et al., 1999). Antagonistic properties 
of Ip5I at guinea-pig vas deferens P2X receptors have also been reported. 
Furthermore, Ip5I was found to be ineffective at GPTC P2Y receptors, as well as 
at P1 receptors mediating negative inotropy of the guinea-pig driven left atrium 
(Hoyle et al., 1997). Recently, effects of diinosine polyphosphates were studied at 
recombinant P2X1-4 receptors. Ip5I was found to be a potent P2X1 re-
ceptor-selective antagonist, displaying moderate inhibitory potency at 
P2X3 receptors, being ineffective at P2X2 and potentiating agonist responses at 
P2X4 receptors (King et al., 1999). The higher potency of Ip5I at recombinant P2X1 
compared to native guinea-pig vas deferens P2X receptors is probably due to 
breakdown of Ip5I by ecto-nucleotidases present in the tissue preparation. 
 
P2T (P2Y12) receptor antagonists as inhibitors of ADP-induced platelet 
aggregation are of special interest. As, in contrast to most other P2 receptor 
subtypes, ATP acts as an antagonist at these receptors it seemed likely that 
modifications of the nucleotide pharmacophore might generate potent and 
selective P2T receptor antagonists. AR-C66096MX (formerly FPL-66096) and its 
dichloro analogue, 2-propylthio-D-,-dichloromethylene ATP (AR-C67085MX) 
were introduced, displaying high potency in blocking P2T receptor-mediated 
ADP-induced platelet aggregation and some 30.000-fold selectivity over native 
P2X or P2Y receptors (Humphries et al., 1994, 1995b). SAR studies generated 
2-(3,3,3-trifluoropropylthio)-N
6-methylthioethyl-D-,-dichloromethylene ATP 
(AR-C69931MX). This compound exhibits enhanced potency and stability and is 
currently in phase II of clinical development (Ingall et al., 1999). SAR rules that 
can be derived from the large number of compounds evaluated are somehow 
similar to those established for nucleotide analogues being agonists at the other 
P2 receptor subtypes: introduction of substituents at C-8 reduces potency, 
replacement of the hydrogen C-2 increases potency, S-propyl being ideal, 
replacement of the terminal anhydride oxygen in the phosphate chain with 
,-dihalomethylene enhances enzymatic stability, and monoalkylation of N
6 of the 
adenine with lipophilic substituents augments potency, in contrast to dialkylation 
which markedly reduces potency (Ingall et al., 1999). 
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Recently, a series of adenine nucleotide derivatives in which the 3'-hydroxyl group 
is replaced by phosphate, including adenosine-3'-phosphate-5'-phosphosulphate 
(A3P5PS; figure 1.2.), adenosine-3'-phosphate-5' phosphate (A3P5P) and 
adenosine-2'-phosphate-5' phosphate (A2P5P), has been introduced and 
proposed to act as competitive antagonists/partial agonists at the turkey 
erythrocyte P2Y receptors; A3P5PS and A3P5P were devoid of agonist action at 
the recombinant hP2Y1 receptor (Boyer et al., 1996a). The effects of these 2'- and 
3'-phosphate analogues were claimed to be selective for the PLC-coupled 
P2Y1 receptor, because no agonistic or antagonistic effects on the AC-coupled 
P2Y receptor of C6-2B glioma cells or on P2Y2,4,6 receptors stably expressed in 
1321N1 human astrocytoma cells, respectively, were observed (Boyer et al., 
1996a). However, further studies on the selectivity and stability of A3P5PS 
indicated that its usefulness as an antagonist in intact tissues might be limited. It 
was degraded by ecto-nucleotidases present in ratVD, the only detectable 
breakdown product being A3P5P (Park et al., 1998). In addition, it was shown to 
activate  ,-mATP-sensitive receptors present in GPTC as well as to induce 
P2Y  receptor-mediated relaxation of the rat duodenum (Bültmann et al., 1998; 
Park et al., 1998). Antagonistic effects of A3P5PS were observed in human 
platelets, inhibiting ADP-induced platelet aggregation and shape change (Park et 
al., 1998) and in GPTC (inhibition of relaxation induced by either ADPS, 
,-mATP or noradrenaline) and ratVD (inhibition of contraction induced by 
,-mATP) (Bültmann et al., 1998). 
 
Of the numerous structural analogues of A3P5P that have been synthesised so 
far some SAR's can be derived for nucleotide analogues displaying agonist as well 
as antagonistic activity at the P2Y1 receptor subtype. N
6-Methyl-2'-deoxy-adeno-
sine-3',5'-biphosphate (MRS 2179; figure 1.2.) was found to be about 10-fold more 
potent as an antagonist than A3P5P and without the partial agonistic activity 
displayed by the parent compound (Camaioni et al., 1998). Therefore it was 
concluded, that alkylation of the exocyclic amine (methyl- and ethyl substituents 
are tolerated) is critical for the biological effects of deoxyadenosine biphosphate 
derivatives, and crucial for pure antagonistic activity (Camaioni et al., 1998). 
Recently, MRS 2179 was shown to be P2Y1-selective within the P2Y receptor 
family, displaying neither agonist nor antagonist activity at P2Y2,4,6, the AC-linked 
P2Y receptor of C6-2B glioma cells, as well as the tp2y subtype (Nandanan et al., 
2000). However, its selectivity for the P2Y1 receptor is not absolute, since 
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MRS 2179 was reported to show considerable antagonistic activities at P2X1 and 
P2X3 receptors, but not at P2X2 and P2X4 receptors (Nandanan et al., 2000). 
Further structural variations reflect the ribose moiety which can be substituted by 
several carbocyclic ring systems (Nandanan et al., 1999, 2000) or even with 
acyclic aliphatic as well as aromatic chains (Kim et al., 2000) without a total loss of 
affinity. The balance of agonist versus antagonist properties is highly dependent 
on ribose modifications, particularly at the 2'-position as substitution generally 
appears to increase the degree of agonism (Nandanan et al., 1999). The 
5'-phosphate group seems to be critical for P2Y1 receptor recognition (Camaioni et 
al., 1998). 2-Alkylthio-substituted analogues display enhanced agonist properties, 
the 2-Cl derivative of MRS 2179, however, was shown to be slightly more potent 
as an antagonist at tP2Y1 (Nandanan et al., 1999). Substituents at the 8-position 
of the adenine base generally lead to compounds with decreased P2Y1 receptor 
affinity (Camaioni et al., 1998; Nandanan et al., 1999). 
 
A novel type of P2Y1 receptor antagonists has been introduced recently. Those 
compounds were synthesised by coupling via a carbonyl linker the adenosine 
5'-hydroxyl group to an oligo-aspartate chain. The compounds were reported to 
act as antagonists at hP2Y1 receptors expressed in 1321N1 human astrocytoma 
cells, one derivative termed AdoOC(O)Asp2 displayed P2Y1 receptor-blocking 
potency comparable to A3P5P (Sak et al., 2000). The observation that the 
phosphate chain can be exchanged by negatively charged peptide fragments is 
considerably important, because those compounds might be devoid of side effects 
such as inhibition of ATP-degrading enzymes as well as themselves being 
resistant to breakdown by ecto-nucleotidases. 
 
 
 
 
 
 
 
 
 
Fig. 1.2.  Chemical structure of principle P2 receptor antagonists (see 
pages 54, 55). 
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1.1.4.  Suramin and derivatives 
 
1.1.4.1.  Non-P2 receptor activity 
 
Suramin (synonym: antrypol, Bayer 205, Belganyl, Fourneau 309, Germanin, 
Moranyl, Naganin, Naganol, Naphuride; figure 1.5.) was originally synthesised in 
the beginning of the last century by german workers at Farbenfabriken Bayer AG 
among a series of approximately 2000 compounds that were tested for 
trypanocidal activity. Since the 1920s the compound has been widely used for the 
prophylaxis and treatment of early stages of human trypanosomiasis and is still in 
use for the latter purpose. Van Hoof et al. (1947) observed that congolese patients 
suffering from trypanosomiasis and onchocerciasis were cured of both diseases 
following treatment with suramin. To date, suramin remains the only generally 
available macrofilaricide effective against Onchocerca volvulus (the causative 
agent of river blindness) (for review see Hawking, 1978; Goa et al., 1991). 
 
Due to the finding that suramin is a competitive inhibitor of retroviral reverse 
transcriptase (De Clercq, 1979), the RNA-directed DNA polymerase of 
retroviruses, and, the subsequent demonstration that suramin can block the 
infectivity and cytopathic effect of the human immunodeficiency virus (HIV) in vitro 
(Mitsuya et al., 1984), research on suramin has gained considerable impetus. The 
antiviral action of suramin against a number of other viruses, including the 
hepatitis B virus, has been tested. However, as established for the treatment of 
acquired immunodeficiency syndrome (AIDS) it's toxic side effects in addition to a 
low level of clinical activity limited the usefulness of suramin in the treatment of 
chronic active hepatitis (Cheson et al., 1987; Loke et al., 1987). 
 
The adrenal toxicity found in patients suffering from AIDS and treated with 
suramin suggested that this drug might be useful for the treatment of diseases 
associated with adrenocortical hyperfunction, such as adrenal carcinoma and 
Cushing's syndrome (Stein et al., 1989). Solid tumours noticeably regressed under 
suramin therapy in patients with adrenocortical carcinoma, nodular lymphoma and 
stage D prostate cancer refractory to conventional hormonal manipulation. 
However, mechanisms underlying suramin's antitumour activity are incompletely 
understood and are probably multiple (for review see Baghdiguian and Fantini, 
1997). Besides the inhibition of steroid hormone production, suramin's 
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interference with the recognition of a number of growth factors by their membrane 
receptors as well as inhibition of angiogenesis (Pesenti et al., 1992) may account 
for the observed antineoplastic effects of suramin. Additionally, the ability of 
suramin to bind to plasma proteins and thereby inhibiting the synthesis and/or 
activity of several protein and enzyme systems, including DNA polymerases, 
complement, and adenosine triphosphate might explain another facet of suramin's 
antitumour activity (for review see La Rocca et al. 1990). 
 
Among the targets suramin exerts its diverse biological effects are the G protein 
-subunits. Butler et al. (1988) characterised suramin as an inhibitor of 
receptor-G protein-coupling in membranes. Subsequently, three distinct effects of 
suramin on G-subunits were established: first, suramin and suramin analogues 
(submicromolar to micromolar concentration range) suppress the rate of 
spontaneous GDP-release from purified G protein  subunits (i.e. suramin inhibits 
the guanine nucleotide exchange reaction, and is -by definition- a direct G protein 
inhibitor), second, the effect of suramin on GDP-release is reversed upon addition 
of an effector, indicating that the binding of an effector and of suramin are 
mutually exclusive and third, suramin and suramin analogues disrupt ternary 
complex formation (of agonist-receptor-G-protein). The antagonistic activity of 
suramin is attributed to its polyanionic nature, but because of its many negative 
charges it is unlikely to permeate readily the plasma membrane. Therefore and 
with regard on its many pharmacological actions suramin can only be considered 
as a lead in the search of more selective G protein inhibitors (Freissmuth et al., 
1996; Hohenegger et al., 1998; for review see Höller et al., 1999). 
 
As far as other receptors than P2 are concerned, antagonistic action of suramin 
has been described for GABA and NMDA receptors, respectively (Nakazawa et 
al., 1995). 
 
1.1.4.1.1. Structure-activity  relationships 
 
Since the structure of suramin was established by Fourneau et al. (1924), a large 
series of analogues has been prepared. It has been known for many years that 
small variation in the structure of the suramin molecule considerably reduced the 
trypanocidal activity. For example NF037 (see figure 3.11.), in which the two 
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methyl groups of suramin are replaced by two hydrogens, displays only 5 % of the 
trypanocidal activity of suramin (Fourneau et al., 1924). 
 
In contrast, inhibition of HIV-1 reverse transcriptase is much less sensitive to 
structural modification and structure-activity relationships are completely different 
from those of its trypanocidal or antifilarial activity (Jentsch et al., 1987). Braddock 
et al. (1994) found an absolute requirement of intervening rings between the 
substituted naphthyl rings but failed to reveal clear SAR's pertaining to the 
substitution pattern of the naphthyl rings testing the inhibitory potencies of 
suramin-derived compounds on the fibroblast growth factor (bFGF). 
 
SAR's concerning the inhibitory properties of suramin and its analogues on 
G protein -subunits are complicated because of the existence of a large number 
of different G protein  subunits (more than 20 individual proteins) and the fact 
that the ability of suramin and of its analogues to disrupt 
receptor-G protein-coupling is highly dependent on the nature of the receptor-G 
protein tandem investigated; e.g. suramin is 10-fold more potent than its 
di-demethylated derivative NF037 in uncoupling the adenosine A1 receptor, but 
the two compounds are equipotent in uncoupling the dopamine D2 receptor, 
although both receptors interact with the same G protein subfamily (Beindl et al., 
1996; for review see Freissmuth et al., 1999). 
 
1.1.4.2.  Suramin and suramin-derivatives: P2 receptor antagonism 
 
Dunn and Blakeley (1988) were the first to show that suramin (figure 1.5.) 
antagonises P2X receptor-mediated effects. In many studies, suramin has since 
been found to be a non-selective antagonist at native P2X and P2Y receptors 
(Ralevic and Burnstock, 1998), with relatively low potency (pA2 values 
approximately 5). Antagonism by suramin is often non-competitive. However, on 
P2X receptors present in rabbit isolated ear artery suramin was found to be a 
slowly-equilibrating but competitive antagonist (Leff et al., 1990). Furthermore, 
suramin inhibits ecto-nucleotidases (Crack et al., 1994; Beukers et al., 1995; 
Ziganshin et al., 1995; Bültmann et al., 1996c; Heine et al., 1999; Damer et al., 
1998; see 1.1.5.7.), an ability which may complicate interpretation of its 
antagonistic activity when it is used against ligands which are biologically unstable 
(Crack et al., 1994). 
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Of the recombinant receptors, suramin was shown to block homomeric P2X1 
(IC50  1 M), P2X2 (IC50   5 M), P2X3 (IC50   3 M), P2X5 (30 M, 94  % 
inhibition), and P2X7 receptors (IC50  60 M), and to be a weak antagonist at rat 
P2X4 receptors (Collo et al., 1996; Ralevic and Burnstock, 1998; Jones et al., 
2000; Guile et al., 2001). Moreover, antagonism of suramin was reported at 
heteromeric P2X2P2X3 (IC50   6 M), P2X2P2X6 (IC50   6 M) as well as 
P2X1P2X5 receptors (IC50  2 M) whereas at heteromeric P2X4P2X6 receptors 
suramin is only a poor antagonist as could be expected from its weak activity at 
the respective homomeric receptors (Lê et al., 1998; Bianchi et al., 1999; Haines 
et al., 1999; King et al., 2000). Among the recombinant P2Y receptor subtypes, 
P2Y1, p2y3 and P2Y11 receptors were shown to be blocked by suramin 
(pA2  values between 5 and  6); it also antagonises P2Y2 receptor-mediated 
responses, but with an about 10 times lower affinity than that found at the P2Y1 
receptor subtype (von  Kügelgen and Wetter, 2000). Suramin is inactive at 
recombinant hP2Y4 and only weakly active at rP2Y4 and P2Y6 orthologues (see 
von Kügelgen and Wetter,  2000). Additionally, suramin (100 M) has been 
demonstrated to abolish p2y8  receptor-mediated responses (Bogdanov et al., 
1997). Regarding its antagonistic profile, suramin cannot be considered to be 
selective for any particular P2 receptor subtype. However, it proved to be a useful 
tool to differentiate among the recombinant P2X receptor subtypes (see 
1.1.2.2.1.1.; table 1.2.; Humphrey et al., 1998) as well as to discriminate between 
P2Y2 and P2Y4 receptor-mediated responses (King et al., 1998). Moreover, 
suramin represents the structural lead for a number of compounds that have been 
analysed for their potentially P2 receptor blocking abilities. 
 
Particularly one derivative, the symmetrical 3'-urea of 8-(benzamido)naphthalene-
1,3,5-trisulphonate (NF023; Fig. 3.15.) was found to be a highly specific 
P2  receptor antagonist displaying selectivity for native P2X1-like receptors in 
certain vascular and visceral smooth muscle preparations (pA2 = 5.5 - 6.0; 
Bültmann et al., 1996c; Lambrecht, 1996; Lambrecht et al., 1996a, 1999; Ziyal, 
1996; Ziyal et al., 1996, 1997). It was less potent at P2Y1-like receptors in rat 
duodenum, guinea-pig taenia coli and ileum, and rat mesenteric arterial bed, and 
ineffective at UTP-sensitive P2Y2-like receptors in rat and hamster mesenteric 
arterial beds (Ziyal et al., 1996; Lambrecht 1996) as well as at P2Y4-like receptors 
in cultured aortic smooth muscle cells from spontaneously hypertensive rats 
(Harper et al., 1998). 
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This selectivity profile of NF023 has been confirmed in studies with cloned 
P2X  receptors (Soto et al., 1999). The compound was found to antagonise 
homomeric rat and human P2X1 receptors with the highest potency (pIC50 values 
6.6 and 6.7, respectively), P2X3 receptors displayed an intermediate sensitivity 
with pIC50 values of 5.1 and 4.4 for rat and human subtypes, respectively, and 
P2X2 was the least sensitive subtype (in the presence of 100 M NF023, the 
current through P2X2 was blocked by 60 %), whereas human and rat 
P2X4 receptors were insensitive to NF023 at concentrations up to 100 M. The 
heteromeric P2X2P2X3  receptor was shown to be indistinguishable from the 
homomultimeric rP2X3 receptor in its sensitivity towards NF023 (Soto et al., 1999; 
Lambrecht, 2000). Antagonistic activity of NF023 was found to be weak at 
recombinant P2Y1 receptors (pIC50 = 4.6), and the compound was shown to be 
inactive at P2Y2, P2Y4 and P2Y6 receptors (J.L. Boyer and T.K. Harden, personal 
communication). Like the parent compound suramin, NF023 inhibits 
ecto-nucleotidases activity (Beukers et al., 1995; Bültmann et al., 1996c, 
Lambrecht, 2000), but unlike suramin, it has a high P2X1- versus 
ecto-nucleotidases-selectivity. 
 
1.1.4.2.1. Structure-activity  relationships 
 
Up to 1996, only a few studies dealt with a systematical analysis of 
structure-activity relationships concerning antagonism of suramin-related 
compounds at P2  receptor subtypes as well as their inhibitory activity at 
ecto-nucleotidases. Antagonistic potencies of suramin and the derivatives NF212, 
NF213 and NF023 on P2X1-like receptor-mediated vasopressor effects induced by 
,-mATP in the pithed rat were found to be markedly different, even between 
compounds which are closely related, suggesting a clear-cut structure-activity 
relationship to exist. NF023 was at least as potent as suramin, whereas NF212 
and NF213, which differ from suramin with respect to the number and the 
arrangement of methyl-moieties attached to the aminobenzoyl groups (figure 
3.11.) were less potent than the parent compound. The unsymmetrical analogue 
8-(2-methyl-3-(3-aminobenzamido)-benzamido)-naphthalene-1,3,5-trisulphonic 
acid (NF105) was found to be ineffective (Schlicker et al., 1989; Urbanek et al., 
1990). 
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In a binding study performed at turkey erythrocyte membrane P2Y1-like receptors 
suramin and its desmethyl-derivative NF037 (figure 3.11.) displayed similar 
affinities, indicating that methyl moieties are not a prerequisite for binding. Binding 
affinities of the so-called small ureas NF058 (figure 3.15.) and NF023 were 
markedly decreased, therefore shortening of the chain of the large urea by two 
aminobenzoyl groups was found to be less favourable for gaining a higher affinity 
towards P2Y1-like receptors. The even smaller dibenzamide analogues 
8-(3-(3-nitrobenzamido)benzamido)-naphthalene-1,3,5-trisulphonic acid (NF018) 
and 8-(3-(3-aminobenzamido)benzamido)-naphthalene-1,3,5-trisulphonic acid 
(NF019) were only moderately less potent than suramin, and further simplification 
of the structure revealed that at least one benzoyl group is necessary to obtain 
affinity for the receptor. Analysis of benzamide derivatives differing in the 
substitution pattern of the remaining phenyl ring culminated in 8-(3,5-di-
nitro-phenylenecarbonylimino)-1,3,5-naphthalenetrisulphonic acid (XAMR0721), 
the affinity of which was only reduced to half of that of suramin (van Rhee et al., 
1994). However, there are studies that seriously call into question the validity of 
the [
35S]ADPS-binding assay on turkey erythrocyte membranes indicating that 
the nucleotide may bind to P2Y receptors and other ATP-binding proteins with 
almost equal affinity (Harden et al., 1995). Accordingly, caution has to be adopted 
assessing these observations. The results obtained for XAMR0721 in binding 
studies could not be confirmed in functional studies at GPTC P2Y receptors where 
the compound was about 80-fold less potent as an antagonist than suramin 
(Bültmann et al., 1996a, 1996c). 
 
When suramin and some derivatives were examined for their inhibitory effects on 
ecto-nucleotidases present on human blood cells, similar potencies were found for 
the parent compound, the large urea NF031 (see figure 3.13.C.), and NF023, 
whereas NF058 and the dibenzamide derivative NF018 as well as three 
benzamide derivatives including XAMR0721 were almost inactive. Therefore, a 
relation between molecular size and ectoN-inhibitory activity - larger derivatives 
displaying higher activity - has been proposed (Beukers et al., 1995). 
 
Analysis of a series of suramin derivatives at P2X1-like receptors present in ratVD, 
GPTC P2Y receptors and ATP-breakdown in ratVD, confirmed results obtained in 
previous studies (Bültmann et al., 1996c). A novel aspect of SAR's was provided 
by N-[3-(N-(1,3,5-trisulpho-8-naphthyl) carbamoyl) phenyl]-N'-[3-(N-(1-naphthyl)-
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carbamoyl)phenyl]-urea (BSt101), a non-symmetrical derivative of NF023 lacking 
the three sulphonic acid residues at one of the naphthalene rings. The compound 
was only slightly less potent than NF023 in blocking P2X1-like receptors, indicating 
that negative charges on both ends of the molecule, are not a prerequisite for high 
P2X1-like receptor-blocking potency (Bültmann et al., 1996c). 
 
1.1.5.  ATP-degrading enzymes (ecto-nucleotidases) 
 
Many cell types and presumably all tissues have the capacity to metabolise 
extracellular nucleotides and also nucleosides by surface-located enzymes. A key 
function of the enzymes presumably is in the inactivation of nucleotides that have 
been released as signalling substances or during pathological events and in 
subsequent purine salvage. Nucleotide-degrading enzymes, usually referred to as 
ecto-nucleotidases, comprise several unrelated enzyme families. Although 
recently, a uniform nomenclature has been introduced by Zimmermann and 
colleagues (2000), a somehow confusing accumulation of different designations 
defining identical enzymes or different enzymes defined by equal designations, 
respectively, is still persisting in the current literature. Similar to the P2 receptor 
field, this confusion will be further resolved with the molecular identification and 
subsequent characterisation of the properties of individual enzymes. 
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Fig. 1.3.  Extracellular pathways for the degradation of nucleotides. 
 
1.1.5.1.  The E-NTPDase family 
 
The E-NTPDase family (ecto-nucleoside triphosphate diphosphohydrolase family) 
is often also referred to as the ecto-apyrase, NTPase or E-ATPase family. 
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Members of the E-NTPDase family can hydrolyse extracellular ATP and ADP as 
well as other nucleoside 5'-di- and triphosphates albeit with variying preference for 
the individual type of nucleotide. Enzyme activity is activated either by Ca
2+ or 
Mg
2+ and has an alkaline pH optimum. NTPDases are not inhibited by known 
inhibitors of various intracellular ATPases such as P-type (vanadate), F-type 
(oligomycin) and V-type ATPases (N-ethyl maleimide) (Ziganshin et al., 1994a; 
Plesner, 1995; Zimmermann, 1996a,b). The gene family has members not only 
within vertebrates, related enzymes also exist in invertebrates, plants, yeast and 
protozoans (Handa and Guidotti, 1996; Zimmermann and Braun, 1999). All of 
these sequences share a number of highly conserved domains, the "apyrase 
conserved regions", that presumably are of major relevance for their catalytic 
activity (Handa and Guidotti, 1996). 
 
According to their presumptive membrane topography members of the 
E-NTPDase family may be separated into two groups. The first group comprises 
NTPDase1 - 4 which are highly glycosylated cell-surface located enzymes or 
integral membrane proteins, respectively, with two putative transmembrane 
domains, separated by a large extracellular loop, and intracellular N- and C-termini 
(Maliszewski et al., 1994; Christoforidis et al., 1996). Thus, their membrane 
topology resembles that of P2X receptors (see figure 1.4.). Enzymatic activity of 
NTPDase1 was shown to be dependent on homo-oligomeric assembly: although 
even soluble monomers (mutants lacking both transmembrane regions) were 
shown to be active, and assembly of mutants into dimers and trimers also results 
in nucleotide degrading activities, the wild-type NTPDase1 was reported to 
assemble as a tetramer (Wang et al., 1998). 
 
The lymphocyte surface protein CD39 - now designated NTPDase1 - that has 
been cloned and sequenced previously (Maliszewski et al., 1994), was shown to 
be identical to the human ATP diphosphohydrolase (Christoforidis et al., 1995; 
Kaczmarek et al., 1996; Wang and Guidotti, 1996; Marcus et al., 1997). The 
enzyme was found to hydrolyse ATP and ADP at a molecular ratio of about 1 : 0.5 
to 1 : 0.9. In contrast, NTPDase 2 (CD39L1) revealed high preference for ATP 
over ADP (1:0.03) hydrolysis and was therefore originally named ecto-ATPase 
(Chadwick and Frischauf, 1997; Kegel et al., 1997; Kirley, 1997). Another recently 
sequenced and expressed human enzyme NTPDase3 (HB6) reveals considerable 
sequence identity to both NTPDase1 and 2. When heterologously expressed it 
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hydrolyses ATP and ADP at a ratio of about 1  :  0.3 and thus represents a 
functional intermediate of the other two enzymes (Smith and Kirley, 1998; 
Zimmermann, 2000). Not all members of this protein family are located to the cell 
surface, there are soluble forms in plants and protozoa and membrane-bound 
forms allocated to the Golgi apparatus and to lysosomal/autophagic vacuoles, 
such as two closely related forms of the NTPDase4 (Zimmermann, 1999, 2000). 
 
The second group comprises the NTPDase5 (CD39L4) and putative NTPdase6 of 
which only NTPDase5 has been expressed and characterised. It lacks the 
C-terminal hydrophobic domain and is therefore predicted to have only one 
transmembrane domain at the N-terminus (Zimmermann, 2000). Soluble nucleo-
tidases sequentially degrading ATP to adenosine have been reported to be 
released from electrically stimulated nerve endings of guinea-pig vas deferens 
smooth muscle (Todorov et al., 1997; Kennedy et al., 1997). However, the 
structure of these enzymes is still unknown, a potential candidate may be the 
recently cloned but functionally as yet unidentified putative NTPDase6 (CD39L2) 
(Chadwick and Frischauf, 1998; Zimmermann, 1999).  
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Fig. 1.4. Presumptive  membrane 
topography of mammalian members 
of the nucleoside triphosphate 
diphosphohydrolase- (NTPDase) 
and of the nucleotide pyrophospha-
tase/phosphodiesterase (NPP) 
family. 
 
1.1.5.2.  The E-NPP family 
 
Members of the ENPP-family (nucleotide pyrophosphatase/phosphodiesterase 
family) exhibit a broad substrate specificity and possess both, the capacity of 
hydrolysing phosphodiester bonds of nucleotides and nucleic acids (e.g. 
hydrolysing cAMP to AMP), and pyrophosphate bonds of nucleotides and 
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nucleotide sugars, generating pyrophosphate (PPi) from the cleavage of ATP and 
inorganic phosphate (Pi) from ADP (Zimmermann, 1996a; Zimmermann, 1999). 
Three different types of enzyme (designated NPP1 - 3) have now been cloned 
from human sources and related sequences were shown to be present in mouse 
and rat (Zimmermann, 1999). In the current literature, the individual enzymes are 
referred to as PC-1 (NPP1), PD-I, autotaxin (NPP2), which are presumably splice 
variants of the same NPP2 gene and PD-I, B10 and gp130
RB13-6 (NPP3), which 
denominate an identical protein. The membrane glycoprotein PC-1 was the first 
member of the enzyme family to be identified in molecular terms (van Driel et al., 
1985; van Driel and Goding, 1987). Autotaxin, also catalysing the hydrolysis of 
ATP and GTP to the respective dinucleotides, and AMP to adenosine (a catalytic 
property shared with ecto-5'-nucleotidase) displays an even wider catalytic 
capacity than the other members of this family (Clair et al., 1997). Both PC-1 and 
autotaxin also exist as soluble forms, and the membrane-bound PC-1 protein was 
reported to occur as a homo-dimer, composed of two subunits consisting of 
intracellular N-termini, one transmembrane region per subunit and extracellular C-
termini (van Driel et al., 1985; van Driel and Goding, 1987). Related sequences 
have also been identified in plants, yeast and Caenorhabditis elegans 
(Zimmermann and Braun, 1999). 
 
1.1.5.3. Ecto-5'-nucleotidase 
 
Activity of 5'-nucleotidase is present intracellularly and can also be observed at the 
cell surface. The extracellular form, ecto-5'-nucleotidase is attached to the plasma 
membrane via a glycosyl-phosphatidylinosotol-anchor and is present in all tissues, 
although its expression is generally restricted to specific cell types (Zimmermann, 
1996a). The protein occurs as a homo-dimer with interchain disulphide bridges. It 
hydrolyses a variety of nucleoside-5'-monophophates such as AMP, CMP, UMP, 
IMP and GMP to the respective nucleosides. ATP, ADP and ,-methylene-ADP 
(,-mADP) act as competitive inhibitors of ecto-5'-nucleotidase (Zimmermann, 
1992). Soluble forms of the enzyme exist that at least in part are derived from 
enzymatic cleavage of the glycosyl-phosphatidylinosotol anchor (Zimmermann, 
1992). 
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1.1.5.4. Alkaline  phosphatases 
 
The glycosyl-phosphatidylinosotol-anchored ecto-enzymes alkaline phosphatases 
are phosphomonoesterases present in essentially all tissues. They are capable of 
releasing Pi from a large variety of organic molecules including nucleoside 5'-tri-, 
di- and monophosphates. Its pH optimum is at pH 8.5 and higher, and it is 
effectively inhibited by free phosphate (Fox, 1978). At least four genes encode 
alkaline phosphatase isoenzymes in humans, producing a placental, a placental-
like, an intestinal isoenzyme and a family of proteins that differ from one another 
only by postranslational modification and are present throughout the body. A 
homo-dimeric assembly was described for the enzyme from Escherichia coli 
(Zimmermann, 1996a). A major question is that of the relative physiological 
relevance when alkaline phosphatases are co-expressed with other nucleo-
tide-degrading enzymes. Because alkaline phosphatases have a considerably 
higher Km  value for nucleotides and also a much higher pH optimum than 
members of the NTPDase-family or ecto-5'-nucleotidase, the physiological 
conditions for the activation of alkaline phosphatase and ecto-nucleotidases may 
differ (Zimmermann, 1996a). 
 
1.1.5.5. Adenosine  deaminase 
 
Adenosine deaminase catalyses the conversion of adenosine and deoxy-
adenosine to inosine and deoxyinosine, respectively. It was shown to be present 
in essentially all tissues (Nagy et al., 1990). The enzyme is mainly cytosolic, but it 
also occurs on the surface of a variety of cells (Zimmermann, 1996a). 
Surface-located adenosine deaminase has shown to be associated with a specific 
binding protein that has been identified as an ecto-peptidase (Kameoka et al., 
1993). Furthermore, the association of the enzyme with adenosine A1 receptors 
has been described (Ciruela et al., 1996). At present, it is not known how soluble 
adenosine deaminase can be released from cells; it may be derived from lysed 
cells or may also be secreted. 
 
1.1.5.6. Nucleoside  diphosphokinase 
 
The significance of intracellular nucleoside diphosphokinase (NDPK) in 
intermediary metabolism, catalysing the transphosphorylation of nucleoside 
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diphosphates utilising nucleoside triphosphates, is well established (Stoeckler et 
al., 1978). In contrast, the location and function of NDPK as an extracellular 
enzyme involved in the transfer of terminal phosphates between extracellular 
nucleotides has not been addressed until recently, when it was shown to have 
functional significance in 1321N1 cells (Lazarowski et al., 1997a) and polarised 
human airway epithelial cells (Lazarowski et al., 1997c). Exogenously applied 
ATP, as well as ATP released from 1321N1 cells was shown to serve as a 
-phosphate donor for exogenously added nucleoside diphosphates. Thus, 
observations indicating that UDP acts as an agonist at the P2Y4 receptor 
expressed in 1321N1 cells likely are due to conversion of UDP to UTP in the 
presence of released ATP (Lazarowski et al., 1997a). The molecular identity of 
this extracellular NDPK is not yet clear. Two putative tumour suppressor genes, 
nm23-H1 and nm23-H2, have been cloned and shown to encode for proteins (also 
called NDPK A and NDPK B) that exhibit NDPK activity (Biggs et al., 1990; Kimura 
et al., 1990). However, whether the ecto-NDPK activity is encoded by this genes 
has not been determined (Lazarowski et al., 1997a). 
 
1.1.5.7.  Inhibitors of ATP degradation 
 
Many types of agents have been used albeit without great specificity or potency as 
inhibitors of ecto-nucleotidases, i.e. members of the E-NTPDase family, in various 
animal tissues (for review see Ziganshin et al., 1994a). To date, the ATP analogue 
ARL 67156 is the only compound displaying a certain specificity for 
ecto-nucleotidases inhibition over P2 receptor antagonism. ARL 67156 was shown 
to inhibit ATP degradation in human blood cells (Crack et al., 1995) and the ratVD 
(Khakh et al., 1995b). ATP-evoked contractions of rabbit ear artery and guinea-pig 
vas deferens and urinary bladder were enhanced in the presence of ARL 67156, 
but not responses to the metabolically stable analogue ,-mATP (Crack et al., 
1995; Westfall et al., 1996, 1997). Furthermore, ARL 67156 was reported to 
potentiate the purinergic component of neurogenic contraction of guinea-pig vas 
deferens and urinary bladder by up to two-fold (Westfall et al., 1996, 1997). 
Although, ARL 67156 is a weak P2X receptor antagonist (Crack et al., 1995), if 
used at 10 - 100 M, effective inhibition of ecto-nucleotidases should be achieved, 
with relatively little receptor antagonism. Unfortunately, the compound has not yet 
been tested in assays applying recombinant, molecularly defined 
ecto-nucleotidases. 
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Of the numerous P2 receptor antagonists also displaying inhibitory potency on 
ATP breakdown (see 1.3.2.), suramin, Evans blue, PPADS, and recently several 
PPADS analogues have been examined on recombinant ecto-nucleotidases 
expressed in chinese hamster ovary (CHO) cells (Heine et al., 1997, Hoffmann et 
al., 2000). Evans blue was shown to be an effective inhibitor of rat NTPDase1, 
whereas suramin preferentially inhibits rat NTPDase2. PPADS was reported to be 
the least effective inhibitor, displaying similar activity at both enzymes (Heine et 
al., 1997). However, studying the inhibitory activity of PPADS analogues selectivity 
for either NTPDase1 or NTPDase2 was found to be controlled by several 
structural parameters. In comparison to PPADS inhibitory activity of some of the 
derivatives was shown to be increased (Hoffmann et al., 2000). 
 
1.1.6. Therapeutic  implications 
 
Studies  in vivo have indicated a number of potential physiological and 
pathophysiological roles for ATP in smooth muscle as well as neurons and 
inflammatory cells. Thus, in transgenic mice lacking P2X1 receptors, contraction of 
the vas deferens in response to sympathetic nerve stimulation is substantially 
reduced and their fertility impaired by 90 % (Mulryan et al., 2000). It was therefore 
suggested, that the selective pharmacological blockade of P2X1 receptors should 
produce a similar effect, and might thus provide means for developing a 
non-hormonal male contraceptive pill. However, the relative importance of 
purinergic transmission in the human vas deferens in vivo is far from clear. For 
example, the neurogenic contraction of the rat urinary bladder involves a large 
purinergic component, while in healthy humans it is almost entirely cholinergic. 
Thus, there is at present considerable uncertainty in the extrapolation from 
experimental animals to human clinical practice. 
 
A growing body of evidence suggests that P2X receptors on nerve terminals both 
in the periphery and spinal dorsal horn are involved in sensory processing and 
nociception at sites throughout the body including the joints, viscera, and 
cardiovascular system (see Khakh, 2001). Studies in transgenic mice lacking the 
P2X3 receptor have shown that formalin-induced pain behaviour is reduced and 
that their ability to code intensity of non-noxious heat stimulation is absent 
(Cockayne et al., 2000; Souslova et al., 2000). Interestingly these mice also 
exhibited a decreased urine voiding frequency and an increased bladder capacity 
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with a normal intravesical pressure. This suggests an urinary bladder hyporeflexia, 
whereby the release of ATP on bladder distension no longer excites peripheral 
primary afferent nerve terminals (Cockayne et al., 2000). It is important to note 
that P2X3 receptors are not the only detectors of ATP in pain sensation because 
there is a residual ATP-evoked current in P2X3 knockout mice and a component of 
ATP-evoked pain that persists in vivo (Cockayne et al., 2000; Souslova et al., 
2000). The residual response is probably P2X2 receptor-mediated; P2X2 and 
combined P2X2/P2X3-receptor knockout mice will be useful to test this hypothesis. 
Therefore, P2X3 as well as P2X2P2X3 receptor antagonists might have therapeutic 
potential as antinociceptive drugs. 
 
Recent studies in a P2X7-deficient mouse have confirmed earlier studies, which 
suggested that these receptors may play an important role in initiating the 
processing and release of IL-1 from inflammatory cells (Grahames et al., 1999; 
Solle et al., 2001). Accordingly, P2 receptor ligands selective for the P2X7 subtype 
might be useful as anti-inflammatory drugs. 
 
In the urinary bladder of pithed rats PPADS was shown to antagonise the increase 
in intra-vesical pressure produced by ATP or spinal electrical stimulation (Hegde 
et al., 1998). In contrast to healthy humans, the contribution of purinergic 
transmission to the excitatory innervation of the urinary bladder was reported to be 
enhanced in disease states such as neurogenic bladder, outflow obstruction and 
interstitial cystitis (Hegde et al. 1998; Bayliss et al., 1999). P2X receptor 
antagonists may therefore be potentially useful as novel treatment modalities for 
urge urinary incontinence. 
 
Furthermore, ATP acting as a cotransmitter with noradrenaline (NA) was found to 
induce vasoconstriction in a great variety of isolated vascular preparations from 
various species mediated via P2X1-like receptors (Boarder and Hourani, 1998; 
Lewis et al., 1998; McMillan et al., 1999). Interestingly, in spontaneous 
hypertensive rats and in a hypertensive rabbit model, a significantly greater 
cotransmitter role compared with NA has been demonstrated in blood vessels 
(Burnstock, 1998). If this holds true for human patients suffering from 
hypertension, P2X receptor antagonists, presumably P2X1 receptor-selective 
compounds, might have therapeutic potential in pulmonary vasoconstriction and 
essential hypertension. 
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P2Y1-like receptors present on pancreatic -cells were shown to mediate 
potentiation of glucose-induced insulin secretion (Loubatières-Mariani et al., 1997; 
Petit et al., 1998). In non-insulin-dependent diabetes (NIDDM) the pancreatic 
-cells retain their ability to synthesise and secret insulin, however, their ability to 
respond to glucose stimulus is diminished. Therefore enzymatically stable 
P2Y1  receptor agonists which were reported to be highly effective insulin 
secretagogues in rat isolated pancreas as well as potent agonists at P2Y1 
receptors present in turkey erythrocyte membranes (Fischer et al., 1999a), might 
be useful for the treatment of NIDDM. 
 
The increased resistance to thromboembolism in mice lacking the P2Y1 receptor 
(Fabre et al., 1999; Léon et al., 1999) suggested that this receptor is a potential 
target for new antiplatelet drugs. In vivo administration of the P2Y1 receptor 
antagonist MRS 2179 to mice resulted in prolongation of the bleeding time, ex vivo 
inhibition of platelet aggregation to ADP, and resistance to thromboembolism 
induced by a mixture of collagen and epinephrine or by thromboplastin (Léon et 
al., 2001). Whether P2Y1 antagonists have therapeutic potential in other 
thrombosis models remains to be established. Whereas the P2Y1 receptor is 
mainly involved in shape change and initiation of platelet aggregation, the recently 
cloned P2Y12 (previously referred to as P2T, P2TAC or P2YADP) is responsible for 
completion and amplification of the platelet aggregation to ADP and other 
aggregating agents (see Gachet, 2000). The thienopyridine compounds ticlopidine 
and clopidogrel are marketed antithrombotic agents that have proved to be 
efficient in a number of clinical trials evaluating their effects on ischaemic heart 
diseases, peripheral vascular disease, and stroke (Savi and Herbert, 2000). 
Similarly, the ATP analogues of the AR-C series, which are potent competitive 
P2Y12 antagonists, were shown to be efficient antithrombotics in animal models, 
and some of them are in phase II clinical trials for the treatment of acute coronary 
syndromes (Humphries, 2000). 
 
Cystic fibrosis (CF) is characterised by abnormal fluid transport across many 
epithelia including airways, pancreas, sweat glands and small intestine. One 
therapeutic goal is to improve mucociliary clearance, and thereby prevent 
progressive lung damage caused by infections. The disease is caused by the 
absence or dysfunction of the cystic fibrosis transmembrane conductance 
regulator (CFTR), a chloride channel expressed by epithelial cells, and by an 
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increase in active Na
+ absorption. One promising treatment is the use of inhaled 
UTP and amiloride (a K
+-sparing diuretic) (Bennett et al., 1996). UTP (INS-316), 
by activating P2Y2 receptors in epithelial cells, bypasses the defective 
Cl
- secretion to activate an alternative Ca
2+-dependent Cl
- secretory pathway (Parr 
et al., 1994). Because extracellular UTP is susceptible to hydrolysis by 
ecto-nucleotidases and phosphatases present in the airways, stable UTP 
analogues may have a therapeutic advantage. Therefore, UTPS and especially 
several dinucleoside-polyphosphates are the subject of a number of patents 
claiming their use in lung diseases, CF, and primary ciliary dyskinesia, ear 
diseases (otitis media) and eye diseases (dry eye) (see Guile et al., 2001; Fujihara 
et al., 2001). Phase II clinical trials are currently in progress with two compounds, 
UTP (INS-316) in CF patients and INS-365 (diuridine-tetraphosphate), also as a 
drug candidate for the treatment of CF and beyond that in dry eye syndrome 
patients. 
 
P2Y2 receptor antagonists might have therapeutic potential as anti-inflammatory 
drugs. The majority of compounds described are 4-thiouridine derivatives with a 
large, semi-planar, hydrophobic aromatic ring system as substituent in 5-position 
(see Guile et al., 2001). 
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1.2.  Aim of the thesis 
 
P2 receptor pharmacology still lacks specific and selective competitive antagonists 
to discriminate clearly between receptor subtypes. Although a number of 
promising compounds have been examined for this purpose, including suramin, 
PPADS, several histochemical dyes, MRS 2179, Ip5I and TNP-ATP, none of them 
can be considered as ideal (Jacobson et al., 1998a; Ralevic and Burnstock, 1998; 
Lambrecht, 2000; Guile et al., 2001). All compounds are limited in their usefulness 
by their irreversibility of the antagonism or by the lack of potency, subtype-
selectivity and P2 receptor specificity (see 1.1.3.). The ability of most of the 
antagonists to inhibit ecto-nucleotidases and thereby protect ATP and other 
metabolically unstable nucleotide agonists from degradation further complicates 
their use (Humphrey et al., 1995; Kennedy and Leff, 1995). Moreover, studies 
which systematically analyse structurally related compounds in order to assess 
structure-activity relationships for a certain series of analogues at P2 receptor 
subtypes and ecto-nucleotidases, especially for antagonists potentially displaying 
selectivity for a certain P2X receptor subtype, are almost missing. Definitely one 
reason for this is the absence of suitable binding assays. To date, only agonist 
radioligands have been identified for P2 receptors, that have the potential to label 
binding sites for ATP in tissues and cells in a highly non-specific manner 
(Humphrey et al., 1995). The usefulness of these radioligands is further 
compounded by their potential liability. Therefore, a high affinity P2 receptor 
antagonist either selective for a certain P2 receptor subtype or non-selective 
would be a valuable pharmacological tool to improve radioligand binding assays, 
which in turn are critical to the use of high throughput screening to identify novel, 
non-purine, non-nucleotide pharmacophores. 
 
Subject of this thesis was the pharmacological evaluation of compounds related to 
the non-selective P2 receptor antagonist suramin (see 1.1.4.2.) with the aim to 
assess their inhibitory potency at native P2 receptor subtypes and 
ecto-nucleotidases in relation to suramin and the small urea NF023, which has 
been characterised as P2X1-receptor-selective antagonist in smooth muscle 
preparations as well as in studies at cloned P2X receptors (Bültmann et al., 
1996c; Lambrecht, 1996; Ziyal et al., 1997; Soto et al., 1999). 
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To this end, symmetrical small ureas varying in the substitution pattern and 
substituents of the benzoyl residue/s (1), exchange of benzoyl (I) in large ureas 
and the benzoyl of small ureas (2), large and small ureas differing in the 
substitution pattern of the aminonaphthalene sulphonic acid residues combined 
with varying linkages of the benzoyl residues (3), large and small ureas with 
modifications of the central urea bridge (4), as well as two small urea derivatives 
with 7- instead of 6-aminonaphtalene sulphonic acid residues (5) (see figure 1.5.) 
were chosen to be analysed in the present study. 
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Fig. 1.5.  Structural modifications of small (X = 0) and large (X = 1) ureas 
related to suramin (R = CH3,, X = 1) evaluated in the present study. 
 
To pharmacologically characterise the compounds screening assays had to be 
developed, in order to examine a larger number of compounds of which only small 
amounts were available. The following tissues/cells being endowed with different 
P2 receptor subtypes/ecto-nucleotidases were selected for this purpose: 
 rabbit vas deferens (P2X; Windscheif, 1995; Lambrecht et al., 1996b; Ziyal, 
1996) 
 guinea-pig taenia coli (P2Y; Burnstock and Kennedy, 1985; Cusack, 1993; 
Dudeck et al., 1995) 
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 folliculated Xenopus laevis oocytes (ecto-nucleotidases; Ziganshin et al., 1995; 
1996) 
 
Of the numerous suramin derivatives examined in the screening assays, NF279 
(figure 3.13.) displayed an outstanding P2X receptor-blocking potency. 
Consequently, it was of major interest in this thesis to investigate the P2 receptor 
subtype selectivity and specificity of this novel antagonist. Moreover, with the aim 
to identify structural requirements for the interaction with P2 receptors, a series of 
derivatives representing the missing link between suramin and NF279 as well as 
the respective small urea analogues, were examined for their inhibitory potencies 
on native P2X receptors present in rat vas deferens (Khakh et al., 1994; 1995b), 
guinea-pig ileum (Kennedy and Humphrey, 1994; Czeche et al., 1998b; 
Lambrecht et al., 2000a) and taenia coli P2Y receptors, and ecto-nucleotidases of 
folliculated Xenopus laevis oocytes. 
 
In vasa deferentia of different species, variation of adrenergic and purinergic 
transmission with regard to the anatomical origin of the segment (prostatic vs. 
epididymal) has been reported (Sneddon and Machaly, 1992). In addition, several 
studies indicated, that contraction of the rat vas deferens induced by either 
electrical field stimulation or by exogenously applied nucleotides might be 
mediated via a heterogeneous P2 receptor population (Bültmann and Starke, 
1994b, Lambrecht et al., 1996b). Whether these P2 receptors are symmetrically 
distributed along the length of the rat vas deferens, and as a consequence, 
prostatic as well as epididymal segments are equally well-suited as 
pharmacological model for the study of native P2X1-like receptors, was a further 
subject of this thesis. 
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2.1.  Drugs and animals 
 
2.1.1.  Commercially available drugs 
 
 ,-Methylene-adenosine-5’-triphosphate dilithium salt (,-mATP; Sigma, 
Deisenhofen, Germany) 
 ,-Methylene-adenosine-5’-diphosphate dilithium salt (,-mADP; Sigma, 
Deisenhofen, Germany) 
 ,-Methylene-L-adenosine-5’-triphosphate tetrasodium salt (L-,-mATP; 
Biotrend, Cologne, Germany) 
 Adenosine-5’-diphosphate disodium salt (ADP; Sigma, Deisenhofen, Germany) 
 Adenosine-5'-monophosphate sodium salt (AMP; Sigma, Deisenhofen, 
Germany) 
 Adenosine-5’-O-(2-thiodiphosphate) dilithium salt (ADPS; Sigma, 
Deisenhofen, Germany) 
 Adenosine-5'-O-(3-thiotriphosphate) tetralithium salt (ATPS; Sigma, 
Deisenhofen, Germany) 
 Adenosine-5'-triphosphate disodium salt (ATP; Sigma, Deisenhofen, Germany) 
 Ammonium molybdate tetrahydrate (Sigma, Deisenhofen, Germany) 
 Carbamoylcholine chloride (carbachol; Sigma, Deisenhofen, Germany) 
 2-Chloroadenosine (2-Cl-Ado; Sigma, Deisenhofen, Germany) 
 2-Chloro-N
6-cyclopentyladenosine (CCPA; Sigma, Deisenhofen, Germany) 
 (-)-Cocaine hydrochloride (E. Merck, Darmstadt, Germany) 
 8-Cyclopentyl-1,3-dipropylxanthine (DPCPX; Sigma, Deisenhofen, Germany) 
 Ethylenediaminetetraacetic acid (EDTA; Sigma, Deisenhofen, Germany) 
 Fiske & SubbaRow reducer (formulation of: 1-amino-2-naphthol-4-sulphonic 
acid sodium sulphite and sodium bisulphite; Sigma, Deisenhofen, Germany) 
 Indomethacin (Sigma, Deisenhofen, Germany) 
 N-2-Hydroxyethylpiperazine-N'-2-ethanesulphonic acid (HEPES; Sigma, 
Deisenhofen, Germany) 
 (-)-Nicotine hydrogentartrate (nicotine; Sigma, Deisenhofen, Germany) 
 (-)-Noradrenaline hydrochloride (NA; Fluka, Buchs, Switzerland) 
 p-Nitrophenylphosphate ammonium salt (PNP; Sigma, Deisenhofen, Germany) 
 Pentobarbitone sodium (Nembutal
®; Sanofi, Hannover, Germany) 
 Suramin (Germanin
®, Bayer, Leverkusen, Germany) 
 Tetrodotoxin (TTX; Sigma, Deisenhofen, Germany) 
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 Yohimbine hydrochloride (Sigma, Deisenhofen, Germany) 
 
2.1.2. Gifts 
 
 Adenosine-5’-O-(2-thiodiphosphate) dilithium salt (ADPS; Dr. H. Woog, 
Boehringer Mannheim, Mannheim, Germany) 
 Arecaidine propargyl ester hydrobromide (APE; synthesised by Dr. U. Moser 
and Mrs. U. Hermanni, Department of Pharmacology, University of Frankfurt, 
Frankfurt/Main, Germany) 
 6-N,N-Diethyl-D-,-dibromomethylene-adenosine-5'-triphosphate (ARL 67156, 
syn. FPL 67156; synthesised by Dr. A. Krayevsky, Engelhardt Institute of 
Molecular Biology, Russian Academy of Sciences, Moscow, Russia) 
 N
6-Methyl-2'-deoxy-adenosine 3',5'-biphosphate (MRS 2179; synthesised by 
Dr.  K. Jacobson and co-workers, National Institutes of Health, Bethesda, 
Maryland, USA) 
 Pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid (PPADS; synthesised by 
Dr. H. G. Bäumert and co-workers, Department of Biochemistry, University of 
Frankfurt, Frankfurt/Main, Germany) 
 All NF compounds examined in this thesis were synthesised by Prof. Dr. 
P. Nickel and co-workers, Department of Pharmaceutical Chemistry, University 
of Bonn, Bonn, Germany. 
 
2.1.3.  Preparation of stock solutions 
 
In general, drugs were dissolved and diluted in distilled water or in physiological 
saline (NaCl 0.9 %; w/v). Stock solutions of indomethacin were made up in 96 % 
ethanol and that of noradrenaline (NA) was stabilised with 0.05 % (w/v) Na2S2O5. 
In each case, control experiments assured that the final concentration of the 
vehicle in the bath fluid had no pharmacological effect itself. 
 
2.1.4. Buffer  solutions 
 
All components of the bath fluids were commercially available chemicals of 
analytical grade purity. 
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Table 2.1.  Composition of bath fluids used in pharmacological experiments on 
rabbit vas deferens (RVD), guinea-pig taenia coli (GPTC) and rat vas deferens 
(ratVD) as well as in studies on ATP breakdown in GPTC and Xenopus laevis 
oocytes. The solution oocyte I was used for the storage of oocytes, experiments 
were performed in oocyte II buffer. 
 
  Concentration (mM) of buffer components 
  Contraction/ relaxation experiments 
in smooth muscle preparations 
Ecto-nucleotidase bioassay 
 RVD  GPTC  RatVD  GPTC  Oocytes  I 
(storage) 
Oocytes II
(exp.) 
CaCl2 1.0  2.5 1.3 2.0 1.0  1.8
KCl 4.7  4.7 4.7 5.0 1.0  2.5
KH2PO4 1.2  1.2  
MgCl2   2.0 1.0  1.8
MgSO4 0.6  0.6 0.6  
NaCl 118.1  133.5 118.0 135.0 90.0  110.0
NaHCO3 25.0  16.3 25.0  
NaH2PO4   0.8  
HEPES   10.0 5.0  5.0
Glucose 11.2 7.8 11.1 10.0  
 
2.1.5. Animals 
 
All laboratory animals were housed in an air-conditioned room with a temperature 
of 23°C, a relative atmospheric humidity of 50 % and an artificial 12-hour light-dark 
cycle. They were fed a standard diet (rabbits, guinea-pigs: Alltromin
® 3022, rats: 
Alltromin
® 1324) and had free access to food and tap water. 
New Zealand white rabbits were purchased from Sawo-Iwanowas (Kissleg/Allgäu, 
Germany) and Koch (Edingen-Neckarhausen, Germany). Dunkin-Hartley 
guinea-pigs and wistar rats were delivered by Harlan Winkelmann, Borchen, 
Germany. 
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2.2. Methods 
 
2.2.1.  Rabbit vas deferens 
 
Preparation. Male New Zealand white rabbits (2.5 - 3.0 kg) were killed by an 
overdose (120 mg/kg) of pentobarbitone sodium (Nembutal
®) injected into the ear 
vein. According to the method described by Eltze (1988), the abdomen was 
opened and the vasa deferentia were excised from the epididymides to the 
prostate and cleared of connective tissue. Each vas deferens was divided into six 
segments of approximately 1.0 cm length. The segments were vertically 
suspended in 6 ml organ baths containing a modified Krebs solution (for 
composition see table 2.1.; pH 7.4; 31°C; aerated with 95 % O2/5 % CO2). 
Additionally, yohimbine (1 M) was added to the buffer in order to block 
2 adrenoceptors. Tissues were loaded with 375 mg tension and were allowed to 
equilibrate for 30 min with a change of the bath fluid every 10 min before starting 
the experiment. Mechanical activity was measured isometrically via a force 
displacement transducer (TF6V5) connected to a DMS DC amplifier (both from 
W.  Fleck, Mainz, Germany), and was registered on a Rikadenki pen recorder 
(Hellige, Freiburg, Germany). 
 
Agonist studies. Given that two consecutive applications of exogenously applied 
,-methylene ATP (,-mATP), at a concentration producing approximately 
half-maximal effect (1 M), resulted in a stable response, a concentration-
response curve (CRC) was constructed by applying increasing doses of the 
agonist. Single doses of ,-mATP were added to the bath fluid with a time 
interval of 30 min, and had an average contact time of about 20 s. In time-
matched control experiments these precautions had been established to be 
necessary to avoid desensitisation (Ziyal, 1996). 
 
Antagonist studies. After contractions to single doses of exogenously applied 
,-mATP (1 M), added in 30-min intervals, resulted in a stable response the 
antagonist was incubated for 60 - 90 min with time inversely related to the 
concentration tested; suramin and NF023 (< 3 M) for 90 min, higher 
concentrations of suramin and its analogues for 60 min. Two antagonist 
concentrations or one concentration of two different antagonists, respectively, 
were investigated in a single preparation. 
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The bath fluid was generally changed approximately every 15 min throughout the 
experiments. During the equilibration time of antagonists, buffer was replaced 
according to the above mentioned washing procedure with an immediate 
readministration of antagonist. When two antagonist concentrations or two 
different antagonists, respectively, were tested in a single tissue, a washout period 
of at least 1 h preceded the second incubation of antagonists. One preparation 
always served as a time-dependent control to assure that during the course of the 
experiments, there was no change in tissue sensitivity towards single doses of 
,-mATP. 
 
Unless stated otherwise, all experiments were carried out at least three times on 
preparations from different animals. 
 
2.2.1.1. Data  analysis 
 
Concentration-effect relationships presented in this thesis were plotted graphically 
in the form of log10 concentration of agonist/antagonist versus effect. CRC’s were 
constructed employing computerised curve fitting techniques using a 4 parameter 
logistic equation on Graphpad software (Version 2.01, Graphpad Software Inc., 
1996) based on the logistic function introduced by Parker and Waud (1971). 
 
(1) EA = Emax [A]
p/([A]
p+EC50
p) 
 
 E A  =  effect of a given concentration [A] of agonist/ antagonist 
 E max  = maximum  effect 
 [A] =  agonist/antagonist  concentration 
  p  =  slope of the CRC 
 EC50/IC50  =  concentration of agonist/antagonist producing 50 % of 
      the individual maximum effect 
 
Agonist potencies. Contractions induced by exogenously applied ,-mATP 
were quantified in mg tension. Agonist potencies were determined graphically 
(effect vs. log10 concentration) and expressed as pD2 values ( = -log EC50, i.e. the 
molar concentration producing 50 % of the individual maximum effect). 
 
(2) pD2 = -log EC50 
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Antagonist potencies. To determine the inhibitory potency of suramin and 
NF023, IC50 values ( = IC50; i.e. the molar concentration producing 50 % inhibition 
of the response to a single dose of 1 M ,-mATP) were derived from non-linear 
regression analysis of semilogarithmic concentration-inhibition (% inhibition vs. 
log10 concentration of antagonist) curves by fitting the logistic function (1) to the 
pooled data points. The pIC50 values were calculated from: 
 
(3) pIC50 = -log IC50 
 
In screening studies performed for the evaluation of the antagonistic properties of 
small and large ureas, the inhibitory effect of a single dose of the respective 
derivative (10 M), on contractions evoked by ,-mATP (1 M), was investigated 
and expressed as inhibition (%): 
 
   E V  100 
(4)  % inhibition = 100 -  
   E C 
 
EC  being the observed effect in controls and EV the effect observed in the 
presence of antagonist. 
 
2.2.2.  Guinea-pig taenia coli 
 
Preparation. Male Dunkin Hartley guinea-pigs, 250 - 500 g, were killed by a blow 
to the neck and exsanguination. The taenia was dissected free without opening 
the caecum and cleared of connective tissue. Segments 1.5 - 2.0 cm long were 
suspended vertically in 6 ml organ baths containing modified Krebs solution (for 
composition see table 2.1., 37°C, gassed with 95 % O2/5 % CO2). After preloading 
the taenia strips with 1 g tension they were allowed to equilibrate for 45 - 60 min 
with a change of bath fluid every 15 min. Mechanical activity was recorded 
isometrically by a force displacement transducer (TF6V5) connected to a DMS DC 
amplifier (both from W. Fleck, Mainz, Germany), and was registered on a 
Rikadenki pen recorder (Hellige, Freiburg, Germany). 
 
Experimental design. After a cumulative concentration-contraction curve to 
carbachol had been constructed in order to determine the maximal contraction of 
each strip, a standard tone was induced by a concentration of carbachol giving 
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about 50 % of the maximal effect (0.1 M, occasionally up to 0.3 M) every 
15 min. When the carbachol contractions reached a plateau and single doses of 
the relaxant agonist ADPS resulted in stable responses, two cumulative 
concentration-relaxation curves to ADPS were determined on each preparation, 
the first before, the second 60 - 120 min after addition of the antagonists. On 
several preparations a second concentration of antagonist was incubated and a 
third CRC was constructed. 
Control experiments (same protocol, no incubation of antagonist) were carried out 
on one preparation per animal. These experiments were considered as 
time-matched controls. 
 
2.2.2.1. Data  analysis 
 
Relaxant responses to exogenously applied ADPS were expressed as a 
percentage of the carbachol pre-contraction, and plotted against agonist 
concentrations in a semilogarithmic manner. EC50 values were determined by 
fitting the logistic function (1) to the pooled data, and pD2 values were calculated 
as described above (cf. 2.2.1.1.). 
 
Antagonist potencies. The potencies of antagonists were calculated from the 
respective rightward shift of the CRC assessed in the presence of antagonist. In 
that case where only one or two concentrations of an antagonist were tested, its 
pA2 value was determined from the individual dose ratios according to the 
following equation (Tallarida et al., 1979): 
 
(5) pA2 = log (DR-1) + pAX 
 
 pAX = -log [Antagonist] 
  DR =  dose ratio, quotient of the agonist's EC50 values in the presence 
and in the absence of antagonist 
 
In cases where three or more antagonist concentrations were investigated, 
pA2 values were calculated by Arunlakshana-Schild analysis (Arunlakshana and 
Schild, 1959). Slopes were obtained by linear regression of the experimental data 
to the following equation using least squares fit: 
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(6)  log (DR-1) = m pAX - log KD 
 
  m = slope of the regression line 
 K D = antagonist dissociation constant 
 
If the slope m was found not significantly different from -1.00 (p > 0.05), the 
antagonism was regarded as purely competitive. The pA2 value ( = -log KD) was 
then calculated as the x-intercept of a regression line with unit slope (m = -1.00, 
"constrained plot") (Tallarida et al., 1979; Tallarida and Murray, 1986). 
 
2.2.3. Ecto-nucleotidases bioassay  
 
2.2.3.1.  Studies on smooth muscle tissues 
 
Preparation. Guinea-pig taenia coli strips were prepared as described for the 
organ baths experiments (cf. 2.2.2.) and stored in physiological saline (0.9 % 
NaCl; w/v). 
 
Experimental protocol. Single pieces of GPTC (2 - 4 mg) were placed in 24-well 
cell culture dishes filled with 250 l HEPES-buffer (table 2.1.) and were pre-
washed for 15 - 20 min. The pre-wash buffer was changed for 250 l buffer 
containing ATP (0.1 or 1 mM, respectively) as substrate, and the tissues were 
incubated (0.1 mM ATP for 30 min, 1 mM ATP for 15 min) and shaken 
continuously (first incubation). Incubation was terminated by removing the buffer 
and adding it to 1 ml of a 2.5 % (w/v) solution of sodium dodecyl sulphate (SDS) in 
order to avoid further breakdown of ATP by soluble enzymes. Tissues were 
washed again for 10 - 15 min and then incubated with 200 l buffer containing a 
given concentration of a compound, tested for its inhibitory potency, for 30 min 
(pre-incubation). 50 l buffer containing ATP (0.5 or 5 mM, giving a final 
concentration of 0.1 or 1 mM, respectively) and the respective compound 
(concentration similar to that used for pre-incubation) were added and incubated 
for 30 or 15 min, respectively (second incubation). When substrate specificity was 
tested, tissues were incubated with 1 mM of the respective substrate for 15 min 
after the first incubation with ATP (1 mM, 15-min incubation) and the washing 
procedures described above. The buffer was again collected in SDS. For the 
inorganic phosphate (Pi) assay, 1 ml of 1.25 % (w/v) ammonium molybdate 
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solution in 2 M HCl and 0.1 ml of 16 % (w/v) Fiske and SubbaRow reducing agent 
(Fiske and SubbaRow, 1925) were added to the samples. The solutions were 
transferred to cuvettes and left for 30 min at room temperature to develop colour. 
The blue reaction product for Pi was measured spectrophotometrically at 700 nm 
in a Hitachi U-2000 spectrophotometer. KH2PO4 was used as a phosphate 
standard. 
 
2.2.3.2.  Studies on folliculated Xenopus laevis oocytes 
 
Preparation. Ovarian lobes were removed surgically from Xenopus laevis females 
anaesthetised with tricaine (0.2 % w/v) solution and oocytes were separated 
mechanically from the inner ovarian epithelial layer. Folliculated oocytes were 
stored at 19 °C for up to 5 days in oocyte ringer solution (ORI) (table 2.1., 
Oocyte I). 
 
Experimental protocol. Ecto-nucleotidases (ectoN) assays were carried out at 
20  1 °C in a modified Ringer buffer solution. Oocytes were placed in 24-well 
dishes, typically three oocytes per well, in 250 l buffer solution (table 2.1., 
Ooycte II). The further experimental protocol was similar to that described above 
(cf. 2.2.3.1.; Ziganshin et al. 1995). Compounds investigated for their inhibitory 
properties were pre-incubated for 30 min. When oocytes were broken by handling 
during assays, these results were discarded and experiments were repeated. 
 
2.2.3.3. Data  analysis 
 
The amount of phosphate produced in the presence of a compound tested 
(second incubation) was calculated as a percentage of that produced in the first 
incubation. Unless stated otherwise, results were obtained from at least two 
experiments performed in quadruplicate. Tissues incubated with buffer containing 
ATP (100 M) in the first as well as in the second incubation served as 
time-matched controls in order to determine whether there was a change in 
enzymatic activity during the time course of the experiment. Background levels of 
Pi, by contamination with free Pi and the spontaneous breakdown of ATP over the 
time course of the experiment (without cells), were measured and subtracted to 
determine the production of Pi by enzymatic activity alone. 
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2.2.4.  Rat vas deferens 
 
Preparation. Wistar rats were killed by asphyxiation with carbon dioxide. Vasa 
deferentia were removed and freed from connective tissue and adhering fat. 
Tissues were bisected transversely such that each vas gave two equal 
preparations, one prostatic and one epididymal, i.e. four preparations per animal. 
The preparations were mounted vertically in 6 ml organ bath under 750 mg resting 
tension and immersed in modified Krebs buffer (for composition see table 2.1., 
pH 7.4, 37°C, aerated with 95 % O2/5 % CO2) containing indomethacin (6.0 M). 
Tension changes were measured isometrically, via a force displacement 
transducer (TF6V5) connected to a DMS DC amplifier (both from W. Fleck, Mainz, 
Germany), and the recordings were displayed on a Rikadenki pen recorder 
(Hellige, Freiburg, Germany). The tissues were allowed to equilibrate for 30 min, 
with a change of bath fluid every 10 min. Tension was maintained at 750 mg for 
the duration of the experiments. 
 
Agonist studies. When consecutive applications of exogenous agonist resulted in 
a stable response, single dose CRC’s were constructed by applying increasing 
doses of ,-mATP (0.1 - 300 M), adenosine-5'-O-(3-thiotriphosphate) (ATPS; 
0.3 - 100 M),  ,-methylene-L-ATP (L-,-mATP; 1 - 100 M) and ADPS 
(1 - 300 M) at 15- to 60-min intervals. Tissues were washed immediately after the 
responses had peaked (average contact time of approximately 20 s). Studying 
desensitisation of P2X receptors, 2 to 5 cumulative doses of ,-mATP (10 M), 
L-,-mATP (30 M) or ADPS (30 M), respectively, were applied at 2-min 
intervals. 
 
Antagonist studies. Contractions were obtained to single doses of ,-mATP 
(10 M), ATPS (10 M), L-,-mATP (30 M) or ADPS (30 M), respectively, 
added in 30-min intervals, in the case of IC50 determination, or single dose CRC’s 
of  ,-mATP (15- to 60-min intervals) as well as CRC’s to ADPS (15-min 
intervals for single doses) were constructed, in the absence and in the presence of 
antagonists (60 to 120 min exposure). One or two antagonist concentrations were 
investigated in a single preparation, with a 1-h washout period preceding the 
incubation of the second antagonist concentration (usually one order of magnitude 
higher than the first). 
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The bath fluid was generally changed every 15 min throughout the experiments. 
During equilibration time of antagonists, buffer was replaced followed by an 
immediate readministration of antagonist. One preparation (same protocol, no 
incubation of antagonist) always served as time-dependent control. 
 
2.2.4.1. Data  analysis 
 
Analysis of concentration-effect relationships established in ratVD was 
complicated by the fact that none of the agonists' CRC’s did reach a well-defined 
maximum and, as a consequence, estimation of agonist potency on the basis of 
the EC50 level was impossible. 
 
Agonist potencies. Contractions induced by exogenously applied agonists were 
quantified in mg tension. Agonist potencies were determined graphically (effect vs. 
log10 concentration) as pEC1000 and pEC500 values (i.e. the concentration of 
agonist developing 1000 mg and 500 mg tension, respectively.). 
 
Antagonist potencies. To determine the inhibitory potency of suramin and the 
suramin-derived large ureas as well as of NF023 and its analogues, IC50 values 
(i.e. the molar concentration of antagonist producing 50 % inhibition of the 
response to a single dose of agonist) were derived from non-linear regression 
analysis of the semilogarithmic concentration-inhibition curves (% inhibition vs. 
log10 concentration of antagonist) employing computerised curve-fitting techniques 
based on the 4 parameter logistic function (cf. 2.2.1.1.). pA2 values were 
calculated according to equation (5) from dose ratios determined at an appropriate 
portion of the CRC, obtained in the presence of antagonist, which was parallel to 
that of the control curve. This was the 1000-mg tension level for analysis of CRC’s 
to  ,-mATP and the 500-mg tension level for CRC’s to ADPS, respectively. 
Apparent pA2 values (pA2*) were calculated according to the equation introduced 
by Cheng and Prusoff (1973). In those cases where IC50 values have been deter-
mined using ,  -mATP as agonist, an EC                   50 of 1 M has been taken for calculation.    
 
(7) pA2* = IC50/(1+[A]/EC50) 
  [A]  =  agonist concentration (,-mATP 10 M) 
 EC50 =  concentration  of  ,-mATP producing 50 % of the maximum 
effect (1 M) 
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2.2.5. Statistics 
 
Data are presented as mean  S.E.M. with n indicating the number of 
experiments. Differences between mean values were tested for statistical 
significance by Student's t-test; p < 0.05 was accepted as being significant. 
Regression lines were calculated using least-squares fit. Calculations were 
performed on a personal computer employing the programs Pharm/PCS (version 
4.1, Pharmacological Calculation System; Tallarida and Murray, 1986) as well as 
GraphPad Prism (version 2.01, GraphPad Software Inc.). 
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3.1.  Screening of suramin- and NF023-related compounds 
 
3.1.1.  Rabbit vas deferens 
 
3.1.1.1.  Concentration-response curves to ,-methylene ATP 
 
In order to compare the potency of ,-methylene ATP (,-mATP) and the extent 
of agonist-induced contraction with regard to the anatomical origin of the tissue 
(numbering 1 - 6 from prostate to epididymides), single dose CRC’s to 
exogenously applied ,-mATP (30-min intervals) were constructed. ,-mATP 
caused concentration-dependent transient contractions in all segments of rabbit 
vas deferens (RVD) (figure 3.1.). 
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Fig. 3.1.  Concentration-response curves for contractile responses of rabbit 
vas deferens obtained to single doses of ,-mATP (30-min intervals) with regard 
to the anatomical origin of the tissue (numbering 1 - 6 from prostate to 
epididymides). Data shown are means +/- S.E.M. with n = 3 - 20 for each point. 
Some error bars were within the width of the symbols. 
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At a concentration of 1 M, segments 2 - 4 generated similar tension, and 
although segments 1, 5 and 6 were less capable of developing tension, a 
statistically significant difference was only found for segment 1 (table 3.1.). 
 
Table 3.1.  Development of tension (mg) in rabbit vas deferens challenged by 
exogenous ,-mATP (1 M) depending on the segment (1 - 6, counting from the 
prostate to the epididymides). Data are presented as means  S.E.M. from 3 to 
4 observations. 
 
Segment 1  Segment 2  Segment 3  Segment 4  Segment 5  Segment 6 
501  31  1340  174  1370  239  1256  219  946  175  865  211 
 
In contrast to the tension generated, differences in the agonist potency of 
,-mATP in RVD were only poor, pD2 values in segments 2 - 4 being slightly 
higher than in segments 1, 5 and 6, respectively. Segments 2 - 6 were generally 
chosen for further investigations on P2X receptors present in RVD (table 3.2.). 
The overall pD2 value calculated for ,-mATP was 6.05  0.13 for segments 
2 - 6. 
 
Table 3.2. Potency  of  ,-mATP (pD2 values; mean  S.E.M.) in inducing 
contraction of rabbit vas deferens depending on the segment used (1 - 6, counting 
from the prostate to the epididymides). 
 
Segment 1  Segment 2  Segment 3  Segment 4  Segment 5  Segment 6 
5.93  0.02  6.12  0.04  6.25  0.09  6.13  0.08  5.91  0.06  5.85  0.08 
 
3.1.1.2.  Inhibitory potency of suramin and NF023 
 
In RVD, contractions elicited by ,-mATP (1 M) were concentration-dependently 
blocked by suramin (5, 10, 30, 50 and 100 M) and NF023 (1, 3, 10 and 30 M). 
Analysis of the resulting concentration-inhibition curves (CIC's) (figure 3.2.) yielded 
pIC50 values of 4.75  0.03 for suramin and 4.97  0.03 for NF023. 
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Fig. 3.2.  Inhibitory potency of suramin and NF023 on contractions of rabbit 
vas deferens induced by ,-mATP (1 M). Concentration-inhibition curves for 
increasing concentrations of antagonists are shown. Data presented are 
means  S.E.M. (n = 3 - 15). 
 
3.1.1.3.  P2X receptor-screening of suramin- and NF023-related compounds 
 
Effects of suramin analogues (10 M) on contractions of RVD elicited by 
,-mATP (1 M) were investigated. When responses to ,-mATP were reduced 
in the presence of a derivative, the extent of reduction was expressed as inhibition 
(%) of contraction obtained in the respective control experiment. Results are 
presented in combination with screening results established in guinea-pig taenia 
coli and in the ecto-nucleotidases bioassay (cf. 3.1.4.). 
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3.1.2.  Guinea-pig taenia coli 
 
3.1.2.1.  Concentration-response curves to carbachol 
 
The potency of the muscarinic agonist carbachol to evoke contraction of 
guinea-pig taenia coli (GPTC) was investigated in order to determine the 
appropriate concentration (giving about 50 % of the maximum effect) required to 
maintain a constant pre-contraction of the tissue. Carbachol, applied in a 
cumulative fashion, produced concentration-dependent contraction of GPTC 
yielding a pD2 value of 6.84  0.04 (figure 3.3.). The following relaxation-
experiments were carried out at a standard tone induced by 0.1 - 0.3 M 
carbachol. 
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Fig. 3.3.  Concentration-response curve for contractions induced by carbachol 
in guinea-pig taenia coli. All data points are means  S.E.M. with n = 11 - 15 for 
each point. Some error bars were within the width of the symbols. 
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3.1.2.2.  Inhibitory potency of suramin and NF023 
 
The adenine nucleotide adenosine-5’-O-2-thiodiphosphate (ADPS) caused 
concentration-dependent relaxation of the carbachol-pre-contracted GPTC 
(pD2 = 6.36   0.05, n = 14). Increasing concentrations of suramin and NF023 
shifted the curve progressively to the right without changing the maximum 
(figure 3.4. A. and B.). For suramin (30 - 300 M), the regression line according to 
Arunlakshana and Schild (1959) was linear with a slope of -0.81  0.14 (not 
significantly different from -1.00), resulting in a pA2 value of 4.45  0.06 
(constrained plot). pA2 values calculated for NF023 decreased with increasing 
concentrations of the antagonist (pA2 values of 4.72  0.09, 4.40  0.03 and 
4.07  0.14 for 30, 100 and 300 M, respectively). In accord with this deviation 
from competitive antagonism, the plot according to Arunlakshana and Schild was 
linear with a slope (-0.35  0.13) significantly different from unity. 
 
3.1.2.3.  P2Y receptor-screening of suramin- and NF023-related compounds 
 
Effects of suramin analogues (10 M) on concentration-relaxation curves to 
ADPS in GPTC were investigated. When CRC’s to ADPS were shifted to the 
right in the presence of a derivative, its antagonistic potency was calculated from 
the individual dose ratios and expressed as pA2 value (for results see 
section 3.1.4.). 
 
 
 
 
 
 
Fig. 3.4. (page 95) Antagonism of ADPS-induced relaxation of 
carbachol-pre-contracted guinea-pig taenia coli by suramin (A.) and NF023 (B.). 
Concentration-response curves for ADPS in the absence and in the presence of 
increasing concentrations of the antagonists are shown. All points are means 
+/- S.E.M. with n = 3 - 13 for each point. Some error bars were within the width of 
the symbols. For suramin, Schild analysis (A., shown in the insert) yielded a slope 
of -0.81  0.14 (not significantly different from -1.00), and a pA2 value (constrained 
plot) of 4.45  0.06 was estimated. 
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3.1.3. Ecto-nucleotidases  bioassay 
 
3.1.3.1.  Studies on smooth muscle tissues 
 
3.1.3.1.1. Characterisation of nucleotide-degrading enzymes in guinea-pig 
taenia coli 
 
Spontaneous ATP breakdown, when incubated in buffer without tissue, as well as 
the amount of inorganic phosphate (Pi) released from the tissue were negligible 
(data not shown). Resting ATPase activity was equivalent to 
25.2  0.6 nmol Pi mg
-1 wet tissue (n = 32) in Ringer buffer when ATP (1 mM) was 
present for 15 min. Over a 15-min incubation period, an average amount of 
3.5  mg tissue per well metabolised 35.3  0.8 % of the total amount of ATP 
added. The rate of hydrolysis of ATP (1 mM) by GPTC was linear for incubation 
periods up to 30 min duration (figure 3.5.). 
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Fig. 3.5. Time course of 
ATP (1 mM) hydrolysis 
determined by the 
formation of inorganic 
phosphate (Pi). Data are 
shown as means  S.E.M. 
(n = 8 - 28). Some error 
bars were within the width 
of the symbols. 
 
 
The extent of degradation (Pi formation) of ATP, ADP and AMP, used as 
substrates, at a concentration of 1 mM was: ATP (taken as 100 %) > ADP 
(44.6  1.7 %, n = 20)  AMP (40.2  10.0 %, n = 20) (figure 3.6. A.). Omission of 
the divalent cations Ca
2+ and Mg
2+ (in the presence of 1 mM NaEDTA) diminished 
hydrolysis of ATP, ADP and AMP to 27.8  1.8 %, 15.6  2.4 % and 16.1  7.0 %, 
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respectively, (n = 4 - 28) of the respective controls in the presence of Ca
2+ and 
Mg
2+ (figure 3.6. B.). 
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Fig. 3.6.  A. Degradation of ADP and AMP (1 mM, incubated for 15 min) by 
strips of guinea-pig taenia coli and inhibitory effect of suramin (0.3 mM, 30-min 
pre-incubation) on the hydrolysis of the nucleotides, respectively. Data are 
presented as mean percentages of the amount of inorganic phosphate (Pi) 
produced in the presence of  ATP (1 mM, incubated for 15 min) + S.E.M. 
(n = 8 - 20). B. Degradation of ATP, ADP and AMP in the absence of the divalent 
cations Ca
2+ and Mg
2+ in GPTC (buffer containing 1 mM NaEDTA). Data shown 
are percentages (mean + S.E.M.) of control incubations in the presence of the 
divalent cations (n = 4 - 28). 
 
p-Nitrophenylphosphate (0.5 mM, 15 min), a substrate for the non-specific alkaline 
phosphatases, was hardly dephosphorylated by GPTC (4.1  0.3 % of Pi 
formation in controls; n = 12). Furthermore, the 5'-nucleotidase inhibitor ,-
methylene ADP (100 M) did not affect ATP hydrolysis (100.4  6.0 % of Pi 
formation in controls; n = 16). 
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3.1.3.1.2. Inhibitory effects of suramin on nucleotide-degrading enzymes 
present in guinea-pig taenia coli 
 
Tissues were incubated with ATP in the absence and in the presence of suramin 
(0.1 and 0.3 mM). In contrast to results obtained for the lower ATP concentration 
(0.1  mM; 30-min incubation), suramin displayed a concentration-dependent 
inhibition of Pi generation when degradation of a higher concentration of 
ATP (1 mM; 15-min incubation) was examined (figure 3.7.). 
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Fig. 3.7. Inhibitory  effect  of 
suramin on degradation of ATP 
(0.1 mM, incubated for 30 min, 
and 1 mM, incubated for 15 min) 
in guinea-pig taenia coli. Data 
are presented as percentages 
(means + S.E.M.) of formation of 
inorganic phosphate (Pi) in the 
respective control incubations 
(n = 8 - 30). 
 
Nevertheless, the extent of inhibition by suramin was considerably low for ATP 
0.1 mM (73.6  2.5 % for 0.1 mM and 73.0  2.3 % of Pi generation in controls for 
0.3 mM of suramin, respectively) as well as for ATP 1 mM (79.8  2.7 % for 
0.1 mM and 69.4  3.3 % of Pi generation in controls for 0.3 mM of suramin, 
respectively). Additionally, suramin (1 mM) decreased Pi formation from ATP 
(1 mM) to 72.4  4.6 % of controls indicating that the inhibitory effect of suramin 
was limited, even if the higher ATP concentration was tested (figure 3.8.). 
Figure  3.6. A. shows the inhibitory effect of suramin on ecto-nucleotidases 
degrading ADP and AMP. Suramin (0.3 mM) reduced Pi generation of ADP 
controls (1 mM, 15-min incubation, n = 8) to 70.7  2.7 % and of AMP controls 
(1 mM, 15-min incubation, n = 8) to 78.4  4.4 %, respectively. Thus, the inhibitory 
activity of suramin on ecto-nucleotidases, degrading ATP, ADP or AMP was 
almost similar. In contrast, suramin (1 mM) had no effect on Pi formation in the 
absence of divalent cations (96.9  6.0 % of Pi generation in controls of ATP 
1 mM; n = 8) (figure 3.8.). 
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Fig. 3.8.  Inhibitory effect of suramin 
(1 mM) on degradation of ATP (1 mM, 
incubated for 15 min) in guinea-pig 
taenia coli in the presence and in the 
absence of Ca
2+ and Mg
2+  (buffer 
containing 1 mM NaEDTA). Data are 
presented as percentages (means 
+  S.E.M.) of formation of inorganic 
phosphate (Pi) in the respective 
controls (first incubation) (n = 8). 
 
 
3.1.3.2.  Studies on folliculated Xenopus laevis oocytes 
 
The suitability of the Xenopus laevis oocytes ecto-nucleotidases (ectoN) assay for 
the screening of the inhibitory activity of a large number of suramin analogues on 
ATP-degrading enzymes was investigated, testing the inhibitory effects of suramin 
(0.1 - 1 mM), NF023 (0.1 mM and 0.3 mM) and the ectoN inhibitor ARL 67156 
(0.1  mM and 0.3 mM) on ATP breakdown. Pi generation (4.82  0.13 nmol 
Pi/oocyte in controls of ATP 0.1 mM incubated for 30 min, n = 24) was 
progressively decreased in the presence of increasing concentrations of suramin, 
NF023 and ARL 67156 (second incubation). All compounds inhibited ATP 
breakdown to approximately a similar extent (table 3.3.; figures 3.9. and 3.10.). 
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Fig. 3.9.  Inhibitory activity of suramin 
(0.1  -  1 mM) on degradation of ATP 
(0.1 mM, incubated for 30 min) in Xenopus 
laevis oocytes. Data are presented as 
percentages (means + S.E.M.) of formation 
of inorganic phosphate (Pi) in the respective 
control experiments (first incubation) 
(n = 7 - 16). 
 3. Results 
Table 3.3.  Inhibition of ATP breakdown by ecto-nucleotidases present in 
folliculated  Xenopus laevis oocytes by suramin, NF023 and ARL 67156. Data 
presented are means  S.E.M., obtained from 7 to 31 observations (n. d. = not 
determined). 
 
Concentration (mM) % Pi generation in controls 
 Suramin  NF023  ARL  67156 
0.1 66.2   1.0  78.5  3.6  81.3  3.1 
0.3 58.8   1.8  68.9  2.1  57.1  2.5 
1 49.3   2.3  n. d.  n. d.  
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Fig. 3.10.  Inhibitory activity of NF023 and ARL 67156 (0.1 and 0.3 mM) on 
degradation of ATP (0.1 mM, incubated for 30 min) in Xenopus laevis oocytes. 
Data are presented as percentages (means + S.E.M.) of formation of inorganic 
phosphate (Pi) in the respective control experiments (first incubation) (n = 7 - 12). 
 
3.1.3.3.  Ecto-nucleotidases screening of suramin- and NF023-related 
compounds 
 
Effects of suramin analogues (300 M) on ATP breakdown in Xenopus laevis 
oocytes were investigated. When the amount Pi generated was decreased in the 
presence of a derivative (second incubation), its inhibitory activity was expressed 
100 3. Results 
as inhibition (%) of Pi produced in control incubations (first incubation) (for results 
see next section, 3.1.4.). 
 
3.1.4.  Inhibitory activity of suramin- and NF023-related compounds on 
native P2 receptors and ecto-nucleotidases 
 
To give a comprehensive overview, compounds were divided into two major 
groups: the suramin-related large ureas and the NF023-derived small ureas. A 
further subdivision according to structural variations appeared to be appropriate to 
simplify comparison within the subgroups as well as between the two major 
families. The inhibitory activity of the derivatives was examined on P2X receptors 
present in RVD (see 3.1.1.3.), on P2Y receptors mediating relaxation of GPTC 
(cf. 3.1.2.3.), and on ATP breakdown by ecto-nucleotidases present in Xenopus 
laevis oocytes (cf. 3.1.3.3.). Suramin and NF023 served as reference drugs. 
 
3.1.4.1. Large  ureas 
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3.1.4.1.1.  Variations in the substitution pattern of the benzoyl residues 
 
Fig. 3.11. Principle structure 
of large ureas I, varying in the 
substitution pattern of the 
benzoyl residues (for detailed 
chemical structure and results 
see table 3.4. a.). 
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Table 3.4.a.-d.  (following pages) Screening results of suramin-related large 
ureas obtained in studies at P2X receptors in rabbit vas deferens (RVD), 
P2Y  receptors in guinea-pig taenia coli (GPTC), and on ATP breakdown by 
ecto-nucleotidases (ectoN) present in folliculated Xenopus laevis oocytes. Data 
presented are means  S.E.M. of at least four observations on different animals, 
or cells from different animals, in the case of studies on oocytes, respectively. For 
detailed descriptions of experimental protocols and analysis of results the reader 
is referred to chapter 2, section 2.2. and chapter 3, sections 3.1.1. to 3.1.3., 
(n.s. = not significant). 
 
Table 3.4.a. 
 
Large ureas I  R
1 R
2 P2X  (RVD) 
% Inhibition 
P2Y (GPTC) 
pA2 values 
EctoN 
% Inhibition 
Suramin CH3 H  26.0   5.6  n.s.  41.2  1.8 
NF037 H  H 64.7   1.6  4.83  0.23  57.0  5.3 
NF157 F  H 16.0   3.3  n.s.  41.4  4.8 
NF198 phenyl  H 73.1   3.3  5.07  0.13  56.6  3.3 
NF212 CH3 CH3 12.1   6.0  4.24  0.31  38.3  2.7 
NF213 H  CH3 21.8   5.4  n.s.  30.6  5.9 
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3.1.4.1.2.  Variations of the benzoyl residues 
 
N
N
H
O N
O
H
 
 
 
NF356 
 
 
 
 
NF506 
HN
HO3S
HO3S
N N
O
2
O
HO3S
HH
 
 
 
Fig. 3.12. Chemical structure of NF356 and NF506 (for results see table 
3.4.b.). 
 
Table 3.4.b. 
 
Large ureas II  P2X (RVD) 
% Inhibition 
P2Y (GPTC) 
pA2 values 
EctoN 
% Inhibition 
NF356 47.0   9.3  5.04  0.12  52.2  2.8 
NF506 53.0   13.9  n.s.  62.7  3.0 
 
3.1.4.1.3. Variations in the substitution pattern of the aminonaphthalene 
sulphonic acid residues in combination with different linkages of 
the benzoyl residues 
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Fig. 3.13.  Principle structure of 1'-3', 1''-3''-linked (A.), 1'-4', 1''-3''-linked (B.) 
and 1'-4', 1''-4''-linked (C.) large ureas III, varying in the substitution pattern of the 
aminonaphthalene sulphonic acid residues (for detailed chemical structure and 
results see table 3.4.c.). 
 
Table 3.4.c. 
 
Large ureas III  Fig. 
3.13.
R
1 R
2 P2X  (RVD) 
% Inhibition
P2Y (GPTC) 
pA2 values 
EctoN 
% Inhibition
NF037 A.  SO3H H  64.7   1.6  4.83  0.23  57.0  5.3 
NF551 A.  H  SO3H 20.7   8.1  4.60  0.12  49.6  5.4 
NF280 B.  SO3H H  20.4   7.5  4.60  0.25  43.1  5.8 
NF032 B.  H  SO3H 6.0   3.1  n.s.  28.6  2.4 
NF279 C.  SO3H H  80.7   7.0  n.s.  66.4  2.6 
NF031 C.  H  SO3H 4.6   2.7  n.s.  52.8  6.6 
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3.1.4.1.4.  Variations of the central urea group 
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Fig. 3.14. Chemical structure of suramin-related large ureas IV with central 
groups differing from the urea-bridged parent compound (for screening results see 
table 3.4.d.). 
 
Table 3.4.d. 
 
Large ureas IV  R  P2X (RVD) 
% Inhibition 
P2Y (GPTC) 
pA2 values 
EctoN 
% Inhibition 
NF059 CH3 9.4   3.7  n.s.  32.5  4.1 
NF064 CH3 24.0   4.9  n.s.  47.9  1.5 
NF513 H  38.8   5.8  n.s.  50.8  3.4 
NF299 CH3 6.8   3.7  n.s.  43.7  5.9 
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3.1.4.2. Small ureas 
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3.1.4.2.1.  Variations of the benzoyl residue substituent 
 
Fig. 3.15.  Principle structure of small 
ureas I, varying in the substitution pattern of 
the benzoyl residues (for detailed chemical 
structure and results see table 3.5.a.). 
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Table 3.5.a.-e. (following pages) Screening results of NF023-related small ureas 
obtained in studies at P2X receptors in rabbit vas deferens (RVD), P2Y receptors 
in guinea-pig taenia coli (GPTC) and ATP breakdown by ecto-nucleotidases 
(ectoN) present in folliculated Xenopus laevis oocytes. Data presented are means 
 S.E.M. of at least four observations on different animals, or cells from different 
animals, in the case of studies on oocytes, respectively. For detailed descriptions 
of experimental protocols and analysis of results the reader is referred to chapter 
2, section 2.2. and chapter 3, sections 3.1.1. to 3.1.3. 
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Table 3.5.a. 
 
Small ureas I  R  P2X (RVD) 
% Inhibition 
P2Y (GPTC) 
pA2 values 
EctoN 
% Inhibition 
NF023 H  48.3    3.8 n.s. 31.1   2.1 
NF058 CH3 8.4   6.0  n.s.  35.6  3.3 
NF144 C(CH3)3 0  n.s.  n.d. 
NF195 phenyl  31.7   2.3  n.s.  39.5  2.5 
NF156 F  25.0   11.4  n.s.  34.6  2.1 
NF255 Cl  29.2   7.7  n.s.  44.5  2.3 
 
 
3.1.4.2.2.  Exchange of the benzoyl residue 
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Fig. 3.16.  Chemical structure of small ureas II, in which the benzoyl fragment is 
exchanged for either isomeric biphenyl residues or a furanyl residue (for results 
see table 3.5.b.). 
107 3. Results 
Table 3.5.b. 
 
Small ureas II  R
1 R
2 P2X  (RVD) 
% Inhibition 
P2Y (GPTC) 
pA2 values 
EctoN 
% Inhibition 
NF139 SO3H H  50.6   3.1  n.s.  33.4  3.7 
NF192 SO3H H  76.9   6.7  5.60  0.09  66.3  2.7 
NF130 SO3H H 16.1   1.4  n.s.  62.7  3.0 
NF136 SO3H H  69.5   6.0  5.56  0.10  51.2  3.0 
NF201 SO3H H 70.1   2.7  4.83  0.13  28.2  3.8 
NF359 H  SO3H 4.0   2.2  n.s.  30.6  1.4 
 
 
3.1.4.2.3.  Variations in the substitution pattern of aminonaphthalene 
sulphonic acid residues in combination with different linkages of 
the benzoyl residue 
 
A.  B. 
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Fig. 3.17. Principle structure of 1'-3'-linked (A.) and 1'-4'-linked (B.) small 
ureas III, varying in the substitution pattern of aminonaphthalene sulphonic acid 
residues (for detailed chemical structure and results see table 3.5.c.). 
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Table 3.5.c. 
 
Small ureas III  R
1 R
2 R
3 R
4 P2X  (RVD)
% Inhibition
P2Y (GPTC) 
pA2 values 
EctoN 
% Inhibition
NF550 (A.)  H  SO3H -  -  65.9   6.4  5.43  0.07  43.3  4.0 
NF278 (B.)  SO3H H  SO3HS O 3H4 . 7    2.5  n.s.  26.1  3.5 
NF013 (B.)  H  SO3H SO3HS O 3H3 . 7    1.5  n.s.  18.3  3.8 
NF289 (B.)  SO3H H  SO3H H 2.7   1.7  n.s.  12.5  2.0 
NF295 (B.)  SO3H H  H  SO3H2 . 8    1.7  n.s.  11.4  2.5 
 
 
3.1.4.2.4. 1'-4'-linked small ureas connected to 7-aminonaphthalene di- and 
tri-sulphonic acid residues 
 
R
3
R
2
R
1
N N
O
HH 2
NH
O
 
 
Table 3.5.d. 
 
Small ureas IV  R
1 R
2 R
3 P2X  (RVD) 
% Inhibition 
P2Y (GPTC) 
pA2 values 
EctoN 
% Inhibition 
NF347 SO3H SO3H SO3H 8.7   4.0  n.s.  36.2  4.5 
NF291 SO3H SO3H H  1.8   0.7  n.s.  28.3  5.6 
 
Fig. 3.18.  Principle structure of 1'-4'-
linked small ureas IV connected to 7-amino-
naphthalene di- and trisulphonic acid 
residues (for results see Table 3.5.d.). 
 3. Results 
3.1.4.2.5.  Variations of the central urea group 
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Fig. 3.19.  Chemical structure of NF344, NF343 and NF300 (small ureas V, for 
results see table 3.5.e.) 
 
Table 3.5.e. 
 
Small ureas V  P2X (RVD) 
% Inhibition 
P2Y (GPTC) 
pA2 values 
EctoN 
% Inhibition 
NF344 0  n.s.  27.2   6.5 
NF343 2.4   1.3  n.s.  44.7  4.0 
NF300 9.3   3.3  n.s.  27.6  2.7 
 
 
As shown in the tables 3.4.a.-d. and 3.5.a.-e., the antagonistic properties of large 
and small ureas at native P2 receptor subtypes and ecto-nucleotidases are 
controlled by different structural parameters; 
 the molecular size of the compounds, 
 the position and number of aminonaphthalene sulphonic acid residues 
 the nature and substitution pattern of the aromatic rings 
 the structure of the bridge linking the moieties of these symmetrical com-
pounds. 
As a result, analogues with different receptor-selectivity profiles were obtained. 
For a detailed structure-activity relationship analysis see 4. Discussion. 
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3.2.  Detailed pharmacological characterisation of large ureas III and small 
ureas III 
 
Derivatives of large and small ureas type III (for chemical structure see figure 
3.13., table 3.4.c. and figure 3.17., table 3.5.c.) were investigated for their 
inhibitory potencies at P2X1-like receptors present in prostatic segments of rat vas 
deferens (ratVD), P2Y receptors in GPTC and P2Y1-like receptors in guinea-pig 
ileal longitudinal smooth muscle (GPI). Additionally, the P2 receptor specificity as 
well as the concentration-dependent inhibitory potency of the P2X1-selective 
compounds NF279 and NF031 on ATP-breakdown in Xenopus laevis oocytes 
were examined. The respective parent compounds suramin (large ureas) and 
NF023 (small ureas) were used as reference drugs. 
 
3.2.1.  Inhibitory potency at P2X1-like receptors (rat vas deferens) 
 
The potency of small and large ureas III to inhibit P2X1-like receptor-mediated 
contraction of prostatic segments of ratVD induced by ,-mATP (10 M) was 
determined. pIC50 values were derived from non-linear regression analysis of 
concentration-inhibition curves obtained for each compound. 
 
3.2.1.1.  Large ureas III 
 
,-mATP (10 M) elicited rapid, transient contractions (1499.7  78.4 mg tension, 
n = 15) of prostatic segments of ratVD which were reduced and finally abolished 
by increasing concentrations of the large ureas NF037, NF551, NF280, NF032, 
NF279, NF031 and suramin. Non-linear regression analysis of the resulting 
concentration-inhibition curves (figure 3.20.) yielded pIC50 values from which 
apparent pA2 values (pA2*) were calculated according to the equation introduced 
by Cheng and Prusoff (1973) (see 2.2.4.1., table 3.6.). 
 
Among these large ureas, the structural isomers NF279 and NF031 displayed the 
highest potency in blocking P2X1-like receptor-mediated contractions of ratVD. 
Thus, the effect of NF279 on CRC’s to single doses of ,-mATP was also 
examined, for results see section 3.2.1.3. 
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A. 
 
Fig. 3.20. Inhibitory  potency  of 
large ureas III. The graphs show 
concentration-inhibition curves 
obtained for the large ureas 
NF037 and NF551 (A.), NF280 
and NF032 (B.), NF279 and 
NF031 (C.), and the parent 
compound suramin (broken lines) 
in prostatic segments of rat vas 
deferens. Given are mean 
%  inhibition (n = 2 - 5) of 
contractions induced by single 
doses of exogenously applied 
,-mATP (10 M). Error bars 
are not shown. For 
corresponding pIC50 values see 
table 3.6. 
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Table 3.6.  Inhibitory potency (pIC50 and apparent pA2 [pA2*]) of suramin and its 
structural analogues on contractions induced by ,-mATP (10 M) in prostatic 
segments of rat vas deferens (for chemical structure see figures 3.11. and 3.13., 
the corresponding graphs are shown in figure 3.20.). Data are presented as 
means  S.E.M. from 3 to 5 observations. 
 
 Substitution  pattern   
Compound naphthalene 
-SO3H 
linkage of 
benzoyl moieties
pIC50 pA2* 
Suramin 1,3,5  1'-3',  1''-3''  4.68   0.02  5.72  0.02 
NF037 1,3,5  1'-3',  1''-3''  4.79   0.17  5.83  0.18 
NF551 1,3,6  1'-3',  1''-3''  4.84   0.07  5.88  0.06 
NF280 1,3,5  1'-4',  1''-3''  4.31   0.07  5.35  0.07 
NF032 1,3,6  1'-4',  1''-3''  4.45   0.05  5.49  0.05 
NF279 1,3,5  1'-4',  1''-4''  5.71   0.09  6.75  0.09 
NF031 1,3,6  1'-4',  1''-4''  4.96   0.04  6.00  0.04 
 
3.2.1.2.  Small ureas III 
 
The potency of NF023-derived small ureas III to inhibit contractions of ratVD to 
single doses of exogenously applied ,-mATP (10 M) was assessed as 
described for the large ureas III (see 3.2.1.1.). For concentration-inhibition curves 
see figure 3.21.; the resulting pIC50 values as well as apparent pA2 values are 
given in table 3.7. The derivatives NF278 and NF013 were without effect when 
concentrations lower than 100 M were investigated. Therefore their inhibitory 
activity was only tested at a single concentration. 
 
 
 
Table 3.7.  (page 114) Inhibitory potency of NF550 and its parent compound 
NF023 (pIC50 and apparent pA2) and inhibition (%) of NF278 and NF013 (100 M), 
respectively, on contractions of prostatic segments of rat vas deferens induced by 
,-mATP (10 M). Data shown are means  S.E.M. (n = 3 - 4). For chemical 
structures see figures 3.15. and 3.17., the corresponding graphs are shown in 
figure 3.21.
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 Substitution  pattern     
Compound naphthalene 
-SO3H 
linkage of 
benzoyl 
moiety 
pIC50 pA2* %  Inhibition
NF023 1,3,5  1'-3'  4.93   0.03  5.97  0.02   
NF550 1,3,6  1'-3'  5.13   0.07  6.17  0.07   
NF278 1,3,6  1'-4'      7.3   3.7 
NF013 1,3,5  1'-4'      20.3   6.7 
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Fig. 3.21. Inhibitory potency of NF550 and its parent compound NF023 on 
contractile responses of prostatic segments of rat vas deferens induced by 
,-mATP (10 M). The graph shows concentration-inhibition curves obtained for 
NF550 and NF023 and inhibitory activity of 100 M of NF278 and NF013. Data 
shown are means +/- S.E.M. (n = 3 - 4) of inhibition (%) of ,-mATP-induced 
contractions. Error bars falling within the area of a symbol are not shown (for 
results see table 3.7.). 
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3.2.1.3.  Inhibitory properties of NF279 
 
3.2.1.3.1.  Effect of NF279 on concentration-response curves to ,-
methylene ATP 
 
As illustrated in figure 3.22., CRC’s to single doses of ,-mATP (15- to 60-min 
intervals) did not reach a well-defined maximum, thus, the EC50 value as an 
estimate of agonist potency could not be determined. In the absence of 
antagonist, increasing concentrations of ,-mATP elicited increasing contractions 
(pEC1000 = 5.48   0.06, n  = 9) of prostatic segments of ratVD. CRC’s were 
reproducible over the time course of experimentation, as evidenced by the fact 
that in time-matched control experiments the first CRC’s (pEC1000 = 5.29  0.11, 
n = 2) was almost superimposible by the second CRC’s (pEC1000 = 5.17  0.15, 
n = 2; figure 3.22.B.). Incubation of NF279 at 1 M, 3 M and 10 M for 60 min 
produced concentration-dependent antagonism of contractile responses to 
,-mATP indicated by a rightward shift of the ,-mATP CRC’s in the presence 
of antagonist (figure 3.22. A.). Additionally, an increase in the slope of the 
,-mATP CRC’s, which was not depending on the NF279 concentration tested, 
was observed. 
 
To test whether the antagonism of NF279 was competitive, dose ratios were 
calculated from equieffective concentrations of ,-mATP (read from the 1000 mg 
tension level of the respective CRC’s) in the absence and in the presence of the 
antagonist. pA2 values, calculated for each concentration of NF279 from individual 
dose ratios were significantly different from each other (table 3.8.). To assure that 
the increase in pA2 values is not due to non-sufficient pre-incubation of NF279, 
especially when low concentrations of the antagonist were examined, similar 
experiments were performed applying NF279 (1 M) 120 min prior to generation 
of the second agonist CRC’s. However, no difference was found comparing 
pA2 values determined for NF279 (1M) after 60 and 120 min of pre-incubation 
(pA2 = 6.07  0.08 for 60 min and 6.01  0.40 for 120 min of pre-incubation of the 
antagonist), respectively. 
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Fig. 3.22.  A. Antagonism of NF279 on ,-mATP-induced contractions of 
prostatic segments of rat vas deferens (for corresponding pA2 values see 
table 3.8.). Concentration-response curves in the absence and in the presence of 
increasing concentrations of NF279 are shown. B. The graph shows 
concentration-response curves obtained in time-matched control experiments. 
Values are means  S.E.M.; error bars falling within the area of the symbols are 
not shown. 
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Table 3.8.  Antagonism of NF279 (60-min incubation) on ,-mATP-induced 
contractions of rat vas deferens. pA2 estimates (means  S.E.M.) were calculated 
from the individual dose ratios obtained for each antagonist concentration (n = 3). 
 
NF279 1  M 3  M 10  M 
      
pA2 value  6.07  0.08  6.41  0.07  7.06  0.08 
 
3.2.1.3.2.  Time course and reversibility of NF279's inhibitory effect 
 
Investigating the time course of NF279's (3 M) inhibitory effect to single doses of 
,-mATP (10 M), a maximum was reached at about 180 min of incubation and 
the antagonism was almost completely reversed on repeated wash out after 
90 min as responses to ,-mATP totally recovered to their respective pre-NF279 
controls (figure 3.23.). Over the same time period (300 min), responses of control 
tissues to 10 M ,-mATP remained unchanged (figure 3.23). 
 
0 60 120 180 240 300
0
500
1000
1500
2000
Increase in
tension (mg)
Time (min)
Incubation Wash out
 
 
Fig. 3.23.  Kinetics of onset ()and offset () of NF279’s (3 M) antagonistic 
effect on contractions induced by ,-mATP (10 M) in prostatic segments of rat 
vas deferens; ,   indicate data from time-matched controls. Data shown are 
mean +/- S.E.M.; error bars exceeding the size of the symbols are not shown 
(n = 2 - 3). 
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3.2.2.  Inhibitory potency on P2Y receptors (guinea-pig taenia coli) 
 
The potency of large and small ureas III to inhibit P2Y receptor-mediated 
relaxation of the carbachol-pre-contracted GPTC induced by ADPS was 
determined by calculating pA2 values from the shift of the agonist's concentration-
relaxation curves obtained in the absence and in the presence of large and small 
ureas III (for potency of ADPS as well as the pA2 values obtained for the parent 
compounds suramin and NF023 see section 3.1.2.2., figure 3.4. A. and B.). 
 
3.2.2.1.  Large ureas III 
 
At a concentration of 100 M all compounds except NF031 (300 M) caused a 
rightward shift of the ADPS CRC’s without changing the maximum or altering the 
contraction induced by carbachol (for resulting pA2 values see table 3.9.). 
Increasing concentrations of NF037 shifted the ADPS CRC’s progressively to the 
right. The regression according to Arunlakshana and Schild (Arunlakshana and 
Schild, 1959) was linear with a slope of -0.80  0.28 (not significantly different 
from -1.00) and a pA2 value of 4.85  0.11 (constrained plot) was estimated 
(figure 3.24.). 
 
Table 3.9.  Inhibitory potency (pA2   S.E.M.) of large ureas III on relaxant 
responses of carbachol-pre-contracted guinea-pig taenia coli to ADPS 
(n indicating the total number of experiments). 
 
Large ureas III  pA2  n  Concentration tested (M) 
NF037 4.86   0.10  11  10, 30, 100 
NF551 4.60   0.08  7  10, 100 
NF280 4.87   0.06  7  10, 100 
NF032 3.95   0.13  4  100 
NF279 4.10   0.29  3  100 
NF031 3.30   0.16  3  300 
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Fig. 3.24. Concentration-res-
ponse curves of ADPS in 
carbachol-pre-contracted gui-
nea-pig taenia coli in the 
absence (control) and in the 
presence of NF037 (10, 30 and 
100  M). Responses (mean 
+/-  S.E.M.) are expressed as 
percentage of  relaxation of the 
carbachol-induced  contraction. 
Schild analysis (shown in the 
insert) yielded a slope of -0.80 
 0.28 (not significantly different 
from -1.00), and a pA2 value 
(constrained plot) of 4.85  0.11 
was estimated. 
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3.2.2.2.  Small ureas III 
 
The antagonistic potency of small ureas on P2Y receptors mediating relaxation of 
the carbachol-pre-contracted GPTC was determined investigating a concentration 
of 100  M of NF278 and NF013. pA2 values of 4.27  0.15 for NF278 and 
4.53  0.11 for NF013 (means  S.E.M., n = 4) were calculated from the individual 
dose ratios of the ADPS CRC’s generated in the absence and in the presence of 
the respective compound. As established for the parent compound NF023 (see 
3.1.2.2.) pA2 values determined for NF550 decreased when increasing 
concentrations of the antagonist were investigated, being 5.43  0.07 for 10 M, 
4.78  0.17 for 30 M and 4.57  0.10 for 100 M (n = 3 -4 for each concentration) 
of NF550 (figure 3.25.). 
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Fig. 3.25.  Limited antagonism of NF550 on P2Y receptors mediating relaxation 
of carbachol-pre-contracted guinea-pig taenia coli. The graph shows 
concentration-relaxation curves to ADPS in the absence (control) and in the 
presence of increasing concentrations of NF550. Schild analysis (shown in the 
insert) yielded a slope of -0.11  0.18 (significantly different from -1.00). Data 
shown are means  S.E.M. of 4 to 16 observations, some error bars are within the 
width of the symbols. 
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3.2.3.  Inhibitory potency on P2Y1-like receptors (guinea-pig ileum) 
 
The potencies of large and small ureas to antagonise isometric contractile 
responses mediated via P2Y1-like receptors present in guinea-pig ileal longitudinal 
smooth muscle preparation were determined by calculating pA2 values from the 
shift of the CRC’s obtained to ADPS in the absence and in the presence of the 
antagonists (for results see tables 3.10.; 3.11.). All experiments on GPI were 
performed by Sittah Czeche and Matthias Ganso (for experimental design see 
Czeche et al., 1998b; Lambrecht et al., 1999, 2000b; Braun et al., 2001). 
 
3.2.3.1.  Large ureas III 
 
All compounds produced a rightward shift of the CRC’s obtained to single doses of 
ADPS. pA2 values of suramin, NF037, NF551 and NF280 were very similar; 
NF279 displayed a moderately, and NF032 as well as NF031 showed a markedly 
reduced inhibitory activity (table 3.10.). 
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Fig. 3.26.  Antagonism of NF279 on ADPS-induced contractions of guinea-pig 
ileal longitudinal muscle (for corresponding pA2 values see table 3.10.). 
Concentration-response curves in the absence (control) and in the presence of 
increasing concentrations of NF279 are shown (contractions obtained to 100 M 
of ADPS in the respective control were taken as 100 %). 
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Table 3.10.  Antagonistic potencies of large ureas III on contractile responses of 
guinea-pig ileal longitudinal smooth muscle to ADPS (0.1 - 300 M). pA2 values 
of suramin and NF279 were derived from Schild analysis. The corresponding 
graphs for NF279 are shown in figure 3.26. 
 
Large ureas III  pA2  n  Concentration tested (M) 
Suramin 5.68   0.24  12  10, 30, 100 
NF037 5.73   0.08  8  10, 30 
NF551 5.62   0.02  4  10 
NF280 5.72   0.10  4  10 
NF032 4.91   0.06  4  100 
NF279 5.32   0.08  10  10, 30, 100 
NF031 4.62   0.09  5  100 
 
 
3.2.3.2.  Small ureas III 
 
As established for the large ureas III, NF023, NF550, NF278 and NF013 shifted 
the concentration-response curves of ADPS to the right. Among the small ureas, 
NF550 displayed the highest potency in blocking P2Y1-like receptor-mediated 
contractions of the GPI. NF278 and NF013 were nearly equipotent, and the 
P2X1-selective compound NF023 showed the lowest P2Y1 receptor-blocking 
activity (table 3.11). 
 
Table 3.11.  Antagonistic potency of small ureas III on contractile responses of 
guinea-pig ileal longitudinal muscle evoked by ADPS. The pA2 value of NF023 
was derived from Schild analysis. 
 
Small ureas III  pA2  n  Concentration tested (M) 
NF023 4.74   0.08  9  100, 300, 1000 
NF550 5.87   0.08  13  10, 30 
NF278 5.05   0.14  4  30 
NF013 5.21   0.13  6  30 
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3.2.4.  Inhibitory potency of NF279 and NF031 on ATP breakdown (Xenopus 
laevis oocytes) 
 
In addition to results obtained for NF279 and NF031 (0.3 mM) from the screening 
of suramin-related large ureas (cf. 3.1.4.1.3.), the inhibitory activity of each 
compound was examined at a concentration of 0.1 mM on ATP breakdown in 
Xenopus laevis oocytes. 
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Fig. 3.27. Inhibitory effect of NF279 and NF031 (0.1 and 0.3 mM) on 
degradation of ATP (0.1 mM, incubated for 30 min) in Xenopus laevis oocytes. 
Data are presented as percentages (means + S.E.M.) of formation of inorganic 
phosphate (Pi) in the respective controls (first incubation) (n = 7 - 8). 
 
As described for the parent compound suramin (for results see section 3.1.2.2.), 
both analogues exhibited a dose-dependent inhibition of ATP-degrading enzymes 
present in Xenopus laevis oocytes. At a concentration of 0.1 mM, the 
Pi generation was decreased to 51.3  1.9 % (NF279) and 60.0  1.1 % (NF031) 
of the respective control incubations (figure 3.27.). For 0.3 mM of NF279 and 
NF031, 33.6  2.6 % and 47.2  3.6 %, respectively, of the Pi generated in the 
respective controls were determined. 
123 3. Results 
3.2.5. P2 receptor specificity of NF279 and NF031 
 
To determine the P2 receptor specificity of NF279 and NF031, the effects of 
100 M of each compound on responses to various agonists in ratVD 
(1A-adrenoceptors; contraction), GPI (adenosine A1-; relaxation), GPI (histamine 
H1- and muscarinic M3 receptors; contraction) and GPTC (adenosine A2B- and 
nicotinic acetylcholine receptors; relaxation) were investigated (table 3.12.). 
NF279 and NF031 had no significant effects on either the potency (table 3.12.) or 
maximum response to the agonists in the different tissues. 
 
Table 3.12.  P2 receptor specificity of NF279 and NF031. Potencies (pD2 values; 
mean   S.E.M.; n = 3 - 4) of the agonists noradrenaline in rat vas deferens 
(ratVD), 2-chloro-N
6-cyclopentyladenosine (CCPA), histamine and arecaidine 
propargyl ester (APE) in guinea-pig ileum (GPI), and 2-chloro-adenosine 
(2-Cl-Ado) and nicotine in guinea-pig taenia coli (GPTC) in the absence (controls) 
and in the presence of the respective suramin analogue (100 M). Experimental 
methods used are described in detail in the literature (see Lambrecht et al., 1999). 
 
Receptor/ agonist/ tissue  Control  NF279 
(100 M) 
Control NF031 
(100 M) 
1A/ noradrenaline /ratVD  5.97  0.32  5.82  0.40  5.85  0.32  5.79  0.30 
A1/ CCPA/ GPI*  8.46  0.07  8.59  0.07  8.45  0.07  8.46  0.06 
A2B/ 2-Cl-Ado/ GPTC
+)  ** 4.56   0.11  4.46  0.21  4.63  0.22  4.43  0.20 
H1/ histamine/ GPI*  6.04  0.07  6.04  0.07  6.11  0.09  6.17  0.09 
M3/ APE/ GPI*  7.53 0.01 7.60   0.05  7.44  0.04  7.49  0.03 
N/ nicotine/ GPTC**  4.45  0.07  4.26  0.17  4.57  0.06  4.44  0.11 
+)  In the presence of the A1 receptor-selective antagonist 8-cyclopentyl-1,3-
dipropylxanthine (100 M). 
*/ ** Determined in experiments performed by *S. Czeche and **B. Niebel. 
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3.3.  Regional variation of purinergic responses in rat vas deferens 
 
Differences of inhibitory potencies (pIC50 values) of the large urea NF279 
assessed in prostatic and epididymal segments of ratVD (for results see 3.3.3.1.) 
were the starting point for a detailed analysis of agonist and antagonist potencies 
with regard to the anatomical origin of the segment of ratVD. 
 
3.3.1. Agonists 
 
All agonists applied elicited rapid and transient concentration-dependent 
contractions of prostatic and epididymal segments of the ratVD (except for 
ADPS, which induced contractions of a more sustained type). However, none of 
the agonists' CRC’s did reach a well-defined maximum even at high 
concentrations (figure 3.28.). For this reason, equieffective concentrations of 
,-mATP, L-,-mATP, ATPS and ADPS (inducing 1000 mg of tension of 
prostatic and epididymal portions of ratVD) were determined to compare their 
agonistic potencies. ,-mATP was the most potent agonist in prostatic as well as 
in epididymal segments. In prostatic portions L-,-mATP and ATPS were 
equipotent whereas L-,-mATP was slightly more potent than ATPS in eliciting 
contraction of epididymal segments of ratVD. ADPS, being equieffective in both 
segments of ratVD, displayed the lowest potencies among the agonists examined 
(table 3.13.). 
 
Table 3.13. Agonistic potency (pEC1000) of nucleotide analogues in inducing 
contractions of prostatic and epididymal segments of rat vas deferens. 
Comparison of equieffective concentrations of the agonists derived from 
non-linear regression analysis of the concentration-effect curves for either agonist 
(n = 3 - 6). 
 
Segment  ,-mATP L-,-mATP ATPS ADPS 
prostatic  5.72 4.75 4.71 4.20 
epididymal  5.37 5.05 4.74 4.18 
125 3. Results 
A. 
0.1 1 10 100 1000
0
1000
2000
3000
,-mATP
ADPS
ATPS
L-,-mATP
Agonist (M)
Increase in tension (mg)
 
B. 
0.1 1 10 100 1000
0
1000
2000
3000
,-mATP
ATPS
Agonist (M)
Increase in tension (mg)
ADPS
L-,-mATP
 
 
Fig. 3.28.  Potency of the nucleotide agonists ,-mATP, L-,-mATP, ATPS 
and ADPS in eliciting contractions of rat vas deferens. Concentration-response 
curves of the agonists determined in prostatic (A.) and epididymal (B.) segments 
are shown. Contraction was measured in mg tension, ranking was based on the 
1000 mg-level (dotted line). Error bars falling within the area of a symbol are not 
shown. Mean values ( S.E.M.) were derived from 3 to 6 individual 
determinations. 
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Tetrodotoxin (TTX; 1 M, pre-incubated for 10 min) had no effect on contractions 
induced by ,-mATP (10 M) or ADPS (30 M) in prostatic as well as 
epididymal segments of ratVD (table 3.14.). 
 
Table 3.14.  Effect of tetrodoxin (TTX) on contractile responses (mg tension 
generated) of prostatic and epididymal segments of ratVD induced by ,-mATP 
(10 M) or ADPS (30 M), respectively. Data presented are mean values 
( S.E.M.) from 3 individual observations. 
 
Agonist (M)  prostatic (mg tension)  epididymal (mg tension) 
 Control  TTX  (1  M) Control TTX  (1  M) 
,-mATP (10)  1971  240  2060  209  1529  97  1607  97 
ADPS (30)  599  46  576  86  1057  75  1008  84 
 
 
3.3.2. Desensitisation  studies 
 
To further characterise the P2 receptor subtypes mediating contraction of prostatic 
and epididymal segments of the ratVD, desensitisation of responses to high doses 
of  ,-mATP, L-,-mATP and ADPS was studied. Contractions of both 
segments of the ratVD completely vanished after 2 to 4 cumulative applications of 
,-mATP (10  M) or L-,-mATP (30 M), respectively. In contrast, no 
desensitisation of contractile responses to ADPS (30 M) could be observed. 
Differences in the time course of desensitisation were obvious when 
,-mATP-induced contractions in prostatic and epididymal segments were 
compared: contraction of epididymal segments desensitised clearly slower than 
that of prostatic segments (29.5  2.5 s and 14.0  0.9 s, respectively, time 
measured when the maximal response decreased to 50 %, n = 4 - 5). 
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3.3.2.1.  Contractions induced by ,-methylene ATP and L-,-methylene 
ATP 
 
Contractile responses of ratVD induced by ,-mATP (10 M) were decreased to 
9.0  3.7 % and to 31.0  2.9 % of those obtained in controls of prostatic and 
epididymal segments (n = 3), respectively, when the tissues were desensitised by 
2 to 4 cumulative doses of L-,-mATP (30 M). In the reverse experiments, using 
,-mATP (10 M, 2 to 3 cumulative doses) as desensitising agent, contractions 
to L-,-mATP were nearly abolished, being 1.8  0.5 % in prostatic and 
6.0  3.3 % in epididymal segments (n = 3). 
 
3.3.2.2.  Contractions induced by ,-methylene ATP and ADPS 
 
ADPS-induced contraction of ratVD decreased to 15.6  2.2 % in prostatic 
segments after the tissues were desensitised by 2 to 3 cumulative applications of 
,-mATP (10 M). In contrast, in epididymal portions, desensitisation using 
,-mATP (10 M) left a residual response to ADPS (30 M) of 84.1  18.5 %. 
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3.3.3. Antagonists 
 
Inhibitory potencies (pIC50 values) of a series of suramin-related compounds and 
of pyridoxalphosphate-6-azophenyl-2',4'-disulphonic acid (PPADS) on contractions 
to  ,-mATP in prostatic and epididymal segments of the ratVD were studied. 
Additionally, the effect of NF279 on CRC’s to ,-mATP in epididymal segments 
of ratVD was determined and compared to the results obtained for the 
antagonistic potency of NF279 in prostatic segments (cf. 3.2.1.3.1.). 
 
3.3.3.1.  Comparison of pIC50 values 
 
Differences in the antagonistic potencies of a series of P2 receptor antagonists 
were observed testing their inhibitory activity on contractile responses of prostatic 
and epididymal portions of the rat vas deferens induced by single doses of 
,-mATP (10  M). Potency estimates (pIC50 values) determined in prostatic 
segments were higher (up to 4.2-fold) than those derived from non-linear 
regression analysis of concentration-inhibition curves assessed in epididymal 
portions of ratVD (table 3.15.). 
 
Table 3.15.  Differences in the antagonistic potencies of a series of P2 receptor 
antagonists on contractions of prostatic and epididymal segments of rat vas 
deferens induced by single doses of ,-mATP (10 M). Data are means  S.E.M. 
from at least 3 observations (for the corresponding graphs see figure 3.29.). 
 
Compound ratVD  IC50 [E]/IC50 [P] 
 prostatic  segments 
pIC50 
epididymal segments 
pIC50 
 
Suramin 4.68   0.02  4.53  0.02  1.4 
NF037 4.79   0.17  4.24  0.10  3.5 
NF279 5.71   0.09  5.12  0.11  3.9 
NF031 4.96   0.04  4.59  0.03  2.3 
NF023 4.93   0.03  4.51  0.04  2.6 
PPADS 5.36   0.06  4.74  0.14  4.2 
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Fig. 3.29. Concentration-
inhibition curves obtained for 
the large ureas suramin, 
NF037 NF279 and NF031, 
the small urea NF023 and 
the pyridoxal-5-phosphate-
derived compound PPADS 
in prostatic and epididymal 
segments of rat vas 
deferens. Given are mean 
percentages of inhibition 
  S.E.M. (n = 3 - 4) of 
contractions induced by 
single doses of exogenously 
applied  ,-mATP (10 M). 
The corresponding pIC50 
values are given in 
table 3.15. 
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3.3.3.2.  Effect of NF279 on concentration-response curves to ,-methylene 
ATP in epididymal segments of rat vas deferens 
 
As described for the inhibitory effects of NF279 in prostatic segments of ratVD 
(cf.  3.2.1.3.1.), increasing concentrations of the antagonist (3, 10 and 30 M, 
60-min exposure) shifted the CRC’s to ,-mATP in epididymal segments 
progressively to the right. pA2 values calculated for each concentration of NF279 
from the individual dose ratios, which were determined from equieffective 
concentrations of ,-mATP (read from the 1000 mg tension level of the 
respective CRC’s) in the absence and in the presence of the antagonist, were 
lower than those obtained in prostatic segments (table 3.16.). 
 
Table 3.16.  Antagonistic potency of NF279 on ,-mATP-induced contractions of 
rat vas deferens with respect to the anatomical origin of the segment (60-min 
pre-incubation). pA2 values (mean  S.E.M.) were calculated from the individual 
dose ratios for each antagonist concentration (n = 3). 
 
NF279 (M) pA2 value 
  prostatic segments  epididymal segments 
1 6.07   0.08  n.d. 
3 6.41   0.07  5.70  0.18 
10 7.06   0.08 5.93  0.21 
30 n.d.  6.41   0.12 
 
 
Similarly to the results obtained in prostatic segments, there was an increase in 
pA2 values when the effect of increasing concentrations of NF279 was 
investigated on CRC’s to ,-mATP in epididymal segments of ratVD. An 
enhancement of contractions to ,-mATP which was observed in the presence of 
NF279 (3 M) also occurred in the time-matched controls (without incubation of 
antagonist; see figure 3.30.B.). However, no corrections were made to the agonist 
concentration ratios because this effect became relevant for contractions higher 
than 2000 mg tension. Comparing equieffective concentrations on the 1000 mg 
tension level no significant difference was detectable (pEC1000 = 5.47  0.05 for 
the overall controls and 5.57  0.09 for the overall time control, respectively). 
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Fig. 3.30.  A. Antagonism of NF279 on ,-mATP-induced contractions of 
epididymal segments of rat vas deferens (for corresponding pA2 values see table 
3.16.). B. Time-matched control experiments. Values are means  S.E.M.; error 
bars falling within the area of the symbols are not shown. 
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3.3.3.3.  Inhibitory potency of NF279 on contractions of rat vas deferens 
induced by L-,-mATP and ATPS 
 
The inhibitory potency of NF279 on contractile responses of both segments of 
ratVD induced by agonists with selectivity profiles distinct from that of ,-mATP 
was examined. Concentration-inhibition curves of NF279 were constructed using 
single doses of exogenously applied L-,-mATP (30 M) and ATPS (10 M), 
and compared to concentration-inhibition curves of NF279 obtained to single 
doses of ,-mATP (10 M) (cf. 3.2.1.1.; 3.3.3.1.). Because of differences in the 
potencies of the agonists applied, a comparison on the basis of the resulting 
pIC50  values would have led to misinterpretations. A possibility to transform 
IC50 values into the dissociation constant of an antagonist (designated here as 
apparent pA2 value  [pA2*]) was introduced by Cheng and Prusoff (1973). The 
applicability of the Cheng-Prusoff relationship for the calculation of antagonist 
dissociation constants from experiments in which a functional response such as 
muscle contraction is measured was described by Eglen and Whiting (1989). 
Instead of agonist affinities or as proposed by Eglen and Whiting (1989) 
EC50 values, equieffective concentrations of the agonists (read from the 1000 mg 
tension level, cf. 3.3.1.) were used for calculation. The IC50 values were derived 
from non-linear regression analysis of the concentration-inhibition curves obtained 
to increasing concentrations of NF279 in the presence of a single concentration of 
the respective agonist (for results see table 3.17.). 
 
The resulting pA2* values should not be considered as the antagonists 
dissociation constants (i.e. antagonist affinities), they are of use as rough 
estimates allowing a comparison of the antagonistic potencies of NF279 obtained 
from the experimental protocol described above. Comparing the antagonistic 
potency of NF279 on contractions induced by single doses of ,-mATP (10 M) 
in prostatic and epididymal segments of ratVD on the basis of the pA2* values, 
differences enhanced (cf. table 3.15.; 3.17.), as could have been expected, 
regarding the relation between the agonist and the antagonist concentration: the 
higher the potency of the agonist (i.e. the higher the agonist concentration used to 
evoke a contractile response) the higher the concentration of antagonist required 
to inhibit 50 % of the agonist-induced response (i.e. the higher the resulting IC50). 
pA2*  values obtained for NF279 in prostatic segments using ,-mATP, 
L-,-mATP and ATPS as agonists were similar. In epididymal segments, the 
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highest potency for NF279 was found when contractions were induced by the 
P2X1-selective agonist L-,-mATP. 
 
Tab. 3.17.  Inhibitory potency (pIC50 and apparent pA2 [pA2*]) of NF279. Data 
(pIC50 = means  S.E.M.; pA2* = means) were derived from non-linear regression 
analysis of the antagonist's concentration-inhibition curves. pA2* values were 
calculated by use of the Cheng-Prusoff relation (Cheng and Prusoff, 1973). 
 
Agonist (M)  Prostatic segments  Epididymal segments 
 pIC50 pA2* pIC50 pA2* 
,-mATP (10)  5.71  0.09  6.51  5.12  0.11  5.64 
L-,-mATP (30)  5.91  0.03  6.34  5.43  0.05  6.07 
ATPS (10)  6.00  0.02  6.18  5.57  0.06  5.76 
 
 
3.3.4.  Contractions of epididymal segments of rat vas deferens induced by 
ADPS 
 
Two observations supported the view, that the P2 receptors mediating 
contractions of epididymal segments of ratVD elicited by ADPS might be, at least 
in part, different from the P2 receptor population activated by ,-mATP: 
(1) desensitisation using ,-mATP decreased contractile responses of epididymal 
segments of ratVD induced by ADPS to about 80 % of those obtained in control 
experiments (see 3.3.2.2.). (2) No desensitisation of ADPS-evoked contraction 
neither in prostatic nor in epididymal segments was observed. Due to the lack of 
desensitisation of contraction elicited by ADPS, the possibility of constructing 
CRC’s in a cumulative instead of single dose fashion was examined. The resulting 
CRC’s (see figure 3.31.) were almost superimposable. As previously described for 
CRC’s obtained to a variety of agonists in ratVD, CRC’s to ADPS did not reach a 
well-defined maximum as well, thus, agonist potencies could not be determined on 
the basis of their EC50 values. Comparison of equieffective concentrations (read 
from the 500 mg tension level) yielding pEC500 values of 4.84  0.08 for CRC’s to 
single doses of ADPS (added in 15-min intervals) and 4.93  0.11 for CRC’s of 
cumulatively applied ADPS confirmed that applying the cumulative design no 
desensitisation of responses occurred. Based on this observation, all further 
135 3. Results 
experiments were carried out constructing CRC’s to cumulative applications of 
ADPS. 
 
0.1 1 10 100 1000
0
500
1000
1500
ADPS (single dose)
ADPS (cumulative)
Increase in tension (mg)
ADPS (M)
 
 
Fig. 3.31. Comparison of single dose (15-min intervals) and cumulative 
concentration-response curves to ADPS in epididymal segments of rat vas 
deferens. Data shown are means  S.E.M. from 6 observations, some error bars 
were within the width of the symbols. 
 
3.3.4.1.  Inhibitory effects of suramin, NF023, NF279 and MRS 2179 
 
In order to identify the P2 receptor subtype(s) mediating contraction induced by 
ADPS, the inhibitory effect of a series of P2 receptor antagonists with different 
selectivity profiles was examined on the agonist's CRC’s in epididymal segments 
of ratVD. MRS 2179 (10 and 100 M) had no effect on contraction induced by 
ADPS (pEC500 = 4.90  0.09 in the absence, and pEC500 = 4.77  0.08 in the 
presence of 10 M as well as 4.88  0.06 in the presence of 100 M MRS 2179; 
n = 3; see figure 3.32.A.). In contrast, higher concentrations of suramin, NF023 
and NF279 shifted the ADPS CRC’s to the right. Additionally, a marked increase 
of contraction elicited by ADPS was observed, especially in the presence of 
lower concentrations of the antagonists. Because of the complex nature of 
antagonism and the incompleteness of the CRC’s (cf. figure 3.32.B.-D.), 
quantification of the extent of inhibition by calculating dose ratios from 
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equieffective concentrations in the absence and in the presence of antagonist, 
seemed to be not useful. Therefore the antagonists' effects on single doses of 
ADPS (30 and 100 M) were extracted from the CRC’s (see figure 3.32.B.-D.) 
and expressed as a percentage of contractile responses obtained in the 
respective controls (i.e. in the absence of antagonists) (see figure 3.33.). 
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Fig. 3.32.  (legend see page 138) 
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Fig. 3.32.  Antagonism of MRS 2179 (A.), suramin (B.), NF023 (C.) and NF279 
(D.) on ADPS-induced contractile responses of epididymal segments of rat vas 
deferens: concentration-response curves of ADPS in the absence and in the 
presence of different concentrations of the antagonists. The data 
(means  S.E.M.) were derived from 3 to 4 observations, some error bars were 
within the area of the symbols. 
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As illustrated in figure 3.33., contractions induced by ADPS (30 M) were 
augmented in the presence of 1 and 3 M of NF279 (129  6 % and 146  6 %, 
respectively, of contractions induced in the control CRC’s) and rather not affected 
by 10 M of NF023 (107  10 %) as well as by 10 and 30 M of suramin 
(111  5 % and 93  10 %, respectively). Inhibition of ADPS (30 M) -induced 
contractions appeared, when higher concentrations of NF279 (10 M: 79  3 % 
and 30 M: 35  9 %), NF023 (30 M: 69  9 %; 100 M: 34  10 % and 300 M: 
7  4 %) and suramin (100 M: 3  2%) were present. An increase of ADPS 
(100 M) -evoked contractions was found for NF279 (1 M: 132  3 %, 3 M: 
176  3 % and 10 M 115  8 %) and to a lesser extent for NF023 (10 M: 
118  1 % and 30 M: 106  3 %) as well as for suramin (10 M: 114  5 % and 
30 M: 109  6 %). Responses of epididymal segments of ratVD induced by 
ADPS (100 M) were inhibited using higher concentrations of NF279 (30 M: 
77  2 %), NF023 (100 M: 84   6 % and 300 M: 54  4 %) and suramin 
(100 M: 69  12 %). 
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Fig. 3.33.  (legend see p. 140) 
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Fig. 3.33.  (pages 139 and 140) Effects of suramin (A.), NF023 (B.) and NF279 
(C.) on contractions of epididymal segments of rat vas deferens induced by 
ADPS (30 and 100 M). Responses are expressed as percentage (means 
+  S.E.M.) of contractions obtained in the respective control experiments 
(n = 3 - 4). 
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4.1.  Screening of suramin- and NF023-related compounds 
 
4.1.1.  Applicability of the rabbit vas deferens for the evaluation of 
compounds displaying P2X receptor-blocking potency 
 
Electrical field stimulation of the vas deferens of mouse, rat, rabbit and guinea-pig 
produces a biphasic contractile response, which is thought to result from the 
combined action of ATP and NA released as cotransmitters (for review see von 
Kügelgen and Starke, 1991; Sneddon et al., 1996). The initial phase of the 
contraction is blocked by either desensitisation with ,-mATP or by the 
P2 receptor antagonist suramin and is therefore thought to be mediated by ATP 
released from sympathetic nerves acting on P2 receptors present on the smooth 
muscle. The second component of the neurogenic response is blocked by 
-adrenoceptor antagonists, and is thought to be mediated by NA acting on 
-adrenoceptors. The rank order of agonist potency for eliciting contraction of the 
RVD, being ,-mATP >>  2-MeSATP   ATP  UTP (Lambrecht et al., 1992; 
Windscheif, 1995), indicates the presence of P2X receptors. However, the fact 
that ,-mATP was the most potent but least efficacious agonist might suggest 
that ATP and 2-MeSATP act at an additional P2 receptor subtype present in the 
RVD smooth muscle. As contractions of RVD were also seen in response to UTP, 
this second subtype may be a member of the P2Y receptor family; both 
recombinant P2Y2 and the rat orthologue of the P2Y4 receptor were shown to be 
sensitive to ATP and UTP (Lazarowski et al., 1995; Bogdanov et al., 1998b). 
Heterogeneity of P2 receptors has been reported not only for ratVD (Bültmann 
and Starke, 1994b; Bültmann et al., 1999b), mouse vas deferens (von Kügelgen 
et al., 1990) and guinea-pig vas deferens (Bailey and Hourani, 1994) but also for 
the RVD (Lambrecht et al., 1996b). Moreover, in native tissues, the presence of 
more than one P2 receptor subtype appears to be the rule rather than the 
exception (see Ralevic and Burnstock, 1998). In the light of these observations, a 
screening assay for the assessment of P2X receptor-blocking potencies of 
suramin derivatives based on electrical field stimulation (EFS), resulting in release 
of the naturally occurring non-selective ligand ATP to induce contraction of the 
RVD, did not appear to be the appropriate method. The dual effect of the parent 
compound suramin, to antagonise P2 receptors and inhibit ATP-degrading 
enzymes with nearly similar potency, thereby producing a phenomenon referred to 
as "self-cancellation" when its antagonistic effect is examined using agonists, 
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including ATP, which are not metabolically stable, also argues against those 
studies applying EFS (Crack et al., 1994). A further problem is, that the amount of 
ATP being released by nerve stimulation might be affected by several factors, 
including the frequency of stimulation and the effect (inhibitory as well as 
potentiating) of other transmitter substances which are known to be co-released 
with ATP (von Kügelgen and Starke, 1991). Finally, breakdown products of ATP, 
such as adenosine, were shown to be active in RVD. Adenosine has been shown 
to act at A1 receptors mediating inhibition of both the purinergic and adrenergic 
component of the mechanical response (Windscheif, 1995). 
 
To circumvent the problems discussed above, the metabolically stable nucleotide 
agonist  ,-mATP, which was reported to be selective for P2X receptors 
(Bianchi  et al., 1999), was applied to evoke contraction of the RVD. CRC’s, 
constructed in order to establish whether differences in the sensitivity towards 
,-mATP exist with regard to the anatomical origin of the segments, yielded 
similar potency estimates but marked differences in the tension generated for the 
prostatic segment compared to the segments 2 - 6 (tables 3.1. and 3.2.). A 
regional variation of purinergic and adrenergic responses in RVD with NA being 
more effective in eliciting contractions of the prostatic end while contractions 
evoked by ATP were significantly lower in prostatic compared to the epididymal 
segments was reported by Windscheif (1995). However, whether those 
differences are due to differential sensitivity of the segments (i.e. postjunctional 
receptor distribution, post-receptor activation events) has not been addressed. In 
contrast, regardless of the species studied, the opposite, NA being more potent in 
epididymal than in prostatic portions, and ATP and ,-mATP being more potent 
in the prostatic end, has been observed (Sneddon and Machaly, 1992). The 
reason for this discrepancy is unclear. 
 
The selectivity of ,-mATP for recombinant homomeric P2X1 and P2X3 as well as 
heteromeric P2X2P2X3 and P2X1P2X5 receptors, being inactive at all other P2 
receptor subtypes that have been cloned so far, is well established (Ralevic and 
Burnstock, 1998; Lambrecht, 2000; North and Surprenant, 2000). Comparison of 
the rank order of potency estimates for suramin, PPADS, and NF023 antagonising 
,-mATP-induced contractions of RVD and inhibiting P2X1, P2X3 and 
P2X2P2X3 receptor-mediated currents elicited by ATP or ,-mATP, respectively, 
resulting in PPADS  NF023  suramin for the P2X receptor in RVD and the same 
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profile for the rP2X1 receptors, clearly indicates that the properties of the 
,-mATP-sensitive P2 receptor present in RVD correspond well with those of 
recombinant P2X1 receptors (Lambrecht et al., 1999; Lambrecht, 2000; Soto et 
al., 1999; see table 4.1.). 
 
Table 4.1.  Comparison of pIC50 and pA2 values determined at P2X receptors 
mediating contraction to ,-mATP in rabbit vas deferens and recombinant rat 
P2X receptor subtypes (data taken from Lambrecht et al., 1996b, 2000b; Bianchi 
et al., 1999; Soto et al., 1999; 
aLambrecht and Niebel, personal communication). 
 
Tissue/Receptor pA2/pIC50 
 PPADS  Suramin  NF023 
RVD 6.34/5.55
a 5.10/4.75  5.68/4.97 
rP2X1 n.d./7.06  n.d./   5  5.96/6.62 
rP2X3 n.d./6.11  n.d./5.44  n.d./5.07 
rP2X2P2X3 n.d./5.90  n.d./6.09  n.d./5.85 
 
 
In order to investigate a large number of compounds, of which only very small 
amounts were available, the pIC50 method was further simplified, testing the effect 
of 10 M of the derivatives, a concentration similar to the IC50 assessed for NF023 
(see table 4.1.), on contractions evoked by 1 M ,-mATP. Compared to vasa 
deferentia of other species, the RVD offers a further advantage, allowing to test 
8 different compounds in parallel, because of the number of segments obtained 
per animal. This screening assay therefore proved to be a valid method to 
examine the P2X1 receptor-blocking potency of suramin- and NF023-derivatives. 
 
4.1.2.  Applicability of the guinea-pig taenia coli for the evaluation of 
compounds displaying P2Y receptor-blocking potency 
 
The guinea-pig taenia coli has been the prototype tissue for the study of native 
P2Y receptors (Burnstock and Kennedy, 1985; Cusack, 1993). However, recent 
investigations indicate that besides the P2Y receptor, relaxation of the 
carbachol-pre-contracted tissue is also mediated by a yet unidentified P2 receptor 
subtype sensitive to ,-mATP (Windscheif et al., 1995; Dudeck et al., 1995; 
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Bültmann et al., 1996a; Lambrecht et al., 1996b, 1999). The rank order of agonist 
potency obtained for nucleotides eliciting relaxation of the carbachol-pre-
contracted GPTC, 2-MeSATP  ADPS  ,-mATP  ATP  adenosine (Dudeck 
et al., 1995) confirms the presence of a heterogeneous P2 receptor population. 
Further indications were the biphasic Schild plots observed for PPADS blocking 
,-mATP- as well as ATP- and 2-MeSATP-induced relaxation of GPTC 
(Windscheif et al., 1995). In addition, differences in antagonist potency reported 
for PPADS, DIDS, and the suramin-derived compounds NF023 and 8-(3,5-dinitro-
phenylenecarbonylimino)-1,3,5-naphthalenetrisulfonic acid (XAMR0721), all of 
these antagonists being more potent in blocking responses elicited by ,-mATP 
compared to those induced by ADPS (Dudeck et al., 1995, Bültmann et al., 
1996a, Lambrecht et al., 1996b), are in favour of a mixed P2 receptor population 
mediating relaxation of GPTC. The capacity of some of the antagonists to inhibit 
ecto-nucleotidases as well, should not be relevant for studies applying the 
metabolically stable nucleotide analogues ,-mATP and ADPS (Welford et al., 
1986) and therefore a contribution of the inhibition of ATP-degrading enzymes to 
the differences observed seems to be very unlikely. Based on the selectivity of 
,-mATP for P2X1, P2X3 and heteromeric P2X2P2X3 and P2X1P2X5 receptors 
(North and Surprenant, 2000) the presence of at least one of these proteins in 
GPTC must be anticipated. However, the biphasic Schild plot obtained for PPADS 
blocking ,-mATP-induced relaxation might indicate a heterogeneity even within 
the  ,-mATP-sensitive receptors in GPTC (Windscheif et al., 1995). Another 
surprising finding is the slow onset of the relaxant response of GPTC to ,-mATP 
(Windscheif et al., 1995), a feature which is usually attributed to effects mediated 
via G protein-coupled P2Y receptors rather than ionotropic P2X receptors, as well 
as to the involvement of further transmitter substances/second messengers. 
Therefore, the effects of TTX, indomethacin and 8-SPT on CRC’s to ,-mATP 
were investigated. However, none of these compounds affected the 
,-mATP-induced relaxation of GPTC, thereby indicating that the agonist's site of 
action is most likely directly on P2 receptors present on the smooth muscle 
(Dudeck et al., 1995). 
 
There is also controversy about the ADPS-sensitive receptor being a species 
orthologue of the recombinant P2Y1 receptor (Ralevic and Burnstock, 1998; 
Lambrecht et al., 1999). 
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Table 4.2.  Comparison of antagonist potency estimates (pA2 and 
apIC50 values) 
obtained at turkey P2Y1 receptors (Boyer et al., 1996a; J. L. Boyer and 
T.  K.  Harden, personal communication; Charlton et al., 1996; Camaioni et al., 
1998), for ADPS-induced relaxation mediated via taenia coli P2Y receptors 
(Lambrecht et al., 1996b; Bültmann et al., 1998; 
bpA2 determined in one 
experiment for MRS  2179 30 M, results not shown), and for ADPS-induced 
contractions of guinea-pig ileal longitudinal smooth muscle (Czeche et al., 1998b; 
Lambrecht et al., 1999; G. Lambrecht, personal communication). n.d. = not 
determined. 
 
Receptor  PPADS  Suramin  NF023 NF279 A3P5PS  MRS  2179
tP2Y1 5.98  5.77  4.58
a 4.63
a 6.46  6.48
a 
P2Y  (GPTC)  4.59 4.71 4.35 4.10 5.11 5.81
b 
P2Y  (GPI)  6.20 5.68 4.74 5.32 n.d.  6.38
a 
 
 
Comparing antagonist potency estimates obtained at the recombinant turkey P2Y1 
with native P2Y receptors present in guinea-pig taenia coli and ileum, strikingly all 
compounds are roughly 10-fold less potent in taenia coli. The differences in 
potency for NF279 between tP2Y1 and GPI P2Y receptors can be explained at 
least in part by differences in the experimental protocols applied, i.e. 
pre-incubation of antagonist in the tissue experiments and co-application of 
agonist and antagonist in the tP2Y1 assays (J. L. Boyer and T. K. Harden, 
personal communication). However, this could not be accounted for the 
intraspecies differences observed for the two native P2Y receptors of guinea-pig 
(GPI and GPTC). On the one hand, antagonism of MRS 2179, NF023, NF279 and 
PPADS argue in favour of the P2Y1 receptor subtype as inactivity of these 
antagonists was reported for P2Y2, P2Y4, and P2Y6 receptors (Lambrecht, 2000; 
Nandanan et al., 2000; von Kügelgen and Wetter, 2000). ,-mATP-sensitive P2X 
receptors can be ruled out because no cross-desensitisation of relaxation of 
GPTC induced by ADPS and ,-mATP, respectively, was observed (Dudeck et 
al., 1995; North and Surprenant, 2000) and due to the weak antagonistic activity of 
NF023 (Soto et al., 1999). Moreover, ADPS was shown to be inactive at 
recombinant P2X2 receptors and only weakly active at the P2X4 subtype (Bianchi 
et al., 1999). A contribution of these receptor subtypes can furthermore be 
excluded based on the antagonistic effect of MRS 2179 (Nandanan et al., 2000). 
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On the other hand, the potency observed for the antagonists is much lower in 
GPTC compared to the P2Y receptor present in the ileal longitudinal muscle (table 
4.2.), the pharmacology of which is very similar to that of the recombinant P2Y1 
receptor (Czeche et al., 1998b; Lambrecht et al., 1999). However, the rank order 
of antagonist potencies for recombinant tP2Y1 and taenia coli P2Y is very similar. 
On the basis of the remarkable impact of species differences with respect to the 
potency or activity of agonists and antagonists (see 1.1.2.2.1.1. and 1.1.2.2.2.1.), 
observed for example for species orthologues of P2X4 and P2Y4 receptors, it can 
be speculated that the taenia P2Y and the ileum P2Y might represent two 
isoforms of the guinea-pig P2Y1 receptor. Taking into account, that the exchange 
of one amino acid renders PPADS-sensitivity to the PPADS-insensitive rat P2X4 
wild type receptor (Buell et al., 1996b), it is obvious, that very small variations of 
the primary structure of the receptor protein can have dramatic effects on its 
pharmacological characteristics. Nevertheless, the presence of a functional P2Y 
receptor subtype in GPTC that has not yet been cloned, cannot be excluded on 
the basis of these observations. Thus, this question will be resolved with the 
cloning of the P2 receptors from guinea-pig ileum and taenia coli. Unfortunately, 
except for the P2X2 subtype, none of the other known recombinant P2 receptors 
have been cloned from guinea-pig tissue so far (Housley et al., 1999). Hence, the 
GPTC, although it is still one of the standard tissues to study native P2Y 
receptors, does not seem to be the ideal one, because of the problems discussed 
above. However, by the use of the metabolically stable agonist ADPS, some of 
these problems can be circumvented, and even though the absolute potency 
determined for various antagonists in GPTC and GPI is clearly different, the rank 
order of antagonist potencies differs only marginally (table 4.2.). 
 
In accordance with the screening assay applied for the study on native 
P2X receptors in RVD, inhibitory effects suramin analogues on CRC’s to ADPS 
were investigated at a single concentration of 10 M. On the basis of the results 
obtained in GPTC, the fact that examination of a higher concentration of the 
compounds would have been more useful, has to be discussed. Unfortunately, 
most of the analogues as well as even the reference drugs suramin and NF023, 
did not show any significant inhibitory potency at the concentration investigated. 
Therefore, it is obvious, that a comparison of their potentially differing antagonistic 
effects on native P2Y receptors is impossible. On the other hand, the screening 
assays were not primarily designed to assess SAR's for suramin- and 
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NF023-derived large and small ureas, but to identify interesting compounds 
(displaying higher antagonistic potency and/or selectivity), worth performing a 
more detailed pharmacological characterisation with. Accordingly, to test equal 
concentrations of potential antagonists at both the native P2X and P2Y receptors 
allows to assess the selectivity of a certain analogue more exactly. 
 
4.1.3.  Comparison of the applicability of guinea-pig taenia coli and 
Xenopus laevis oocytes as ecto-nucleotidases bioassays 
 
The exact identity of the ATP-degrading enzymes located on the cell surface of 
several smooth muscle preparations is still unknown. However, it is apparent from 
a number of studies, that enzymatic degradation of ATP (and other nucleotides) 
and some of its synthetic analogues may influence the pharmacological 
characterisation of P2 receptors, and lead to misinterpretations. On the one hand, 
the potency of agonists susceptible to enzymatic breakdown was underestimated 
(Humphrey et al., 1995; Kennedy and Leff, 1995) and thus, some of the 
P2 receptors originally characterised by rank orders of agonist potencies had to be 
redefined (cf. 1.1.). On the other hand, a phenomenon called "self-cancellation" 
occurred with antagonists such as suramin displaying dual enzyme inhibitory and 
P2 receptor antagonistic properties (Crack et al., 1994; Humphrey et al., 1995). 
Inhibition of ATP breakdown results in a potentiation of effects of ATP or other 
enzymatically unstable nucleotides and a leftward shift of the agonists' CRC, in 
contrast, P2 receptor blockade causes a rightward shift of the CRC and therefore 
suramin appeared to be rather inactive in certain preparations (Humphrey et al., 
1995). 
 
At present, there are two families of ecto-nucleotidases thought to play a 
predominant role in the inactivation of extracellular nucleotides. The members of 
the E-NTPDase family (syn. ecto-ATPases, ecto-apyrase, ecto-ATP-diphospho-
hydrolase) are capable of hydrolysing nucleoside 5'-tri- (and) diphosphates 
generating the respective dephosphorylated mono- or dinucleotide and inorganic 
phosphate, and enzymes capable of hydrolysing ATP and ADP to AMP and either 
pyrophosphate or inorganic phosphate belonging to the E-NPP family 
(Zimmermann, 2000; Zimmermann et al., 2000; cf. 1.1.5.). 
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In GPTC, the presence of Ca
2+/Mg
2+-dependent nucleotide-degrading enzymes 
has been demonstrated (Ziyal, 1996). These enzymes were reported to display a 
broad substrate specificity metabolising ATP as well as other purine and 
pyrimidine nucleotides (Ziyal, 1996). In general, the coexistence of several 
nucleotide degrading enzymes in the same tissues is the rule rather than the 
exception (Zimmermann, 1999). For this reason, it is of some relevance when 
studying the impact of ecto-nucleotidases and enzyme inhibitors on the 
pharmacology of P2 receptor agonists and antagonists at native P2 receptors, to 
perform these studies in the same tissue. Unfortunately, the GPTC did not prove 
to be suitable for the investigation of the inhibitory activity of a larger number of 
compounds. In contrast to results obtained in a previous study (Ziyal, 1996), 
applying a similar experimental protocol the extent of inhibition of ATP degradation 
by suramin was considerably lower in the present study. Moreover, the inhibitory 
effect of suramin appeared to be limited. An explanation for these observations 
might be provided by results obtained in a recent study, analysing the inhibitory 
potency of suramin at recombinant NTPDase1 (CD39) and NTPDase2 (CD39L1). 
In this study, suramin at a concentration of 100 M, was reported to be markedly 
more potent in inhibiting NTPDase2 than NTPDase1 (Heine et al., 1999). 
NTPDase1 was shown to hydrolyse ATP directly to AMP, without any detectable 
ADP in the medium. The hydrolysis of ADP, applied as substrate, to AMP 
revealed the same time course as that of hydrolysis directly from ATP to AMP. 
Expression of NTPDase2 alone led to the accumulation of ADP, which was only 
slowly further degraded to AMP by the enzyme. When both enzymes were co-
expressed, AMP and ADP could be detected as hydrolysis products. AMP as a 
result of ATP degradation by both enzymes and of ADP degradation by 
NTPDase1 and ADP due to hydrolysis of ATP by NTPDase2. Assuming that both 
kinds of enzymatic activities are present in GPTC, hydrolysis of ATP by 
NTPDase2 leads to the formation of 1 Pi per molecule whereas breakdown of ATP 
by NTPDase1 generates 2 Pi . Under control conditions, both exogenously applied 
ATP as well as ADP, originating from the breakdown of ATP by NTPDase2 
compete as substrates for NTPDase1, generating either 1 or 2 Pi per molecule 
ATP. In contrast, in the presence of suramin, ATP-degradation by NTPDase2 is 
largely inhibited, but ATP can be metabolised directly to AMP. Therefore, the 
possibility that inhibition of only one of a set of enzymes that might be present in 
GPTC, does not necessarily lead to a marked decrease in the amount of inorganic 
phosphate produced over a certain time course has to be taken into account. 
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However, the reason for the difference in the inhibitory potency of suramin in 
GPTC determined in the previous (Ziyal, 1996) and the present study is not clear. 
 
The nucleotide-metabolising enzymes present on folliculated Xenopus laevis 
oocytes have been demonstrated to degrade all naturally occurring purine and 
pyrimidine nucleoside triphosphates as well as ADP and AMP (Ziganshin et al., 
1995, 1996). In the absence of the divalent cations Ca
2+ and Mg
2+ Pi production 
was found to be decreased to 10  %, indicating the presence of Mg
2+- and/or 
Ca
2+-dependent enzymatic activity (Ziganshin et al., 1995) which is a general 
feature of ecto-nucleotidases. Under the experimental conditions of the present 
study the contribution of intracellular enzymes to the extent of ATP degradation 
can be excluded due to the following observations: neither had ouabain, as an 
inhibitor of the intracellular Na
+/K
+-ATPase, nor oligomycin, an inhibitor of 
mitochondrial (F-type) ATPases as well as sodium azide, a general inhibitor of 
intracellular ATPases which was also reported to have inhibitory effects on 
ecto-NTPDases, but only when applied at very high concentrations (Plesner, 
1995; Zimmermann, 1996b), any effect on measured ATPases activity, i.e. 
generation of inorganic phosphate (Ziganshin et al., 1995). Although degradation 
of AMP indicates the presence of nucleoside monophosphate degrading 
ecto-5'-nucleotidase activity in Xenopus oocytes, this enzyme should not play any 
role when using ATP as substrate, because it is inhibited by micromolar 
concentrations of ATP and ADP (Zimmermann, 1996b). Furthermore, 
nucleotide-degrading activity by the non-specific alkaline phosphatases could be 
separated from ecto-nucleotidases activity because of their pH-optimum of about 
8.5 (Fox, 1978; Zimmermann, 1996a). Additionally, inactivity of alkaline 
phosphatases was confirmed by the lack of generation of Pi from p-nitrophenyl 
phosphate which serves as a substrate for the enzyme (Ziganshin et al., 1995; 
see van der Ven and Hinds, 1996). The amount Pi detected should therefore be 
largely due to the degradation of ATP by enzymes belonging to the E-NTPDase 
family or the NPP  family. The detection of Pi to assess the activity of 
ecto-nucleotidases does not allow to exactly characterise the enzymes involved in 
ATP-degradation, however, it represents a robust and convenient method to study 
effects of potential enzyme inhibitors. When using either ATP or ADP as 
substrate, slight differences were reported to occur in the extent of inhibition of 
certain compounds depending on the substrate analysed (Ziganshin et al., 1996), 
indicating that ATP and ADP might be degraded by separate enzymes. 
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In contrast to results obtained in GPTC, suramin was shown to inhibit 
ecto-nucleotidases present on folliculated Xenopus oocytes in a dose-dependent 
manner, thereby confirming data from previous studies performed in oocytes 
(Ziganshin et al., 1995, 1996) as well as in smooth muscle preparations (Bültmann 
et al., 1996c; Ziyal, 1996), platelets (Beukers et al., 1995) and molecularly defined 
ecto-NTPDases (Heine et al., 1999). Furthermore, inhibition of ATP-degradation 
could also be demonstrated for the suramin-derived compound NF023 and the 
previously introduced ecto-nucleotidases inhibitor ARL 67156 (table  3.3.). Both 
compounds were described to display inhibitory potency on ATP-degrading 
enzymes present in smooth muscle preparations (Crack et al., 1995; Bültmann et 
al., 1996c; Ziyal, 1996), and for ARL 67156 ecto-nucleotidases-inhibiting activity 
has also been reported in blood cells (Crack et al., 1995). In accordance with 
results obtained in previous studies (Bültmann et al., 1996c; Ziyal, 1996), suramin 
was shown to be slightly more potent in inhibiting ATP-degradation than NF023. 
Consequently, the inhibitory potency of the suramin analogues was examined 
using the Xenopus oocytes assay, which in contrast to GPTC smooth muscle 
strips proved to be more suitable for the screening of a larger number of 
compounds. 
 
4.1.4.  Inhibitory activity of suramin-related large ureas and NF023-related 
small ureas at native P2 receptors and ecto-nucleotidases 
 
Assessing and comparing the inhibitory potency of a series of suramin-related 
large ureas with the parent compounds suramin and NF037 (4'-des-
methyl-suramin), respectively, as well as of a series of NF023-derived small ureas, 
provided some interesting antagonist SAR's: 
 
4' substituents (figure 3.11., table 3.4.a.; figure 3.15., table 3.5.a.) 
 
Compared to NF037, the insertion of an electron donating group (suramin) as well 
as an electronegative substituent (NF157) into the 4'-position of the benzamino 
residue led to a decrease in the inhibitory potency at native P2X receptors, 
whereas the activity on ecto-nucleotidases remained largely unchanged. At GPTC 
P2Y receptors no inhibitory activity could be detected. Surprisingly, the phenyl-
substituted derivative NF198 displayed a slightly higher blocking potency at P2X 
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and P2Y receptors, indicating that an electron-enriched, larger substituent is 
well-tolerated in the 4'-position. 
 
The 4''-methyl-substitution in the suramin and NF037 derivatives NF212 and 
NF213 generated compounds with reduced P2X receptor-blocking potencies and 
ecto-nucleotidases inhibitory activity. 
 
Within the group of NF023-derived small ureas, insertion of electronegative 
substituents (NF156, NF255) also decreased the P2X receptor-blocking potency, 
which is almost abolished by substitution with electron donating groups (NF058, 
NF144). As assessed for the large ureas, the ecto-nucleotidases inhibitory activity 
remained rather unaffected. In contrast to NF198, the small urea analogue NF195 
was slightly less potent than its parent compound NF023 in blocking 
P2X receptors, but more potent in blocking P2Y receptors. 
 
In general, 4'-substituents regardless whether electronegative or electropositive 
lead to a decrease in P2X receptor-blocking potency. Accordingly, it has been 
reported, that rearrangement or increase in the number of methyl substituents, as 
in NF212 and NF213, decreased the inhibitory potency at P2X receptors in the 
pithed rat in vivo. In this study, NF023 has been reported to be at least as potent 
as suramin (Urbanek et al., 1990). Subsequent studies performed in ratVD and 
RVD revealed an even higher P2X receptor-blocking potency for NF023 compared 
to suramin (Bültmann et al., 1996c; Ziyal, 1996; see 1.1.4.2.). It was concluded 
from a comparison of suramin analogues, that an increase in molecular size 
enhances P2X affinity until a maximum is reached in NF023 and a further 
increase to suramin tends to reduce affinity (Bültmann et al., 1996c). Analysing a 
larger number of analogues, this conclusion cannot be confirmed regarding the 
results obtained in the present study. The P2X receptor-blocking potencies 
assessed for NF037 and NF023 in the screening assay as well as in ratVD 
(cf. chapter 3.2.) were almost similar, indicating that the reason for the reduced 
P2X potency of suramin might be more probably due to the 4'-methyl substitution 
than to the increase in molecular size. 
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Exchange of aminobenzoyl groups (figure 3.12., table 3.4.b.; figure 3.16., 3.5.b.) 
 
In the large ureas-series two compounds have been analysed that display slightly 
lower P2X receptor-blocking potencies than the parent compound NF037. NF356, 
in which the aminobenzoyl groups are exchanged by aminofuranyl residues and 
the aminobenzimidazolyl derivative NF506. 
 
Among the small ureas, the aminofuranyl analogue NF359 which is structurally 
closely related to NF550 shows a dramatic decrease in inhibitory potency at P2X 
and P2Y receptors. 
 
In contrast, introduction of isomeric biphenyl residues generated compounds 
displaying increased P2X (NF139, NF192, NF136, NF201) and in part also 
increased P2Y receptor-blocking potencies (NF192, NF136) compared to the 
parent compound NF023. This group of derivatives can be described as 
intermediates between the large and small ureas. Interestingly, their P2 receptor 
inhibitory potencies differ depending on the spatial orientation of the 
aminonaphthalene sulphonic acid residues and the urea-bridge, in that the 
stretched form, the para-para-linked derivative NF130 is markedly less potent 
even than NF023, whereas the para-meta- and the ortho-para-linked compounds 
display increased potency at both P2 receptor subtypes. The inhibitory activity on 
ecto-nucleotidases also differs, albeit marginally, among the analogues, indicating 
that there might be possibilities to separate P2 receptor antagonistic properties 
from ecto-nucleotidases inhibition by structural variations within the group of 
suramin analogues. The increased antagonistic potencies displayed by some of 
the biphenyl isomers indicate that an increase in molecular size compared to 
NF023 is not necessarily accompanied by a decrease in P2 receptor-blocking 
potency. 
 
The loss in potency found for NF359 together with the finding that in the group of 
large ureas the exchange of one pair of aminobenzoyl substituents with 
heteroaromatic systems is well-tolerated indicates, that at least one pair of 
aminobenzoyl moieties seems to be important for a certain P2 receptor-blocking 
potency. 
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7-aminonaphthalene di- and trisulphonic acid substituted 1'-4'-linked small ureas 
(figure 3.18., table 3.5.d.) 
 
Compared to their parent compound NF278, no differences in P2 receptor-
blocking and ecto-nucleotidases inhibitory potencies have been observed for the 
small ureas NF347 and NF291. All derivatives display very low potencies in 
blocking P2X receptors in ratVD. On the basis of these findings, the impact of the 
introduction of 7-aminonaphthalene instead of 8-aminonaphthalene trisulphonic 
acid residues cannot be clearly assessed. 
 
Exchange of the central urea bridge (figure 3.14., table 3.4.d., figure 3.19., 
table 3.5.e.) 
 
The introduction of a thiourea (NF513) instead of an urea bridge (NF037) in the 
large urea group led to decreased antagonistic potency at P2X receptors. Further 
variations analysed, the insertion of isophthalic and terephthalic acid (NF059, 
NF064) as well as piperazine (NF299) bridges also resulted in a loss of P2X 
receptor-blocking potency. Similar results were obtained in the small urea series, 
neither the phthalic acid analogues (NF344, NF343) nor the piperazine derivative 
(NF300) displayed considerable P2 receptor-blocking or ecto-nucleotidases 
inhibitory potencies, respectively. Therefore, the urea bridge seems to be the ideal 
link between the two symmetrical moieties. 
 
Recent developments in the series of suramin analogues 
 
Another series of suramin analogues has been introduced very recently (Braun et 
al., 2001; Lambrecht et al., 2002). With the aim of generating additional sites of 
ligand-receptor interaction the number of negatively charged structures within the 
suramin pharmacophore was increased by the introduction of four benzene 
disulphonic acid moieties instead of two naphthalene trisulphonic acid residues. 
Of these analogues, NF449 (figure 4.1.) displayed an outstanding antagonistic 
potency at P2X1-like receptors present in ratVD (pIC50‘s of 7.15 and 6.31 using 1 
or 10 M  ,-mATP, respectively) as well as at recombinant P2X1 receptors 
(Xenopus oocytes, pIC50 = 9.54). Antagonism of NF449 has been shown to be 
specific and selective for the P2X1 receptor subtype as it was found to be inactive 
at 1A adrenoceptors, histamine H1 and muscarinic M3 receptors and only a weak 
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antagonist at native and recombinant P2X3 receptors as well as native P2Y1-like 
and P2Y2 receptors (Braun et al., 2001; Lambrecht et al., 2002). 
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Fig. 4.1.  Chemical structure of NF449. 
 
 
4.2.  Pharmacological characterisation of NF279 and its structural relatives 
 
On the basis of the results obtained in the screening assays, small and large 
ureas varying in the substitution pattern of the benzoyl residues and especially 
one derivative, the suramin analogue NF279, were chosen to be subject of a more 
detailed pharmacological characterisation for two reasons: first, NF279 displayed 
the highest P2X receptor-blocking potency among all compounds analysed, being 
even markedly more potent than NF023; second, the fact that the relatively small 
structural variation from NF037 to NF279 resulted in such a remarkable increase 
in antagonistic potency argues in favour of a specific interaction between the 
compounds and the receptor protein, and third, a detailed pharmacological 
characterisation of analogues might provide some more interesting insights in 
SAR's of suramin-related compounds. 
 
4.2.1.  Inhibitory potency of small and large ureas III on native P2X 
receptors in rat vas deferens 
 
For the analysis of the pharmacological properties of NF279 and its structural 
analogues (see figures 3.13., 3.17.) in terms of antagonistic potencies at native 
homomeric P2X1 receptors, the rat vas deferens (ratVD) was chosen as model 
tissue. Contractions of ratVD elicited by ,-mATP have been characterised in a 
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large number of studies as being mediated by a P2X receptor subtype which 
corresponds well in terms of rank orders of agonist as well as antagonist 
potencies with the P2X1 homomer (Khakh et al., 1994, 1995b; Bültmann et al., 
1999b; Ralevic and Burnstock, 1998; Bianchi et al., 1999; Lambrecht, 2000) which 
was originally cloned from the ratVD (Valera et al., 1994). Therefore, the use of 
the ratVD allowed a better comparison of the potency data obtained in the present 
study with potency estimates determined for other P2 receptor antagonists on 
recombinant rP2X1 homomers and on its native counterpart in the ratVD. 
Heterogeneity of P2 receptors mediating contraction of the ratVD has been 
reported, based on the observation that in contrast to contraction evoked by 
,-mATP contractile responses to ATP were not totally blocked by suramin and 
iso-PPADS (Bültmann and Starke, 1994b). However, results obtained in a recent 
study confirmed earlier presumptions that the lack of effect of these antagonists 
might at least in part to be due to their dual activity: blocking P2 receptors and 
inhibiting ATP degradation by ecto-nucleotidases (Bültmann et al., 1999b), a 
phenomenon that has already been described for suramin and is referred to as 
“self-cancellation” (Crack et al., 1994). Nevertheless, the existence of additional 
subtypes of contraction-mediating P2 receptors cannot be totally ruled out by this 
explanation. Recently, UTP which has previously been shown to be inactive in 
pre-contracted ratVD (Khakh et al., 1994), was reported to elicit contraction of the 
tissue, when Evans blue was present to prevent enzymatic degradation of the 
nucleotide (Bültmann et al., 1999a). Contraction elicited by UTP was shown to be 
insensitive to desensitisation by ,-mATP and persisted in the absence of 
extracellular calcium, indicating that contractile responses to uracil nucleotides 
were most likely to be mediated by a G protein-coupled P2Y receptor subtype. 
The fact that the UTP-induced contraction was inhibited by suramin together with 
a rank order of agonist potency of ATP  UTP  UDP = ADP led to the conclusion, 
that UTP might interact with P2Y2 receptors in the ratVD preparation (Bültmann et 
al., 1999a). Based on the observation that UTP failed to desensitise ATP-induced 
contractions in the continuous presence of ,-mATP the possibility of the 
presence of a third contraction-mediating P2 receptor cannot be ruled out 
(Bültmann et al., 1999a). 
 
However, by the use of the P2X receptor-selective, non-degradable agonist 
,-mATP (cf. 1.1.3.1., 4.1.1., Khakh et al., 1995b; Lambrecht, 2000) contractile 
responses of ratVD seem to be almost exclusively mediated via P2 receptors 
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which closely resemble in their pharmacological properties those of the 
molecularly defined P2X1 homomer (Khakh et al., 1994, 1995b; Valera et al., 
1994; Trezise et al., 1995; Bianchi et al., 1999; see 4.3.). 
 
Antagonistic potencies determined for the reference drugs suramin and NF023 
(tables 3.6. and 3.7.) were very similar to those obtained for the antagonists in 
previous studies comparing the apparent pA2 values calculated from the 
pIC50 values with affinity estimates derived from Schild plots (Khakh et al., 1994; 
Bültmann et al., 1996c). The potency estimates for small and large ureas derived 
from concentration-inhibition curves largely confirmed the results obtained in the 
screening study performed on RVD (figure 4.2.). Among the large ureas the 
1'-4',1''-4''-linked 1,3,5-trisulphonated naphthylurea NF279 displayed the highest 
P2X1-like receptor-blocking potency being about one order of magnitude more 
potent than the 1'-3',1''-3''-linked parent compounds suramin and NF037. The 
P2X1-like receptor-blocking potencies of the 1'-4',1''-3''-linked structural 
intermediates NF280 and NF032 were decreased, even in comparison to suramin 
and NF037. In contrast to the 1'-3',1''-3'' and the 1'-4',1''-3'' analogues, an impact 
of the substitution pattern of the naphthyl moieties’ sulphonic acid residues 
became obvious comparing the potency of NF279 and NF031: a shift of one 
sulphonic acid residue from the 5- to the 6-position in the naphthyl ring led to a 
marked loss in antagonistic potency at ratVD P2X1-like receptors. 
 
The 1'-4'-linked small ureas NF278 and NF013 being only poor P2X1-like receptor 
antagonists, displayed the opposite to the effect observed in the group of large 
ureas. Comparable to the impact of the same structural variation in the large urea 
series, a change in the substitution pattern of the naphthalene sulphonic acid 
residues of the 1'-3' linked derivatives (NF023: 1,3,5; NF550: 1,3,6) did not alter 
the P2X1-like receptor-blocking potency. 
 
Fig. 4.2. (see page 158) Selectivity profile of suramin-related large ureas (A.) 
and NF023-derived small ureas (B.) on native contraction-mediating P2X1-like 
receptors present in rat vas deferens (ratVD) and P2Y1-like receptors mediating 
contraction of guinea-pig ileal longitudinal smooth muscle preparation (GPI) 
(cf. 3.2.). The P2X1-like receptor-blocking potencies of NF278 and NF013 have 
been examined at a single concentration of the respective antagonist, apparent 
pA2 values may therefore be even lower than indicated by the broken line. 
157 4. Discussion 
A. 
Suramin NF037 NF551 NF280 NF032 NF279 NF031
4
5
6
7
pA2 value
P2Y1 (GPI)
P2X1 (RatVD)
 
 
B. 
NF023 NF550 NF278 NF013
4
5
6
7
pA2 value
P2Y1 (GPI)
P2X1 (RatVD)
 
158 4. Discussion 
4.2.2.  Inhibitory potency of small and large ureas III on native P2Y 
receptors in guinea-pig ileum and taenia coli 
 
Suramin competitively antagonised P2Y receptor-mediated relaxation of GPTC 
evidenced by a Schild plot whose slope was not significantly different from unity 
(figure 3.4.). The pA2 value of 4.45 derived from the constrained plot is slightly 
lower than affinity estimates determined for suramin in GPTC in previous studies 
(Bültmann et al., 1996a; Ziyal, 1996). Using ADPS as agonist in GPTC, 
Bültmann and colleagues (1996a) reported pA2 values of suramin to decrease 
when higher concentrations of the antagonist were examined. Although not 
different from unity, a slope of < 1 obtained for suramin and its desmethyl-
derivative NF037 for the regression according to Arunlakshana and Schild (1959) 
in the present study indicate that there is a trend to lower pA2 values, thereby 
confirming those previous observations. Similar to results described for the 
analysis of the antagonistic effects of NF023 at GPTC P2Y receptors, the 
pA2  values obtained in the present study decreased markedly with increasing 
concentrations (cf. 3.1.2.2.; Bültmann et al., 1996c). Accordingly, limited 
antagonism was also observed for the small urea NF550 as CRC’s to ADPS in 
the presence of increasing concentrations of the analogue were almost 
superimposable. The reason for this deviation from competitive antagonism is not 
clear. One possible explanation, the presence of a heterogeneous receptor 
population in GPTC, has been proposed previously (Dudeck et al., 1995; 
Bültmann et al., 1996a; Lambrecht et al., 1996b; see 4.1.2.). Due to the fact that 
no cross-desensitisation of relaxation induced by either ,-mATP or ADPS has 
been reported, a heterogeneity of receptors mediating relaxation induced by 
ADPS has to be anticipated. This might also reflect the differences observed 
comparing the potencies of antagonists in GPTC with those obtained for GPI 
P2Y receptors (table 4.2., 4.3.). 
 
In GPI, ADPS was shown to act at two sites: a P2 receptor located on cholinergic 
neurons, the stimulation of which causes indirect (acetylcholine-mediated) 
contractions via postjunctional muscarinic M3 receptors (Czeche et al. 1998a), 
recently characterised as P2X3 receptor subtype based on its sensitivity to 
,-mATP and the relative potencies of several antagonists (Lambrecht et al., 
2000a); and a postjunctional P2 receptor on the ileal longitudinal smooth muscle 
(Kennedy and Humphrey, 1994; Czeche et al., 1998b). In the presence of 
159 4. Discussion 
atropine, ,-mATP was shown to be inactive and therefore contractile responses 
to ADPS proved to be mediated exclusively via the postjunctional P2 receptor, 
which exactly resembles in its pharmacological properties the molecularly defined 
P2Y1 receptor subtype (Czeche et al., 1998b; Lambrecht et al., 1999). 
 
Table 4.3.  Comparison of potency estimates (pA2 values) obtained for large and 
small ureas inhibiting relaxation of guinea-pig taenia coli (GPTC) induced by 
ADPS or blocking ADPS-evoked contractions of guinea-pig ileal longitudinal 
smooth muscle (GPI). In GPTC, pA2 values determined for NF023 and NF550 
decreased testing increasing concentrations of the antagonists, therefore the 
concentration of antagonist for which the respective pA2 value was calculated is 
given in parentheses. 
 
Large ureas  Suramin  NF037 NF551 NF280 NF032 NF279 NF031 
P2Y  (GPTC)  4.45 4.86 4.60 4.87 3.95 4.10 3.30 
P2Y  (GPI)  5.68 5.73 5.62 5.72 4.91 5.32 4.56 
Small ureas  NF023 NF550 NF278 NF013 
P2Y (GPTC)  4.40 (100 M) 
4.07 (300 M) 
5.43 (10 M) 
4.78 (30 M) 
4.27 4.53 
P2Y  (GPI)  4.74 5.87 5.05 5.21 
 
 
The large ureas NF037 and NF551 were equipotent to their parent compound 
suramin in inhibiting ADPS-induced relaxation of GPTC as well as contraction of 
GPI elicited by ADPS, indicating that the 4'-methyl residues are not a prerequisite 
for binding to the P2Y receptors present in these preparations. Similar results 
were obtained in a binding study performed on turkey erythrocyte membrane 
P2Y  receptors comparing the affinity of suramin and NF037 (van Rhee et al., 
1994). In contrast to the ratVD P2X1-like receptors the 1'-4',1''-4''-linkage in NF279 
and NF031 led to a loss in antagonistic potencies at GPI P2Y1-like receptors, 
whereas the 1'-4',1''-3''-linked compound NF280 was almost equipotent to the 
1'-3',1''-3''-linked derivatives suramin, NF037 and NF551. The substitution pattern 
of the naphthalene sulphonic acid residues affected P2Y1-like receptor-blocking 
potency not only in the 1'-4',1''-4''-linked compounds (comparable to the effect of 
this structural variation at ratVD P2X1-like receptors), the 5- to 6-shift of one 
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sulphonic acid residue also resulted in a decreased antagonistic potency of the 
1'-4', 1''-3''-linked analogue NF032. 
 
Comparing the P2Y1-like receptor-blocking potencies of the small ureas in GPI 
(table 4.3.), where in contrast to GPTC the Schild plot for NF023 was linear with a 
slope (1.01) not significantly different from unity (Czeche et al., 1998b; Lambrecht 
et al., 1999), NF550 being more potent than NF023, its 1'-4'-linked analogue 
NF013 and NF278, a 1,3,6-substitution of the naphthalene sulphonic acid 
residues seems to be in favour of P2Y1-like receptor affinity. As assessed for 
P2X1-like receptors, 1'-4'-linkage generates compounds displaying reduced 
antagonistic potency at P2Y1-like receptors. 
 
4.2.3.  Inhibitory potency of small and large ureas III on ATP breakdown 
(Xenopus laevis oocytes) 
 
The inhibitory activity of large and small ureas on ATP breakdown by ecto-nucleo-
tidases (ectoN) present in Xenopus laevis oocytes was almost similar ranging from 
18 to 65 % inhibition in the presence of 300 M of the respective analogue. The 
assessment of structure-activity relationships for ectoN inhibition is difficult to 
establish because of all compounds being only poor inhibitors of ATP degradation. 
In general, inhibitory potency on ectoN seems to increase in parallel to the 
antagonistic potency of the derivatives at either P2X1-like or P2Y1-like receptors 
(see table 4.4.). In the group of small ureas, inhibitory potencies on ectoN seem to 
correlate well with the P2Y1-like receptor-blocking potencies whereas in the large 
urea series, inhibition of ATP degradation increases with increasing antagonistic 
potencies at P2X1-like receptors. 
 
 
 
 
 
Table 4.4.  (see page 162) Antagonistic potencies (pA2 values) of small and 
large ureas on P2X receptors in rat vas deferens (ratVD) and P2Y receptors in 
guinea-pig ileal longitudinal smooth muscle (GPI) in comparison to the inhibitory 
potency (%) of the analogues (300 M) on ATP breakdown by ecto-nucleotidases 
(ectoN) present in folliculated Xenopus laevis oocytes. 
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Large 
ureas 
Suramin  NF037 NF551 NF280 NF032 NF279 NF031 
P2X  (ratVD)  5.72 5.83 5.88 5.35 5.49 6.75 6.00 
P2Y  (GPI) 5.68 5.73 5.62 5.72 4.91 5.32 4.56 
ectoN  41.2 57.0 49.6 43.1 28.6 66.4 52.8 
Small ureas  NF023 NF550 NF278 NF013 
P2X (ratVD)  5.97  6.17  < 5  < 5 
P2Y  (GPI)  4.74 5.87 5.05 5.21 
ectoN  28.2 43.3 26.1 18.3 
 
 
4.2.4.  Inhibitory properties of NF279 
 
Of the antagonists displaying considerable potency and selectivity for a certain 
P2 receptor subtype, the large urea NF279, which was shown to be significantly 
more potent in blocking ratVD P2X1-like receptors (six-fold) than NF023 
(Lambrecht et al., 1996a; Soto et al., 1999), was further analysed in terms of 
mechanism of P2 receptor antagonism as well as P2 receptor subtype selectivity 
and specificity of its antagonistic effects. 
 
4.2.4.1.  P2X receptor antagonism of NF279 
 
4.2.4.1.1.  Antagonism of NF279 at native P2X receptors 
 
In order to elucidate the mechanism of antagonism by NF279 on P2X1-like 
receptors in ratVD, CRC’s to ,-mATP were determined in the absence and 
presence of NF279. Increasing concentrations of NF279 shifted the CRC’s 
progressively to the right, indicating concentration-dependent antagonism, and 
simultaneously increased the slope in a non-concentration-dependent manner 
(see figure 3.22.). An increase of the slope or maximum response of the 
,-mATP CRC’s has been previously described in ratVD for suramin, NF023 and 
congeners (Bültmann et al., 1996c) as well as for the histochemical dyes Evans 
blue, Trypan blue and RB2 (Bültmann and Starke, 1993; Bültmann et al., 1994; 
Tuluc et al., 1998), and additionally in other tissues containing P2X receptors 
(Trezise et al., 1994; Ziyal, 1996; see Bültmann et al., 1996c). The increase in the 
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maximum response seems to be a common property of reversibly acting 
P2X  receptor antagonists, the underlying mechanism, however, is not known. 
Originally, it was anticipated that it might be due to ,-mATP acting on a low 
affinity P2 receptor which is antagonised by low concentrations of suramin 
(Blakeley et al., 1991; Mallard et al., 1992). This possibility seems to be rather 
unlikely for several reasons: first, the increase in the maximal response seems to 
be independent of the concentration and the antagonist examined; second, TTX 
failed to inhibit contraction of ratVD induced by ,-mATP (cf. 3.3.1.), thereby 
indicating that the agonist acts exclusively postsynaptically and, third, this 
potentiating effect of antagonists has been observed analysing P2X 
receptor-mediated effects in different tissues as well as in vasa deferentia of 
different species. An alternative explanation, that inhibition of ecto-nucleotidases 
by the antagonists might account for the increase in maximum seems not 
conceivable, as well, when using the enzymatically stable agonist ,-mATP. 
However, it has been reported recently that ,-mATP itself inhibits ecto-
nucleotidases present in bovine pulmonary endothelial cells with an IC50 of about 
30 M (Chen and Lin, 1997). Considering the ability of almost all antagonists to 
inhibit ecto-nucleotidases (although for most of the antagonists the concentration 
required for enzyme inhibition is higher than the concentration necessary for 
P2 receptor antagonism) it is possible that rapid breakdown of ATP which can be 
released during contraction of the smooth muscle (Westfall et al., 1996) is 
prevented and therefore endogenous ATP can contribute to the contraction 
induced by exogenously applied ,-mATP. 
 
A further deviation from competitive antagonism observed for NF279 was the 
increase in mean pA2 estimates calculated from the shift of the CRC’s in the 
presence of increasing NF279 concentrations (see table 3.8.). It may result when 
the lower NF279 concentrations have not reached equilibrium (Leff et al., 1990). 
However, there was no difference in affinity estimates determined for the lowest 
NF279 concentration examined after 60- and 120-min pre-incubation, respectively. 
In contrast, NF279 was found to act as a purely competitive antagonist 
(pA2 = 5.95)  on P2X3-like receptors modulating ACh-release in GPI longitudinal 
smooth muscle preparation, indicated by a Schild plot, the slope of which was not 
significantly different from unity (Lambrecht et al., 1999; Lambrecht et al., 2000a). 
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4.2.4.1.2.  Antagonism of NF279 at recombinant P2X receptor subtypes 
 
Electrophysiological studies with the aim to examine the P2X receptor subtype 
selectivity of NF279 revealed remarkable differences in the antagonistic potencies 
determined for NF279 either pre-incubated or co-applicated at the rapidly 
desensitising homomeric P2X1- and P2X3 receptors expressed in Xenopus laevis 
oocytes (Rettinger et al., 2000). When pre-incubated for 10 s NF279 was about 
100-fold more potent in blocking current responses from rP2X1 receptors 
(pIC50  =  7.72) than from rP2X3 receptors (pIC50 = 5.79) (Damer et al., 1998; 
Rettinger et al., 2000). The inhibitory potency determined for NF279 on 
hP2X1 receptors (pIC50 = 7.30) was almost similar to its potency on rP2X1, the 
slight variance may be due to differences in the protein structure or differences in 
the experimental protocols (i.e. the solution exchange times) applied, respectively, 
(Klapperstück et al., 2000; Rettinger et al., 2000), although, for NF023 similar 
pIC50 values (hP2X1: 6.68; rP2X1: 6.62) have been found for the human and the 
rat homologue (Soto et al., 1999). In contrast to NF279, pre-incubation in 
comparison to co-application had no significant influence on the inhibitory potency 
of NF023 on the current induced by ATP (Soto et al., 1999). An explanation of this 
differential action of the two antagonists might come from the comparison of the 
time course and reversibility of their inhibitory actions determined for NF023 
(3 M) in RVD (Ziyal, 1996) and NF279 (1 M) in ratVD (figure 3.23.). The times of 
on-set as well as off-set of NF279's antagonism turned out to be markedly longer 
than those of NF023, being 180 min for NF279 compared to 50 min for NF023 as 
well as 90 min (NF279) compared to 50 min (NF023) for the wash-out of the 
respective compound. 
 
At rP2X1, increasing concentrations of NF279 caused both a shift to the right of 
the ATP CRC and an increasing depression of the maximum current. Since the 
dissociation of NF279 from the receptor is slow compared to the time required to 
reach the maximal response after application of ATP, no equilibrium is reached 
during the occurrence of the peak current on which the analysis is based 
(Rettinger et al., 2000). Whether the antagonism of NF279 can be considered 
competitive can neither be confirmed nor rejected on the basis of the results 
obtained in that study, although the competitive nature of antagonism by the 
structurally related compound NF023 favours this interpretation (Soto et al., 1999). 
Further experiments are needed to clarify this issue. 
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Furthermore, NF279 was shown to concentration-dependently decelerate both, 
activation and desensitisation of the hP2X1 receptor (Klapperstück et al., 2000). 
This effect has so far not been reported for NF023. Recently, desensitisation of 
ratVD P2X1 receptors has been shown to be due to internalisation of the 
agonist-activated receptor. Subsequently, rapid recycling of these receptors to the 
cell-surface is followed by recovery of the receptor from an inactivated state which 
was described to be the rate-limiting step in desensitisation and recovery of 
P2X1 receptors (Ennion and Evans, 2001). Since desensitisation/internalisation is 
dependent on receptor activation, the slowly dissociating antagonist NF279 
competing with ATP may therefore cause deceleration of activation as well as 
desensitisation of P2X1 receptors (see Klapperstück et al., 2000). 
 
At the almost non-desensitising rP2X2 receptor antagonism of NF279 was 
demonstrated to be competitive, and a mean pKB value of 6.44 was calculated 
when the slope of the regression according to Arunlakshana and Schild (1959) 
was constrained to unity (Rettinger et al., 2000). 
 
The hP2X4 receptor was less sensitive to inhibition than rat P2X1, P2X2 and 
P2X3 receptor subtypes (41 % inhibition at 300 M NF279) (Rettinger et al., 2000). 
Antagonistic potency at hP2X7 receptors measured at an activating ATP 
concentration of 1 mM yielded a pIC50 value of 4.5 (Klapperstück et al., 2000). 
Therefore, the P2X receptor selectivity profile of NF279 (P2X1   P2X2   P2X3 
 P2X7 >> P2X4) is unique and different from those of the few P2 receptor 
antagonists which have been examined in terms of P2X receptor subtype 
selectivity. 
 
4.2.4.2.  Antagonism of NF279 at native and recombinant P2Y receptors 
 
In GPI longitudinal smooth muscle preparation increasing concentrations of 
NF279 shifted the concentration-contraction curves obtained to single doses of 
ADPS progressively to the right. A pA2 estimate of 5.32 derived from Schild 
analysis was slightly higher than that found for NF023 (4.74) and in turn 
moderately lower than the antagonistic affinity determined for suramin on GPI 
P2Y1-like receptors (Lambrecht, 2000). This rank order of potency was largely 
confirmed when the antagonistic potencies of the compounds were examined at 
recombinant P2Y1 receptors. NF279 (pIC50 = 4.6) was found to be equipotent to 
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NF023 (pIC50  =  4.6), and both compounds were inactive at recombinant P2Y2, 
P2Y4, and P2Y6 receptors (J.L. Boyer and T.K. Harden, personal communication). 
 
4.2.4.3.  Inhibitory potency of NF279 on ATP breakdown 
 
Like suramin and NF023, NF279 inhibits ecto-nucleotidases activity in Xenopus 
laevis oocytes at very high concentrations (100 - 300 M). 
 
4.2.4.4.  P2 receptor specificity of NF279 and NF031 
 
At a concentration of 100 M NF279 did not interact with 1A receptors in ratVD, 
adenosine A1, histamine H1 and muscarinic M3 receptors in GPI and adenosine 
A2B as well as neuronal nicotinic receptors in GPTC (table 3.12.). Thus, similar to 
NF023 (Lambrecht et al., 1996a) but in contrast to suramin (1.1.4.) the 
antagonism of NF279 appears to be specific for P2 receptors. 
 
 
4.3.  Regional variation of purinergic responses in rat vas deferens 
 
There are several reports addressing the regional variation of adrenergic and 
purinergic responses in vasa deferentia of different species with respect to the 
prostatic and epididymal origin of the segment. In general, segments from the 
prostatic end of the muscle exhibit primarily a rapid, phasic, purinergic response 
whilst segments from the epididymal end show mainly a slower, tonic, adrenergic 
contraction (Sneddon and Machaly, 1992). Moreover, heterogeneity of 
P2 receptors mediating contraction of the ratVD has been postulated, based on 
potency profiles of both agonists and antagonists (Bültmann and Starke, 1994b, 
2001; Bültmann et al., 1999a). However, whether the P2 receptor subtypes are 
distributed symmetrically along the length of the vas deferens and as a 
consequence, prostatic as well as epididymal segments are equally suitable for 
the study of P2X1 receptor-mediated responses, has not been examined so far. 
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4.3.1. Comparison of agonist potencies in prostatic and epididymal 
segments of the rat vas deferens 
 
By the use of agonists with different selectivity profiles slight differences were 
observed comparing their potencies in the two ends of the ratVD. ,-mATP was 
the most potent agonist in prostatic as well as epididymal segments, the potency 
estimates determined in the present study (pEC1000 values) being very similar to 
potency estimates (EC50's) reported previously (Khakh et al., 1995b). A rank order 
of agonist potency of ,-mATP  L-,-mATP  ATPS  ADPS was observed in 
both portions of the ratVD. However, ,-mATP displayed a slightly higher potency 
in prostatic segments and the slope of the agonist's CRC was markedly decreased 
in epididymal segments. In contrast, potency of the P2X1 receptor-selective 
agonist L-,-mATP (Trezise et al., 1995; Rae et al., 1998) differed only marginally 
among the segments and the CRC’s were almost superimposable. As already 
described for ,-mATP, the potency estimates for L-,-mATP correspond well 
with an EC50 that has been determined in a previous study for the agonist in 
prostatic segments of ratVD (Trezise et al., 1995). 
 
Cross-desensitisation studies yielded two interesting observations: first, although 
in prostatic portions the ,-mATP-induced contraction was nearly abolished by 
desensitisation using L-,-mATP, in epididymal segments one third of the 
response remained. Second, contraction elicited by ADPS in prostatic segments 
was markedly decreased after desensitisation using ,-mATP, which was not the 
case for the ADPS-induced contraction in epididymal segments. Moreover, 
especially in the epididymal portions tachyphylaxis rather than desensitisation was 
observed for contraction elicited by ADPS, indicating that the agonist might act at 
one of the non- or slowly-desensitising P2 receptor subtypes. A further interesting 
finding of the present study was the difference in the time course of 
desensitisation induced by ,-mATP. Desensitisation appeared to be faster in 
prostatic than in epididymal portions of the ratVD. This might be in favour of 
,-mATP also acting on a P2 receptor subtype different from the rapidly 
desensitising P2X1 receptor. 
 
The fact that TTX did not alter the responses elicited by ,-mATP and ADPS 
neither in prostatic nor in epididymal segments, respectively, argues against an 
involvement of presynaptic receptors. 
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Accordingly, based on the cross reactivity of L-,-mATP and ,-mATP as well as 
of ,-mATP and ADPS, in prostatic segments of ratVD, P2X1 receptors can be 
regarded at least as the predominating P2 receptor subtype mediating contraction 
induced by all of the three agonists applied (Trezise et al., 1995; Rae et al., 1998). 
In contrast, contractions elicited by ,-mATP and ADPS in epididymal segments 
seem to be mediated via (a) distinct, moderately or slowly-desensitising 
P2  receptor subtype(s) present on the postsynaptical site in addition to the 
P2X1 receptor subtype. Whether this additional site of action is the same for both 
agonists was the subject of a more detailed analysis, applying P2 receptor 
antagonists. 
 
In general, homomeric P2X3 as well as heteromeric P2X2P2X3 and 
P2X1P2X5 receptors are possible candidates for the receptor subtype sensitive to 
,-mATP, regarding the selectivity profile of the agonist (Lambrecht, 2000; North 
and Surprenant, 2000). Whereas ADPS has been reported to act as an agonist 
at the G protein-coupled P2Y1, P2Y6, P2Y11 and P2Y12 receptors as well as P2X1, 
P2X3 and P2X4 receptors (Filtz et al., 1994; Chang et al., 1995; Bianchi et al., 
1999; Communi et al., 1999; Hollopeter et al., 2001; Jin et al., 2001), indicating 
overlapping activities to exist. 
 
4.3.2.  P2 receptor subtype(s) mediating ,-mATP-induced contraction of 
epididymal segments of the rat vas deferens 
 
Assessing and comparing the inhibitory potencies of several P2 receptor 
antagonists on ,-mATP-induced contraction of prostatic and epididymal 
segments of the ratVD, in certain cases marked differences were observed. The 
highest ratios (IC50[epididymal]/IC50[prostatic]) have been obtained for PPADS, 
NF279, and NF037, whereas the non-selective antagonist suramin displayed 
almost similar potencies in epididymal and prostatic ends. In general, pIC50 values 
determined for the antagonists in prostatic ends were higher than those found in 
epididymal segments although, regarding the differences in the agonistic potency 
of  ,-mATP with respect to the anatomical origin of the tissue, the opposite 
should have been the case: IC50 values depend on the concentration of agonist 
applied in the way that the higher potency/concentration of agonist the higher the 
concentration of antagonist required to block the agonist-induced effect. 
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Therefore, pIC50 values derived from epididymal segments would have been 
expected to be slightly higher than those derived from prostatic segments. 
 
As could be anticipated from the comparison of the antagonistic potencies, the 
differences increased when affinities of NF279 (independent of the agonist 
concentration), determined in prostatic and epididymal portions, were compared. 
pA2 values assessed for NF279 (10 M) were one order of magnitude higher in 
prostatic than in epididymal segments of the ratVD. 
 
The pA2 values determined for NF279 (3 M) in the two segments of ratVD 
correspond well with the apparent pA2 estimates calculated from the pIC50 values 
of the antagonist (tables 3.16. and 3.17.). Therefore, the modification of the 
relationship introduced by Cheng and Prussoff (1973) and applied in order to 
generate potency estimates for NF279, which are not depending on the potency of 
the respective agonist, yielded acceptable results. 
 
The fact, that only minor differences have been observed for the antagonistic 
effect of the P2X1 receptor-selective compound NF279 in prostatic and epididymal 
segments of the ratVD when the P2X1 receptor-selective agonist L-,-mATP was 
applied to induce contractions, confirms the presence of functional P2X1-like 
receptors in both ends of the tissue. Whereas the potency differences observed 
using the non-selective agonist ATPS as well as the P2X receptor-selective 
agonist  ,-mATP are in favour of the presence of additional P2 receptor 
subtype(s), at least in epididymal segments. Although these findings confirm the 
results obtained in the agonist studies, due to the absence of antagonists 
displaying selectivity for any of the other P2X receptor subtypes sensitive to 
,-mATP, the identity of the agonists additional site of action cannot be clearly 
delineated. However, it might be further confined regarding the P2 receptor 
subtypes' mRNA and proteins detected in ratVD so far. 
 
P2 receptor subtypes present in ratVD 
 
Based on reverse transcription-polymerase chain reaction (RT-PCR) analysis, not 
only the mRNA encoding for the P2X1 receptor subtype but also P2X2, P2X3 and 
P2X4 receptor mRNA's have been detected in both segments of ratVD (C. Büttner 
and G. Schmalzing, personal communication). Almost recently, the availability of 
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antibodies to unique peptide sequences of the seven P2X receptor subtypes 
enabled a immunohistochemical screening for the presence of P2X receptor 
subtype proteins to be performed in ratVD tissue (Lee et al., 2000). In addition to 
P2X1 receptors, for which strong immunostaining has been observed in the 
smooth muscle membranes (Lee et al., 2000; Mulryan et al., 2000), a more diffuse 
staining pattern was seen with P2X2 receptor antibodies also in the smooth 
muscle cells. P2X3 immunoreactivity has been reported in nerve fibre bundles 
outside the muscle proper, in the adventitial tissue. However, no differences in 
staining pattern between prostatic and epididymal ends of the tissue have been 
observed (Lee et al., 2000). 
 
A further study revealed a more discrete distribution pattern of P2X receptor 
subtypes in ratVD. Immunohistochemical analysis localised the presence of 
P2X1 receptor subunit proteins to the outer longitudinal and circular muscle layers, 
whereas P2X2 immunolabelling was particularly concentrated within the lamina 
propria (Burton et al., 2000) (see figure 4.3.). Two alternatively spliced isoforms of 
the P2X2 receptor subunit mRNA were detected applying RT-PCR (Burton et al., 
2000). One corresponding in sequence to the original clone (P2X2(a)), the other 
being identical with the P2X2(b) isoform encoding a protein with a truncated 
C-terminal domain (Brake et al., 1994; Brändle et al., 1997). P2X2(b) receptor 
subunits have been reported to exhibit a degree of desensitisation not found when 
P2X2(a) receptors were expressed to form homomeric ATP-gated ion channels 
(Brake et al., 1994; Simon et al., 1997). 
 
The cells expressing the P2X2 receptor isoforms were identified as interstitial cells 
of Cajal (ICC). Those cells, localised in the enteric plexuses and between 
gastrointestinal smooth muscle fibres, have been described to co-ordinate 
contraction via a reticular network of processes which synapse with enteric 
neurons and gastrointestinal smooth muscle cells, serving as the pacemaker cells 
for the basal electrical rhythm essential for the orthograde lumenal transport in the 
gut (Hagger et al., 1997; Horowitz et al., 1999). Therefore, P2X2 receptors present 
on ICC in ratVD may be involved in the intrinsic regulation of smooth muscle 
contraction (Burton et al., 2000). 
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Fig. 4.3.  Schematic structure of a cross-section of the rat vas deferens. 
 
In contrast, in mouse vas deferens, the presence of P2X1-6 receptor proteins has 
been detected by use of subtype-specific antibodies (Barden et al., 1999). 
Interestingly, P2X1 receptor clusters of two size categories were found, larger 
ones occurring under most sympathetic varicosities and small-sized clusters being 
present throughout the smooth muscle. From the distribution pattern of the other 
P2X receptor subtypes it was concluded that heteropolymerisation of subtypes 
seems very unlikely at the varicosities in mouse vas deferens, as these usually do 
not possess subtypes other than the P2X1, and P2X2 to P2X6 receptor subtypes 
mainly occur as small size clusters throughout the muscle. It was suggested, that 
the large P2X1 clusters are responsible for the fast junction potential component 
and the large number of small P2X receptor clusters of different subtypes might 
provide the input for the slow junction potential component that has been 
previously observed in the mouse vas deferens smooth muscle (Barden et al., 
1999). Whether these findings are of relevance for the ratVD needs to be 
established. 
 
Studies using P2Y receptor subtype-specific antibodies have not been performed 
in ratVD so far. The only P2Y receptor subtype reported to be present in vas 
deferens tissue, based on RT-PCR mRNA detection, was the rat P2Y4 receptor 
(Webb et al., 1998). 
 
These findings and the results obtained in the present study, support the view that 
in epididymal segments contraction elicited by ,-mATP is not exclusively 
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mediated via P2X1 receptors. Based on the selectivity profile of ,-mATP, an 
involvement of P2Y receptor subtypes as well as homomeric P2X2, P2X4, P2X6, 
and P2X7 receptors can be excluded (Lambrecht, 2000; Bianchi et al., 1999). So 
far, besides the P2X1 subtype, P2X2 and P2X3 receptor proteins have been 
detected in ratVD (Lee et al., 2000). Although mRNA encoding for the P2X4 has 
been reported to be present in ratVD (Bo et al., 1995; C. Büttner and 
G. Schmalzing, personal communication), no immunostaining was observed using 
P2X4 receptor-specific antibodies (Lee et al., 2000). Considering all these facts, 
the unidentified ,-mATP-sensitive P2 receptor present in epididymal segments 
of the ratVD should belong to the P2X receptor subfamily, the most probable 
subtypes are P2X3, as well as P2X2 and/or P2X3 contributing to a heteromeric 
assembly of two or probably more P2X receptor subunits (cf. Torres et al., 1999). 
 
4.3.3.  P2 receptor subtype(s) mediating ADPS-induced contraction of 
epididymal segments of the rat vas deferens 
 
In order to determine the P2 receptor subtype(s) involved in mediating contraction 
of epididymal segments of the ratVD elicited by ADPS and whether these are 
probably similar to the additional site of action of ,-mATP, the effects of the 
non-selective antagonist suramin, the P2X1 receptor-selective suramin analogues 
NF023 and NF279 (Lambrecht, 2000) as well as the P2Y1-selective ligand 
MRS 2179 (see von Kügelgen and Wetter, 2000; cf. 1.1.3.2.) were examined. 
 
MRS 2179 (10 and 100 M) did not alter the CRC obtained to cumulatively applied 
ADPS (figure 3.32.), indicating that the contraction is most probably not mediated 
via P2Y1 receptors. 
 
The non-selective P2 receptor antagonist suramin shifted the ADPS CRC to the 
right, as did NF023 and NF279 (figure 3.32.). The rightward shift was 
accompanied by an increase of the contractile responses induced by ADPS. 
Particularly in the presence of NF279, of which four different concentrations have 
been examined, contractions were augmented by lower concentrations of the 
antagonist (1 and 3 M) in a dose-dependent manner. The simultaneous action of 
ADPS at two different P2 receptor subtypes, one mediating relaxation, the other 
mediating contraction - NF279 being more potent in antagonising the 
relaxation-mediating receptor subtype - might be a possible explanation for these 
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observations. In fact, the presence of relaxation-mediating P2 receptors has been 
postulated in rat and mouse vas deferens (Boland et al., 1992; Mallard et al., 
1992). However, in ratVD pre-contracted with high potassium, ADPS as well as 
,-mATP have been reported to induce solely contraction whereas contractile 
responses elicited by ATP as well as 2-MeSATP were followed by relaxation 
(Bültmann and Starke, 2001). 
 
Due to the lack of desensitisation of ADPS-induced contractions as well as the 
potentiation rather than inhibition of these responses by lower concentrations of 
NF279, the P2X1 receptor is very unlikely to be the predominant site of action of 
ADPS in epididymal segments of the ratVD. Furthermore, NF279, at a 
concentration of 10 M, has been demonstrated to effectively antagonise 
P2X1-like receptors in prostatic segments of the ratVD (cf. 3.2.1.3.1.), whereas 
this concentration causes only a slight shift to the right of the ADPS CRC in 
epididymal segments. However, desensitisation of a small fraction of the 
ADPS-induced contraction in epididymal segments, as well as marked 
desensitisation observed in prostatic segments using ,-mATP as desensitising 
agent, indicates that part of the contraction elicited by ADPS is most probably 
mediated via P2X1 receptors. 
 
ADPS has been previously shown to elicit contraction of vasa deferentia of 
guinea-pig and rabbit (Bailey and Hourani, 1995; Lambrecht et al., 1996b). In 
rabbit vas deferens, suramin as well as NF023 and PPADS have been reported to 
antagonise contractile responses elicited by ADPS, although their potencies 
were low, especially the potency estimate obtained for NF023, when compared to 
pA2 values obtained using ,-mATP as agonist (Lambrecht et al., 1996b). 
 
Based on the fact that ADPS-induced contraction is inhibited by the 
P2X1  receptor-selective antagonists NF023 and NF279 (Lambrecht, 2000), and 
P2Y1 receptors - the only P2Y receptor subtypes at which both antagonists have 
been reported to display, albeit low, activity - can be excluded, an involvement of 
P2X receptor subtype(s) in mediating ADPS-induced effects has to be 
anticipated. However, the exact identity of these P2 receptor subtype(s) remains 
to be established. 
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In the early 70s, adenosine-5'-triphosphate (ATP), which has long been known as 
an intracellular source of energy, has been postulated to act extracellularly as a 
signalling molecule, i.e. as neuro-/cotransmitter. However, it lasted several years 
until the "purinergic nerves hypothesis" introduced by G. Burnstock and 
co-workers as well as the existence of so-called purinergic receptors (P2 
receptors) mediating responses induced by ATP was finally accepted. At present, 
there is no doubt about ATP and other nucleotides such as adenosine-5'-di-
phosphate as well as uridine-5'-tri- and -diphosphate acting as signalling 
substances in the peripheral and central nervous system. 
 
The P2 receptors can be subdivided into two major groups, the P2X receptor 
family of ligand-gated cation channels and the P2Y receptor family of 
G protein-coupled nucleotide receptors. To date seven mammalian P2X receptor 
subunits (P2X1-7) and six P2Y receptors (P2Y1,2,4,6,11,12) have been cloned, 
characterised pharmacologically and accepted as valid members of the 
P2 receptor family. 
 
The neurotransmitting activity of nucleotides is rapidly terminated by enzymatic 
cleavage of the phosphate chain by a group of membrane-bound enzymes 
(sometimes also present in soluble forms) generally referred to as 
ecto-nucleotidases. The final degradation product of ATP, adenosine, which itself 
has been characterised as a neurotransmitter/neuromodulator elicits its mainly 
inhibitory effects acting at P1 receptors (A1, A2A, A2B, A3). 
 
One of the most exciting challenges in the rapidly expanding P2 receptor field is to 
relate the cloned P2 receptor subtypes to the diverse physiological responses 
mediated by native receptors. The identification of potent and selective 
P2  receptor ligands (agonists and antagonists) will aid in defining their 
physiological/ pharmacological function. Unfortunately, most of the P2 receptor 
antagonists evaluated so far are limited in their usefulness by their irreversibility of 
antagonism or lack of potency, subtype-selectivity and P2 receptor specificity. The 
property of many of these antagonists to either inhibit ecto-nucleotidases or to be 
susceptible to enzymatic breakdown, further complicates their use. Therefore, a 
high affinity P2 receptor antagonist would be a valuable pharmacological tool to 
improve radioligand binding assays, which in turn are critical to the use of high 
throughput screening assays to identify novel pharmacophores and - finally - new 
therapeutic agents. 
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Suramin (Germanin
®), which is in use for the treatment of trypanosomiasis and 
onchocerciasis, has been reported to be a non-selective antagonist at 
recombinant and native P2 receptor subtypes. Particularly one analogue, the 
small urea NF023, displayed considerable potency and selectivity in competitively 
blocking P2X receptors present in vascular and non-vascular preparations. This 
was confirmed in studies at recombinant P2X receptor subtypes. 
 
Therefore, a pharmacological evaluation of compounds related to suramin and 
NF023 was performed to gain further insights in structure-activity relationships 
with the aim to identify novel P2 receptor antagonists. 
 
Development of screening assays for the investigation of P2 receptor and 
ecto-nucleotidases inhibitory activities of suramin analogues 
 
To investigate the inhibitory activity of a larger number of suramin analogues 
screening assays were developed. The contraction-mediating P2 receptor subtype 
present in rabbit vas deferens (RVD) has been previously characterised as a 
member of the P2X receptor subfamily. However, several findings indicated that 
contraction elicited by electrical field stimulation, resulting in the release of the 
naturally occurring non-selective ligand ATP, might be mediated by a 
heterogeneous P2 receptor population. Taking these investigations into account, 
the inhibitory activity of suramin analogues was determined on contractions of the 
RVD elicited by a single dose of the exogenously applied P2X receptor selective 
agonist ,-methylene ATP (,-mATP). 
 
Furthermore, the inhibitory activity of the derivatives was investigated in guinea-pig 
taenia coli (GPTC) which is one of the prototype tissues for the study of native 
P2Y  receptors. Originally, the P2 receptor subtype mediating relaxation of the 
carbachol-pre-contracted GPTC has been assumed to be identical to the 
recombinant P2Y1 receptor. However, several studies indicated that relaxation of 
GPTC is mediated by at least two different P2 receptor subtypes. Therefore, the 
original classification has been questioned. 
 
Consequently, in addition to GPTC P2Y receptors, the detailed pharmacological 
evaluation of selected derivatives was performed at P2Y1-like receptors mediating 
contraction of the guinea-pig ileal longitudinal smooth muscle. 
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Inhibitory activities of the small and large ureas on ATP breakdown were 
determined on ecto-nucleotidases of folliculated Xenopus laevis oocytes. 
ATP-degrading activity in the presence of oocytes has been characterised in 
previous studies to be due to the extracellular enzymes present in the follicle 
epithelium. 
 
Structure-activity-relationships of suramin analogues 
 
The inhibitory activities of suramin- and NF023-related compounds determined in 
the screening assays provided some interesting insights in structure-depending 
activity (NF023, suramin and 4'-desmethyl-suramin [NF037] served as reference 
drugs): 
 4'-Substituents either electropositive or electronegative lead to a decrease in 
inhibitory potency of small and large urea derivatives at P2X receptors. 
 Introduction of an electron-enriched 4'-phenyl group enhances the P2X as well 
as P2Y receptor-blocking potency of large ureas, whereas the small urea 
analogue displays reduced antagonistic activity at P2X receptors and an 
increase in P2Y receptor inhibitory activity. 
 
Based on these observations, the reason for the reduced antagonistic activity of 
suramin at P2X receptors when compared to NF023 seems to be more probably 
due to the 4'-methyl substitution than - as originally anticipated - to the increase in 
molecular size. 
 Introduction of isomeric biphenyl instead of aminobenzoyl residues generates 
NF023 analogues displaying increased P2X and in some cases also 
P2Y receptor-blocking potencies. 
 An exchange of the urea bridge resulted in all cases - thiourea, phthalic acid, 
piperazine - in a loss in antagonistic activity at the P2X receptor subtype. 
 
The detailed pharmacological evaluation of suramin and NF023 analogues varying 
in the substitution pattern of the aminonaphthalene sulphonic acid residues as 
well as in the linkage of the aminobenzoyl moiety confirmed preliminary results 
obtained in the screening assays and enabled to suggest further structure-activity 
relationships. 
 
Investigations of the P2X receptor-blocking potency of these compounds were 
performed in prostatic segments of the rat instead of the rabbit vas deferens. This 
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tissue was chosen for two reasons: first, the rat vas deferens (ratVD) has been 
widely used to study native P2X1-like receptors, and second, the presence of P2X1 
receptor subtypes in ratVD has been unambiguously proved by expression 
cloning. Therefore the use of the ratVD facilitates the comparison of results 
obtained from other groups at native P2X1-like receptors. 
 
Among these analogues, the 1'-4',1''-4''-linked large ureas NF279 and NF031 
displayed high antagonistic potency and considerable selectivity for ratVD 
P2X1-like receptors, whereas the antagonistic potency determined for the 
1'-4',1''-3''-linked structural intermediates NF280 and NF032 was markedly 
decreased. Introduction of 1,3,6- instead of 1,3,5-aminonaphthalene trisulphonic 
acid residues resulted in a substantial decrease of antagonistic potency of 
1'-4',1''-4''-linked large ureas without affecting the P2X receptor selectivity. In 
contrast, the same structural variation in the group of small ureas led to a loss in 
P2X receptor selectivity due to an increase in P2Y receptor-blocking potency. 
 
Regarding the inhibitory effect of the suramin derivatives on ecto-nucleotidases in 
folliculated Xenopus laevis oocytes, a general conclusion can be drawn: almost all 
analogues were shown to inhibit ecto-nucleotidases at relatively high 
concentrations in a similar concentration range. Therefore, the higher the 
P2 receptor antagonistic potency of a certain analogue, the higher the P2 receptor 
vs. ecto-nucleotidases selectivity. 
 
Specificity and P2 receptor subtype selectivity of NF279 
 
In prostatic segments of the ratVD, increasing concentrations produced a 
progressive rightward shift, and independent of the concentration an increase in 
the maximum as well as in the slope of the ,-mATP concentration-contraction 
curve. Due to an increase of the resulting pA2 values (6.07 [1 M], 6.41 [3 M], 
7.06 [10 M]), the antagonism of NF279 at P2X1-like receptors cannot be 
regarded as purely competitive. However, the progressive rightward shift in the 
presence of increasing concentrations of NF279 clearly indicates competitive 
interactions between NF279 and ,-mATP. Investigation of the antagonistic 
activity of NF279 on recombinant P2X receptor subtypes might provide a possible 
explanation, as kinetics of NF279 and ATP interacting with P2X1 receptors were 
found to be markedly different. Equilibration with and dissociation from the 
receptor of NF279 was shown to be considerably slow. Therefore, at native 
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P2X1-like as well as recombinant P2X1 receptor subtypes, a competitive 
interaction of NF279 could neither be confirmed nor rejected. On the other hand, 
NF279 displayed competitive antagonism at native P2Y1-like and P2X3-like 
receptors of GPI. The P2X1 receptor-selectivity determined for NF279 in studies at 
native receptors was confirmed and extended, analysing the pharmacological 
profile on recombinant P2X receptor subtypes. The resulting rank order of 
antagonistic potency P2X1 > P2X2   P2X3   P2X7 >> P2X4 as well as the 
P2X1  receptor-blocking potency is unique among the metabolically stable P2 
receptor antagonists described so far. 
 
NF279 was shown to be without influence on 1A receptor-induced contraction in 
ratVD, adenosine A1, histamine H1 and muscarinic M3 receptor mediated effects in 
GPI, adenosine A2B and neuronal nicotinic receptors in GPTC. Thus, the 
antagonism of NF279 appears to be highly specific for P2 receptors. 
 
Heterogeneity of P2 receptors mediating contraction of prostatic and 
epididymal segments of the rat vas deferens 
 
Comparing the inhibitory potency of NF279 and other P2 receptor antagonists on 
contractions of ratVD elicited by ,-mATP, differences were observed with regard 
to the anatomical origin - either prostatic or epididymal - of the segment. 
Investigation of contractions of prostatic and epididymal segments induced by 
agonists and blocked by antagonists with different selectivity profiles revealed a 
differential distribution of P2 receptor subtypes along the length of the tissue. In 
prostatic segments, contraction was shown to be mediated almost exclusively via 
P2X1-like receptors, whereas in epididymal segments in addition to the P2X1-like 
receptor, at least one further P2 receptor subtype is involved in the contractile 
response. Therefore, studies on P2X1 receptor-mediated effects on both 
segments of the ratVD might lead to misinterpretations. Unfortunately, the 
additional P2 receptor subtype(s) present in epididymal segments could not be 
identified by use of the pharmacological tools presently available. However, based 
on the results obtained in the present study and regarding the P2 receptor 
proteins detected in ratVD so far, the unknown receptor most probably belongs to 
the P2X  receptor family and may be the result of an heteromeric assembly of 
different P2X receptor subunits, generating a novel pharmacological phenotype. 
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Zu Beginn der 70er Jahre wurde für Adenosin-5'-triphosphat (ATP), das bereits 
lange als innerhalb der Zelle vorkommender Energieträger bekannt war, eine 
extrazelluläre Wirkung als Neurotransmitter postuliert. Es dauerte allerdings noch 
eine Reihe von Jahren, bis die von der Arbeitsgruppe um G. Burnstock 
aufgestellte Hypothese der "purinergen Nerven" und die damit verbundene 
Existenz von sogenannten P2-Rezeptoren (früher purinerge Rezeptoren) 
allgemein anerkannt wurde. Heute besteht kein Zweifel mehr, dass ATP alle der 
unten genannten Anforderungen an eine als endogener Überträgerstoff innerhalb 
des vegetativen und zentralen Nervensystems fungierende Substanz erfüllt: 
 Synthese und Speicherung des entsprechenden Überträgerstoffes, 
 Freisetzung einer definierten Menge an Transmitter bei einem einlaufenden 
Aktionspotential, 
 Rezeptoren für die Reaktion mit dem Transmitter sowie 
 die rasche Inaktivierung des freigesetzten Neurotransmitters. 
 
Die Familie der P2-Rezeptoren gliedert sich in zwei Unterfamilien, von denen 
jeweils weitere Subtypen existieren. P2X-Rezeptoren sind Ligand-gesteuerte 
Kationenkanäle, die P2Y-Rezeptoren gehören zur großen Familie der G-Protein-
gekoppelten Rezeptoren. Mittlerweile sind sieben P2X-Rezeptor-Subtypen 
(P2X1-7) sowie sechs P2Y-Rezeptor-Subtypen (P2Y1,2,4,6,11,12) molekularbiologisch 
und pharmakologisch charakterisiert und von der IUPHAR (International Union of 
Pharmacology) als Mitglieder der P2-Rezeptor-Familie anerkannt. Neben ATP 
interagieren auch andere Nukleotide wie z. B. Adenosin-5'-diphosphat sowie 
Uridin-5'-tri- und -diphosphat als physiologische Liganden mit einigen Subtypen 
der P2Y-Rezeptor-Familie. 
 
Die Inaktivierung der freigesetzten Nukleotide erfolgt durch enzymatische 
Abspaltung der Phosphat-Gruppen (Dephosphorylierung) durch größtenteils 
membranständige, zum Teil aber auch lösliche Enzyme, die häufig unter dem 
Begriff "Ekto-Nukleotidasen" zusammengefasst werden. Endprodukt dieses 
extrazellulär verlaufenden Abbaus ist Adenosin, das ebenfalls ein Neuro-
modulator/-transmitter ist, und dessen meist inhibitorischen Effekte über 
P1-Rezeptoren (A1, A2A, A2B, A3) vermittelt werden. 
 
Eine der größten Herausforderungen auf dem immer noch vergleichsweise 
"jungen" Forschungsgebiet der Nukleotid-Rezeptoren ist die Verknüpfung der auf 
molekularbiologischer Ebene gewonnenen Erkenntnisse mit erwiesenermaßen 
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durch native P2-Rezeptoren vermittelten physiologischen Effekten. Für die 
Charakterisierung der nativen Rezeptoren sind Antagonisten, die die Wirkung des 
physiologischen Liganden an seinen Rezeptoren möglichst potent, spezifisch und 
möglichst selektiv für einen bestimmten Rezeptor-Subtyp blockieren - sogenannte 
"pharmakologische Werkzeuge" - von großer Bedeutung. Diese könnten z.B. auch 
als Radioliganden in Bindungsstudien eingesetzt werden, um so ein breiteres 
Screening zur Identifizierung neuer Leitstrukturen und - letztendlich - neuer 
Arzneimittel zu ermöglichen. Neben der oft mangelnden Wirkstärke, 
Subtypselektivität und Reversibilität des inhibitorischen Effektes einer Vielzahl der 
bisher eingesetzten Antagonisten ist ihre Wechselwirkung mit 
Nukleotid-abbauenden Enzymen, vor allem für Untersuchungen an nativen 
P2-Rezeptoren, ein erheblicher Nachteil. 
 
Der in der Therapie der Schlafkrankheit sowie der durch Filarien ausgelösten 
Onchozerkose eingesetzte Wirkstoff Suramin (Germanin
®) erwies sich in 
pharmakologischen Untersuchungen an nativen und klonierten P2-Re-
zeptor-Subtypen als unspezifisch wirkender, nicht-selektiver, zum Teil auch nicht-
kompetitiver Antagonist. Aus einer kleineren Anzahl untersuchter Suramin-Deri-
vate zeigte NF023 eine im Vergleich zur Muttersubstanz erhöhte inhibitorische 
Wirksamkeit an vaskulären und nicht-vaskulären P2X-Rezeptoren (P2X1-ähnliche 
Rezeptoren) sowie eine stark verminderte antagonistische Potenz an glattmusklär 
vorkommenden P2Y-Rezeptoren (P2Y1-ähnliche Rezeptoren). Nachfolgende 
Untersuchungen an klonierten P2-Rezeptor-Subtypen bestätigten diese Ergeb-
nisse, und die Substanz ist bis heute einer der wenigen kompetitiven, 
P2X1-Rezeptor-selektiven Antagonisten. 
 
Die Gruppe der Suramin-Derivate bot daher die Möglichkeit: (1) möglicherweise 
weitere interessante P2-Rezeptor-Antagonisten mit neuen pharmakologischen 
Profilen zu identifizieren und (2) durch Untersuchung struktureller Modifikationen, 
Struktur-Wirkungs-Analysen innerhalb dieser Substanzgruppe durchzuführen. 
 
Entwicklung von Methoden zur Charakterisierung der antagonistischen 
Wirkstärke von Suramin-Derivaten an nativen P2-Rezeptor-Subtypen und 
Ekto-Nukleotidasen 
 
Im Rahmen dieser Arbeit wurden zunächst basierend auf bereits bestehenden 
pharmakologischen Modellen Methoden entwickelt, die die Untersuchung einer 
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Vielzahl von Substanzen, die zum Teil nur in geringer Menge verfügbar waren, an 
glattmuskulären P2X- und P2Y-Rezeptoren sowie den Nukleotid-abbauenden 
Ekto-Nukleotidasen ermöglichen. 
 
Der postsynaptische kontraktionsvermittelnde P2-Rezeptor-Subtyp im Samenleiter 
des Kaninchens war bereits in früheren Arbeiten als P2X-Rezeptor (P2X1-ähnlich) 
charakterisiert worden. Aus diesen Arbeiten ergaben sich jedoch Hinweise, dass 
die durch elektrische Feldstimulation - durch Freisetzung des endogenen 
Liganden ATP - ausgelösten Kontraktionen nicht ausschließlich durch diesen P2-
Rezeptor-Subtyp vermittelt werden. Daher wurde der inhibitorische Effekt der 
Derivate des Suramin auf durch exogene Zugabe einer Einzeldosis des P2X-
Rezeptor-selektiven Agonisten ,-Methylen-ATP ausgelöste Kontraktionen des 
Gewebes bestimmt. 
Suramin und NF023 dienten hier, wie auch für die anderen verwendeten 
pharmakologischen Modelle, als Vergleichssubstanzen. 
 
Für die Bestimmung der antagonistischen Wirkstärken der Suramin-Derivate an 
glattmuskulären P2Y-Rezeptoren erwies sich die Taenia coli des 
Meerschweinchens, eines der Prototyp-Gewebe für diesen Rezeptor-Subtyp, als 
brauchbar. Hier wurde der inhibitorische Effekt der Substanzen auf durch den 
P2-Rezeptor-Agonisten ADPS ausgelöste Relaxationen des durch Carbachol 
vorkontrahierten Präparates (in Form von Dosis-Wirkungs-Kurven) durch 
Auswertung des Ausmaßes der Rechtsverschiebung der Dosis-Wirkungs-Kurven 
in Gegenwart des potentiellen Antagonisten (pA2-Wert) bestimmt. Inzwischen ist 
die frühere Charakterisierung des relaxationsvermittelnden P2Y-Rezeptors als 
P2Y1-Rezeptor-Subtyp umstritten. Aus diesem Grund wurde für die detaillierte 
pharmakologische Untersuchung ausgewählter Substanzen die Longitudinal-
muskulatur des Ileum des Meerschweinchens, in der durch ADPS ausgelöste 
Kontraktionen erwiesenermaßen durch P2Y1-ähnliche Rezeptoren vermittelt 
werden, als zusätzliches pharmakologisches Modell verwendet. 
 
Da sich die Taenia coli des Meerschweinchens im Rahmen der vorliegenden 
Untersuchungen aufgrund der geringen, nicht konzentrations-abhängigen 
inhibitorischen Wirkung der Referenzsubstanz Suramin als unbrauchbar für die 
Untersuchung einer potentiellen Hemmung von Nukleotid-abbauenden Enzymen 
durch die Derivate des Suramins erwies, wurden diese an Oozyten des 
Krallenfrosches Xenopus laevis durchgeführt. Die ATP-abbauenden Enzyme im 
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Follikelepithel der Oozyten wurden bereits in vorhergehenden Arbeiten als zur 
Gruppe der Ekto-Nukleotidasen gehörig charakterisiert. 
 
Struktur-Wirkungsanalyse von Suramin-Derivaten 
 
Die im Rahmen des Screenings bestimmten inhibitorischen Effekte einer 
einzelnen Konzentration (10 M) der von Suramin abgleiteten sogenannten 
"großen Harnstoffe" sowie der von NF023 abgeleiteten "kleinen Harnstoffe", läßt 
nur erste Rückschlüsse auf einen möglichen Zusammenhang zwischen Struktur 
und Wirkung zu. In erster Linie wurde dieses breit angelegte Screening 
durchgeführt, um neue, in ihrer Wirkstärke bzw. ihrem pharmakologischen Profil 
den Muttersubstanzen überlegene P2-Rezeptorliganden zu identifizieren. 
Dennoch ließen sich diese vorläufigen Befunde in eingehenderen 
pharmakologischen Untersuchungen ausgewählter Verbindungen bestätigen. Aus 
der Vielzahl der untersuchten Strukturvariationen sollen im folgenden nur einige 
besonders bemerkenswerte Befunde erläutert werden (als Vergleichssubstanz 
diente hier - neben den bereits erwähnten Muttersubstanzen Suramin und NF023 
- das 4'-Desmethyl-Derivat des Suramin NF037): 
 4'-Substitution mit Elektronen-ziehenden wie auch Elektronen-schiebenden 
Substituenten führen sowohl in der Gruppe der großen als auch der kleinen 
Harnstoffe zu einer verminderten inhibitorischen Aktivität am P2X-Rezeptor. 
 Die Einführung eines großvolumigen, Elektronen-reichen Phenylrestes in die 4'-
Position wird in beiden Gruppen, bezogen auf die inhibitorische Aktivität an den 
untersuchten P2-Rezeptor-Subtypen, besser toleriert. 
 
Somit lässt sich die im Vergleich zu Suramin erhöhte antagonistische Potenz von 
NF023 am P2X1-Rezeptor bzw. die verminderte inhibitorische Wirkung an 
P2Y1-ähnlichen Rezeptoren eher auf den fehlenden 4'-Methyl-Substituenten und 
nicht, wie ursprünglich angenommen, auf das Fehlen einer aromatischen 
Teilstruktur zurückführen. 
 Wird das Phenyl-Fragment in der Gruppe der kleinen Harnstoffe durch eine 
Biphenyl-Struktur ersetzt, so konnte, in Abhängigkeit von der Verknüpfung 
dieser Biphenyl-Struktur mit der Harnstoffbrücke und den beiden Naphthalin-tri-
sulfonsäure-Resten, eine Zunahme der inhibitorischen Wirksamkeit der 
entsprechenden Derivate an beiden P2-Rezeptor-Subtypen festgestellt werden. 
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 Der Austausch der Harnstoffbrücke gegen andere Strukturelemente - z.B. 
Thioharnstoff, Phthalsäure, Piperazin - hat in allen untersuchten Fällen eine 
Abnahme der inhibitorischen Aktivität zur Folge. 
 
Detaillierte pharmakologische Untersuchungen von Suramin- (bzw. 4'-Des-
methyl-Suramin) und NF023-analogen Verbindungen mit 1,3,5- sowie 1,3,6-
Naphthalintrisulfonat-Substituenten, die sich außerdem in der Verknüpfung (1'-
4',1''-3'' und 1'-4',1''-4'' [4'-Desmethylsuramin] bzw. 1'-4' [NF023]) der Amino-
benzoyl-Teilstrukturen unterscheiden, ermöglichten weitere Aussagen zu 
Struktur-Wirkungs-Beziehungen. 
 
Zur Bestimmung der antagonistischen Potenz der o. g. Substanzen an 
P2X-Rezeptoren wurden an Stelle des Samenleiters des Kaninchens prostatische 
Segmente des Samenleiters der Ratte verwendet. Gründe für den Wechsel der 
Spezies waren (1) die weit verbreitete Verwendung dieses Präparates für 
Untersuchungen an nativen P2X1-ähnlichen Rezeptoren und (2) der eindeutige 
Nachweis der Anwesenheit des P2X1-Rezeptor-Subtyps, der erstmals durch 
Expressionsklonierung aus diesem Gewebe isoliert wurde. Auf diese Weise ließen 
sich Ergebnisse der vorliegenden Arbeit besser mit Untersuchungen anderer 
Arbeitsgruppen an nativen P2X1-ähnlichen Rezeptoren, vor allem aber 
rekombinanten P2X1-Rezeptoren, vergleichen. 
 
Die 1'-4',1''-4'' verknüpften Verbindungen NF279 und NF031 waren die 
potentesten Antagonisten innerhalb der o. g. Gruppen und zeigten darüber hinaus 
eine beachtliche Selektivität für den P2X1-ähnlichen Rezeptor im Samenleiter der 
Ratte. Im Vergleich zu den Muttersubstanzen war eine reduzierte antagonistische 
Potenz der 1'-4', 1''-3''-verknüpften strukturellen Zwischenstufen NF280 und 
NF032 an P2X1-ähnlichen, für NF032 auch an P2Y1-ähnlichen Rezeptoren zu 
verzeichnen. Ein Einfluss des Substitutionsmusters der Naphthalintrisulfon-
säure-Reste konnte, was die antagonistische Wirkstärke an P2X1-ähnlichen 
Rezeptoren angeht, nur für die beiden 1'-4',1''-4'' verknüpften großen Harnstoffe 
NF279 und NF031 festgestellt werden. Hier zeigte sich jedoch, dass die 
Verschiebung eines Sulfonat-Restes zu einem deutlichen Verlust der 
antagonistischen Potenz an beiden P2-Rezeptor-Subtypen führt. 
 
Auch in der Gruppe der kleinen Harnstoffe konnte ein - wenn auch etwas anderer 
- Einfluss dieser Strukturvariation gezeigt werden. Die Verschiebung eines 
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Sulfonat-Substituenten von der 5- auf die 6-Position des Naphthalin-Ringsystems 
steigerte die antagonistische Wirkstärke an P2Y1-ähnlichen Rezeptoren um mehr 
als eine Zehnerpotenz, während die inhibitorische Aktivität von NF550 an 
P2X1-ähnlichen Rezeptoren im Vergleich zu NF023 unverändert blieb. 
 
Bezogen auf die inhibitorische Aktivität der Suramin- und NF023-Derivate an 
Ekto-Nukleotidasen läßt sich folgendes feststellen: Generell zeigen die 
Substanzen gegenüber den Nukleotid-abbauenden Enzyme im Follikelepithel der 
Oozyten des Krallenfrosches eine relativ ähnliche inhibitorische Wirkstärke. Das 
läßt den Schluss zu, dass mit steigender antagonistischer Potenz der Suramin-
Derivate an einem oder mehreren P2-Rezeptor-Subtypen die Selektivität ihrer 
antagonistischen Wirkung bezogen auf die als Nebeneffekt auftretende Hemmung 
der Ekto-Nukleotidasen zunimmt. 
 
Untersuchungen der P2-Rezeptor-Subtyp-Selektivität und Spezifität von 
NF279 
 
An prostatischen Segmenten des Samenleiters der Ratte führte die Inkubation 
steigender Konzentrationen des Antagonisten NF279 zu einer zunehmenden 
Rechtsverschiebung, und zusätzlich zu einer Konzentrations-unabhängigen 
Steigerung des Maximums sowie zu einer Versteilung der Konzen-
trations-Wirkungs-Kurve von ,-Methylen-ATP. Darüber hinaus war für steigende 
Konzentrationen des Antagonisten eine Zunahme der resultierenden pA2-Werte 
zu verzeichnen (pA2-Werte: 6.07 [1 M], 6.41 [3 M], 7.06 [10 M]), so daß eine 
Regression nach Arunlakshana und Schild (1959) eine Gerade mit einer Steigung 
> 1 (signifikant von 1 verschieden) ergeben hätte. NF279 kann somit nicht als 
"kompetitiver Antagonist" im strengen Sinne bezeichnet werden. Die zunehmende 
Rechtsverschiebung in Gegenwart steigender Konzentrationen des Antagonisten 
ist allerdings ein eindeutiger Hinweis auf eine kompetitive Wechselwirkung von 
,-Methylen-ATP und NF279 am P2X1-ähnlichen Rezeptor des Samenleiters der 
Ratte. Untersuchungen zur antagonistischen Wirkung von NF279 an 
rekombinanten P2X1-Rezeptor-Subtypen ergaben Hinweise, dass die oben 
beschriebenen nicht-kompetitiven Wechselwirkungen möglicherweise durch 
Unterschiede in der Kinetik von Agonist (ATP) und NF279 zustande kommen. 
Dennoch konnte auch im Rahmen dieser Untersuchungen nicht abschließend 
geklärt werden, ob es sich bei NF279 um einen rein kompetitiven P2X1-Rezeptor-
selektiven Antagonisten handelt. Sowohl an den P2Y1-ähnlichen wie auch an den 
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P2X3-ähnlichen Rezeptoren der Longitudinal-Muskulatur des Ileum des 
Meerschweinchens erwies sich NF279 als rein kompetitiver Antagonist (pA2-Werte 
von 5.32 bzw. 5.95). Bezogen auf native P2-Rezeptor-Subtypen ergibt sich damit 
das folgende pharmakologische Profil: P2X (Samenleiter der Ratte) > P2X (Ileum 
des Meerschweinchens) > P2Y (Ileum des Meerschweinchens). Das aus 
Untersuchungen an rekombinanten P2-Rezeptor-Subtypen resultierende, bisher 
einzigartige, pharmakologische Profil - P2X1 > P2X2  P2X3  P2X7 >> P2X4 - 
unterstreicht die Bedeutung von NF279. 
 
NF279 (100 M) zeigte keinerlei Einfluss auf 1A-Rezeptor-vermittelte 
Kontraktionen im Samenleiter der Ratte, Adenosin A1-Rezeptor- und 
Nicotin-Rezeptor-vermittelte sowie A2B-Rezeptor-, Histamin H1- und Muskarin 
M3-Rezeptor-vermittelte Effekte in der Taenia coli bzw. in der 
Longitudinal-Muskulatur des Ileum des Meerschweinchens. Der Antagonismus 
von NF279 erwies sich somit als hoch spezifisch für P2-Rezeptor-Subtypen. 
 
Untersuchungen zur Heterogenität P2-Rezeptor-vermittelter Effekte in 
prostatischen und epididymalen Segmenten des Samenleiters der Ratte 
 
Aus dem Vergleich der antagonistischen Potenz von NF279 und einigen anderen 
P2-Rezeptor-Antagonisten an prostatischen und epididymalen Segmenten des 
Samenleiters der Ratte ergaben sich Hinweise auf eine asymmetrische Verteilung 
kontraktionsvermittelnder P2 Rezeptoren innerhalb des Gewebes. Weitergehende 
Untersuchungen zeigten, dass die Kontraktion prostatischer Segmente - wie 
ursprünglich für den gesamten Samenleiter angenommen - nahezu ausschließlich 
durch P2X1-ähnliche Rezeptoren vermittelt wird, während in epididymalen 
Segmenten  ,-Methylen-ATP und ADPS mindestens einen weiteren 
P2-Rezeptor-Subtyp stimulieren. Die Verwendung beider Segmente für die 
Untersuchung potentieller Antagonisten kann somit, zumindest für Substanzen, 
deren pharmakologisches Profil dem des NF279 ähnelt, zu Fehleinschätzungen 
führen. Leider ist es mit den vorhanden pharmakologischen Werkzeugen nicht 
gelungen, diese(n) weiteren Subtyp(en) eindeutig zu charakterisieren. Basierend 
auf den vorliegenden Ergebnissen und auf Untersuchungen mit 
Subtyp-spezifischen Antikörpern kann nach dem heutigen Kenntnisstand davon 
ausgegangen werden, dass es sich hierbei um einen P2X-Rezeptor-Subtyp 
handeln muss, möglicherweise auch einen durch Assemblierung unterschiedlicher 
P2X-Rezeptor-Untereinheiten bisher noch nicht identifizierten Phänotyp. 
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AC Adenylate  cyclase 
ACh Acetylcholine 
ADP Adenosine-5’-diphosphate 
ADPS Adenosine  5’-O-(2-thiodiphosphate) 
ADPS Adenosine  5’-O-(3-thiotriphosphate) 
AIDS  Acquired immunodeficiency syndrome 
AMP Adenosine-5'-monophosphate 
AMP-PNP  ,-imidoadenosine-5'-triphosphate 
ANAPP3 Arylazidoaminopropionyl-ATP 
ApnA  Adenine dinucleotides ("n" indicating the number 
of phosphates between the two adenosine 
moities) 
A2P5P Adenosine-2'-phosphate-5'  phosphate 
A3P5P Adenosine-3'-phosphate-5'  phosphate 
A3P5PS Adenosine-3'-phosphate-5'-phosphosulfate 
ARC-66096MX 2-Propylthio-D-,-difluoromethylene ATP 
AR-C67085MX 2-propylthio-D-,-dichloromethylene ATP 
AR-C69931MX 2-(3,3,3-trifluoropropylthio)-N
6-methylthioethyl-D-
,-dichloromethylene ATP 
ARL 67156  6-N,N-diethyl-D-,-dibromomethylene ATP 
ATP Adenosine-5’-triphosphate 
ATPS Adenosine-5'-O-3-thiotriphosphate 
Bst101 N-[3-(N-(1,3,5-Trisulpho-8-naphthyl)carbamoyl)-
phenyl]-N'-[3-(N-(1-naphthyl)-carbamoyl)phenyl]-
urea 
BzATP 2',3'-O-(4-benzoylbenzoyl)  ATP 
CHO cells  Chinese hamster ovary cells 
CF Cystic  fibrosis 
CFTR  Cystic fibrosis transmembrane conductance 
regulator 
2-Cl-Ado 2-Chloroadenosine 
CMP Cytidine-5'-monophosphate 
CNS  Central nervous system 
CRC Concentration-response  curve 
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CIC Concentration-inhibution  curve 
DIDS 4,4'-Diisothiocyanatostilbene-2,2'-disulfonate 
DPCPX 1,3-Dipropyl-8-cyclopentylxanthine 
DR Dose  ratio 
EC50  Molar concentration producing 50  % of the 
individual maximal response 
EFS  Electrical field stimulation 
GPI  Guinea-pig ileal longitudinal smooth muscle 
GPTC  Guinea-pig taenia coli 
G protein  Guanyl nucleotide binding protein 
HEK293 cells  Human embryonic kidney cells 
HIV  Human immunodeficiency virus 
HPLC  High-performance liquid chromatography 
ICC  Interstitial cells of Cajal 
INS-316 UTP 
INS-365 Diuridine-tetraphosphate 
IP3  Inositol 1,4,5-triphosphate 
Ip5I Diinosine  pentaphosphate 
iso-PPADS Pyridoxalphosphate-6-azophenyl-2',5'-disulfonic 
acid 
IUPHAR  International Union of Pharmacology 
KN-04 N-[1-[N-methyl-p-(5-isoquinolinesulfonyl)benzyl]-
2-(4-phenylpiperazine)ethyl]-5-isoquinolinesulfon-
amide 
KN-62 1-[N,O-bis(5-isoquinolinesufonyl)-N-methyl-L-tyro-
syl]-4-phenylpiperazine 
,-mADP  ,-Methylene-ADP 
,-mATP  ,-Methylene-ATP 
,-mATP  ,-Methylene ATP 
2-MeSADP 2-Methylthio-ADP 
2-MeSATP 2-Methylthio-ATP 
min Minute(s) 
MRS 2179  N
6-Methyl-2'deoxy-adenosine.3',5'- biphosphate 
MRS 2220  Cyclic pyridoxine-
4,5-monophosphate-6-phenyl-
azo-2',5'-disulfonate 
ms Millisecond(s) 
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NA Noradrenaline 
NANC Non-adrenergic,  non-cholinergic 
NBTG S-p-Nitrobenzyl-6-thioguanosine 
n.d. Not  determined 
NDPK Nucleoside  diphosphokinase 
NECA 5'-N-Ethylcarboxamidoadenosine 
NF018 8-(3-(3-Nitrobenzamido)benzamido)-naphthalene-
1,3,5-trisulphonic acid 
NF019 8-(3-(3-Aminobenzamido)benzamido)-naphtha-
lene-1,3,5-trisulphonic acid 
NF023 8,8'-(Carbonylbis(imino-3,1-phenylenecarbonyl-
imino))bis(1,3,5-naphthalenetrisulphonic acid) 
NF105 8-(2-Methyl-3-(3-aminobenzamido)-benzamido)-
naphthalene-1,3,5-trisulphonic acid 
NIDDM Non-insulin-dependent diabetes mellitus 
oxoATP 2',3'-dialdehyde-ATP 
PAGE  Polyacrylamide gel electrophoresis 
PC Pheochromocytoma 
PCR  Polymerase chain reaction 
PDNP Phosphodiesterase/nucleotide  pyrophosphatase 
Pi Inorganic  phosphate 
PLC Phosholipase  C 
PPi Pyrophosphate 
PPADS Pyridoxalphosphate-6-azophenyl-2',4'-disulphonic 
acid 
PPNDS Pyridoxal-5'-phosphate-6-(2'-naphthylazo-6'-nitro-
4',8'-disulfonate) 
pA2  Negative logarithm of the antagonist 
concentration shifting the agonist-concentration-
response curve two-fold to the right 
pA2* Apparent  pA2 values 
RatVD  Rat vas deferens 
RB2  Reactive blue 2 
RT-PCR  Reverse transcription-polymerase chain reaction 
RVD  Rabbit vas deferens 
s Second(s) 
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SAR Structure-activity  relationship 
SB9 6-[(4,6,8-trisulpho-1-naphthyl)iminocarbonyl-1,3-
(4-methylphenylene)-iminocarbonyl-1,3-phenyl-
ene-azo]-pyridoxal-5'-phosphate 
SCG  Superior cervical ganglia 
8-SPT 8-(p-Sulfophenyl)  theophylline 
 Time  constant 
TM Transmembrane  region 
TNP Trinitrophenyl 
TNP-ATP 2',3'-O-(2',4',6')-Trinitrophenyl-ATP 
UDP Uridine-5'-diphosphate 
UMP Uridine-5'-monophosphate 
UTP/INS-316 Uridine-5'-triphosphate 
w/v  Weight per volume 
XAMR0721 8-(3,5-Dinitro-phenylenecarbonylimino)-1,3,5-
naphthalenetrisulphonic acid 
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